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Abstract 
Body fluids are commonly recovered from crime scenes by forensic investigators and 
their identification are necessary part of forensic casework study. Current body fluid 
identification techniques rely on enzymatic tests, which have limited sensitivity and 
specificity, they require large amount of template, use separate assays for various body 
fluids, and are prone to contamination. Various genes are expressed in different body 
fluids that could be used as genetic markers for body fluid identification, and are used 
in forensic investigations. 
The aim of this study was to use mRNA markers to identify human body fluids, which 
included blood, semen, saliva, vaginal secretion and menstrual blood. Initially, ten 
reference genes (UCE, TEF, GAPDH, 18S rRNA, ACTB, B2M, B-Actin, OAZ1, RPS 29 and 
S15) were studied to establish an appropriate reference gene in body fluid identification. 
These are constitutive genes used for normalisation of gene expression data and control 
of variations in experiments. qRT-PCR efficiency, sensitivity and limit of detection (LOD) 
were investigated using SYBR Green and Taqman probes. The results of the SYBR Green 
efficiency test experiment displayed five markers, UCE, TEF, ACTB, B2M, and RPS29 with 
90-110% efficiency with a slope -3.33 ± 10%. 
Subsequently, Taqman probes were designed for the five markers and then used for the 
Taqman probe experiment. Reference gene stability test was carried out on body fluid 
samples stored up to 6 months at room temperature using the designed Taqman probe 
assays. The results established ACTB and UCE as best candidate reference gene markers 
in this study as both were most stable in samples stored for 6 months. Furthermore, to 
identify each of the five body fluids, thirty-two (32) body fluid specific mRNA markers 
were evaluated, optimised and validated. The experiment was initially carried out with 
non-fluorescent makers to determine the specificity of the markers. These were 
analysed using agarose gel electrophoresis. Further optimization was then carried out 
using fluorescently labelled markers. This was done in five separate multiplexes for each 
body fluid; –semen-plex, saliva-plex, vaginal secretion-plex, menstrual blood-plex and 
blood-plex. An attempt was made to combine all the five-separate multiplex into a single 
multiplex. All body fluids were identified unambiguously with no cross-reactions of non-
target body fluids using the combined multiplex assays. 
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Following further evaluation and validation tests, a total of 14 markers were selected 
and a capillary electrophoresis (CE) based, multiplex assay was developed to identify 
blood, saliva, semen and vaginal secretion samples simultaneously. The markers in the 
developed multiplex assay included ALAS2 and PF4 (blood), STATH and HTN3 (saliva), 
PRM1, TGM4, MSMB, NKX3-1 (semen), ACTB and UCE (reference genes), CRYP2B7P1, 
SFTA2, MUC4 and L. crispatus (vaginal secretion). Extensive validation, which include 
sensitivity, specificity, reduced volume reactions, degradation, reproducibility, mixtures, 
cycle number and mastermix, was carried out in accordance with the guidelines detailed 
in Scientific Working Group in DNA Analysis (SWGDAM). The 14-marker CE-based assay 
displayed high specificity and sensitivity. Each body fluid was detected down to 1:3000 
dilution of mRNA except vaginal secretion that was detected down to 1:1500 dilutions 
of sensitivity. Specificity experiments showed no cross reactions of the assay with non-
target body fluids. Reproducibility study displayed similar results reported from an 
independent laboratory. All body fluids exposed to environmental insult were identified 
up to at least day 30 of 51, with blood being identified up to day 51. In the mixture study, 
all body fluids were identified unambiguously using the developed multiplex assay.  
In conclusion, the results of this study have led to the development of a new and novel 
capillary electrophoresis-based mRNA marker assay for forensic body fluid identification, 
demonstrating its compatibility with forensic laboratory workflows. The use of this assay 
to profile forensic casework samples for body fluid identification would be a future 
application of this work.  
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‘‘...a crime cannot be solved without evidence. Confessions and circumstantial evidence 
sometimes prove untrue, but physical evidence can provide an airtight case against a 
suspect.’’ 
 
‘‘…we all think of death as the ending. For forensics, it’s just the beginning.’’ 
-Nancy Haley 
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1.0 Introduction 
Forensic science encompasses the application of scientific knowledge and its techniques 
for the purposes of law. This includes evidence recognition, collection, processing and 
its interpretation for legal purposes (Lee et al., 2001). Physical evidence is of great 
importance to the courts of law. Indeed, such evidence can be more valuable than an 
eyewitness’ account in particular cases (Wells et al., 2003; Spellman and Tenney, 2010). 
Physical evidence commonly encountered and recovered from crime scenes may 
include human body fluids like blood, semen, saliva, menstrual blood and vaginal 
secretions. Appropriate handling of such samples is necessary as environmental factors 
such as temperature/humidity and effects of microorganisms could have adverse effects 
on the recovery of these body fluids (Jackson and Jackson, 2011). Saferstein, (2006) 
reported the use of physical evidence (semen samples) in the apprehension of a serial 
killer in the United States of America. Following the discovery of bodies of five young 
females along Green river in Seattle, Washington, over a period of 6 months, the police 
in the area commenced an investigation into the cause of the murders. After another 
four years, it was discovered that the number had increased to forty; a development 
that made the police focus on a prime suspect - Gary Ridgeway. Because of lack of 
physical evidence, this case was followed up for over a decade until DNA profiling 
became popular. Ridgeway was arrested and made to undergo a lie detector test, which 
he passed. However, a profile of semen samples recovered from three of his victims and 
a reference sample of his saliva had a match. Other evidence that included paint 
particles on his victims clothing also had a match with the paints collected from his 
workplace. With these evidences in place, Ridgeway confessed to the murder of 48 
women.  
The process of human identification has witnessed a significant advancement over years 
(Schiro 2000, Roewer, 2013). Genetic profiles generated from recovered evidentiary 
items are invaluable in forensic casework. However, current processes of genetic 
profiling cannot identify the cellular source of evidential samples (Lindenbergh et al., 
2012). 
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Adequate identification and establishment of the nature and origin of stains 
complement each other. Therefore, during forensic casework, the identity of body fluids 
and recovery of evidential samples is normally undertaken before submission for genetic 
profiling. The traditional techniques of body fluid identification are mostly non-specific 
and laborious. In addition, they sometimes need a significant portion of the materials 
and might be destructive in nature, affecting the genetic profiling process downstream. 
Over the past decades, there has been a steady rise in the number of crime related cases 
that solely rely on DNA evidence and thus genetic profiling techniques have become 
central in most crime related casework. However, the identification of body fluids has 
not developed at the same pace. It is therefore imperative that body fluid identification 
methods are developed that match in sensitivity and specificity, to the current genetic 
profiling methods for human identification. 
1.1 Body fluids  
Body fluids like blood, semen, saliva, menstrual blood, vaginal secretion, sweat, urine 
and contact traces are frequently encountered by forensic investigators at crime scenes 
(Virkler and Lednev, 2009; Lindenbergh et al., 2012). Most of these specimens pose 
challenges during identification as traditional serological methods are presumptive in 
nature (Ablett, 1983; Mokashi et al., 1975; Kipps et al., 1978). These are only sometimes 
complemented with confirmatory tests. 
1.1.1 Body fluid composition 
Each body fluid is made up of specific, unique and varied components that are 
dependent on their site of secretion and function within the body.  Their general 
functions include excretion (urine and sweat), transportation (blood), lubrication and 
protection (vaginal secretion), and digestion, lubrication, host defence and tooth 
mineralisation and mastication or mixing of food (saliva). Some of these body fluids have 
identical components in varying proportions. These relative variations in their 
components determine the type of identification test that might be required for them 
(Table 1.1). 
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Table 1.1: Human body fluid components (Taken from Virkler and Lednev, 2009; 
Wilson 2005) 
Blood Saliva Semen Urine Sweat Vaginal fluid 
Haemoglobi
n 
Glycoprotei
n 
Acid 
phosphatase 
Urea Urea Mucins 
Fibrinogen Bicarbonate PSA Sodium Lactic 
acid 
Albumin 
Erythrocytes Chloride Spermatozo
a 
Chloride Chloride Ig 
Albumin Potassium Choline Potassium Sodium Transferrin 
Glucose Sodium Spermine Ammonium Potassiu
m 
Lactoferrin 
Ig cAMP Putrescine Phosphate Ig Glucose 
 Amylase Spermidine Calcium  Glycogen 
 Ig Cadaverine Creatinine  Mannose 
 Urea Semenogeli
n 
Uric acid  Glucosamine 
 Phosphate Zinc Bicarbonat
e 
 Fructose 
 Lysozyme Citric acid Chlorine  Neutral lipids 
 Calcium Lactic acid Glucose  Phospholipid
s 
 Amino acids Fructose   Urea 
 Ammonia Urea   Lactic acid 
 Uric acid Ascorbic 
acid 
  Acetic acid 
 Lipid Ig   Butanoic acid 
 Thiocyanate    Propanoic 
acid 
 Glucose    Amino acids 
 Peroxidise    Sodium 
 Citrate    Potassium 
     Chloride 
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1.2 Traditional techniques of body fluid identification 
Forensic body fluids are still being identified using traditional methods. These are mostly 
enzyme based, require a large amount of sample, prone to contamination and currently 
not available for all the body fluids. In addition, they do not have the ability to multiplex, 
which is a major drawback in forensic body fluid identification. The body fluids and their 
traditional tests also require confirmatory tests following initial presumptive tests. 
These are discussed in sections 1.2.1 – 1.2.5. 
1.2.1 Saliva 
Saliva is commonly deposited at various crime scenes by unsuspecting perpetrators. It 
may be found as ‘spits’, around the openings of used cans and bottles, cigarette butts 
and chewing gum, and around bite marks. Due to its colourless form and absence of 
solid particles, it is not easily detectable. Traditional methods of identification include 
Alternative Light Source (ALS) (Gaensslen, 1983; Jones Jr., 2005; Vandenberg and 
Oorschot, 2006) and testing of Amylase 1 (AMY1) activity (the starch-iodine test). AMY1 
is present in other body fluids as well; therefore, a further test is necessary to identify 
saliva to prevent results with false positives (Greenfield and Sloan, 2003). In addition, 
ELISA is an immunological test that has been used to identify the presence of saliva in a 
stain. This technique tests a-amylase activity in saliva stains by combining monoclonal 
antibodies with horseradish peroxidase conjugate (Komuro et al., 1995). 
1.2.2 Semen 
Just like saliva, semen is not easily detected by the naked eye due to its colourless 
nature. ALS has been used to detect the presence of semen in sexual assault cases. This 
technique was reported not to be 100% sensitive to semen stains (Virkler and Lednev, 
2009; Gaensslen, 1983) and other body fluids could not be differentiated, thereby giving 
false positive results (Santucci et al., 1999; Nelson and Santucci, 2002). Seminal Acid 
Phosphatase (SAP) is also commonly used. However, false positives with Vaginal Acid 
Phosphatase (VAP) have been recorded (Gaensslen, 1983). With these two body fluids 
commonly recovered in sexual assault cases as mixtures, a more reliable test is needed 
to distinguish SAP from VAP. Isoelectric focusing and acrylamide gel electrophoresis 
have been employed for this purpose, with little success (Virkler and Lednev, 2009; 
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Toates, 1979; Stolorow et al., 1976). Adequate measures should be undertaken when 
carrying out the tests as long exposure of the enzyme to heat, mould or other chemicals 
could cause rapid degradation.  Other presumptive tests available for semen 
identification give false positives for human body fluids, vegetables and faeces and most 
of these tests have not been validated on forensic casework samples thereby limiting 
their usage (Virkler and Lednev, 2009). 
The presence of semen can be confirmed by microscopic identification of sperm cells on 
a slide stained with Christmas Tree stain in non-azoospermic male individuals 
(Greenfield and Sloan, 2003). This, however, cannot be employed for azoospermic 
individuals (Virkler and Lednev, 2009). Other confirmatory tests include prostate-
specific antigen (PSA) (Greenfield and Sloan, 2003); immuno-electrophoresis and ELISA 
(Tsuda et al., 1984). In addition, Seratec® has employed PSA test in their PSA semi quant 
kit (www.seratec.com). 
1.2.3 Blood  
Bloodstains are frequently encountered at crime scenes. ALS such as ultraviolet light 
shows high specificity with the stain on a dark background. Though it can reveal stains 
covered by paints, an exposure of 30s at about 255 nm light could damage the DNA and 
render it too degraded for amplification (Shaler, 2002; Vandenberg et al., 2006; 
Andersen and Bramble, 1997). Luminol test is often used and has been reported to be 
the most sensitive of all the presumptive tests (Gaensslen, 1983; Spalding, 2003). 
Luminol can reveal the bloodstain even when concealment has been attempted. Other 
tests include Phenolphthalein test also known as Kastle-Meyer (KM) test (Spalding, 
2003); Leucomalachite green test (LMG) (Shaler, 2002) and Bluestar1, (Luczak et al., 
2006; Blum et al., 2006). Although they have all been reported to yield very good results 
in bloodstain identification, a confirmatory test is however, still needed for 
unambiguous identification. 
Specific confirmatory tests that have been reportedly used for blood identification and 
they include direct visualization of blood red and white blood cells in liquid blood 
(Shaler, 2002); Scanning electron microscope (SEM) using energy dispersive X-ray 
analyser (EDX) (Dixon et al., 1976) and Teichman and Takayama crystal tests (Spalding, 
2003) being the most popular. Recently used confirmatory tests include isozyme analysis 
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which indicates the presence of blood by monitoring the isozyme pattern of different 
fluids, comparing the differences in their lactate dehydrogenase (Divall and Ismail, 
1983); Enzyme-Linked Immunosorbent Assay (ELISA) (Komuro, et al., 1995), and Thin 
Layer Chromatography (TLC) (Gaensslen, 1983). 
1.2.4 Vaginal secretion 
Vaginal fluid can be important evidence in cases of sexual assault. It is often recovered 
as a mixture with semen especially when penile penetration is involved. The 
components of the vaginal secretions change depending on the menstrual cycle of the 
female (Gaensslen, 1983). Virkler and Lednev, (2009), described the use of periodic acid 
Schiff (PAS) that reports the detection of glycogenated epithelial cells. The test gives 
false positives especially with saliva as both secretions contain mucosal cells (Wilson, 
2005). In addition, glycogenation in females fluctuate depending on menstrual cycle. 
Other reported traditional methods include the use of vaginal peptidase (Divall, 1984); 
monoclonal antibodies by immune-histochemical techniques to detect the presence of 
oestrogen receptors (Hausmann, et al., 1996); comparison of lactic and citric acid ratio 
in vaginal secretion either singly or in mixtures (Martin and Chesire, 1986). 
1.2.5 Menstrual blood 
Menstrual blood is a complex mixture of circulatory blood, vaginal secretions, microbes, 
cells and tissues associated with menstrual cycle (Divall and Ismail, 1983).  There is no 
known presumptive test for menstrual blood due to its composition. However, this body 
fluid has been successfully differentiated from other body fluids using molecular 
approaches (Lindenbergh, et al., 2012; Harbison and Fleming, 2016). 
The various techniques of body fluid identification carried out using traditional 
serological methods are non-specific and presumptive in nature (Virkler and Lednev, 
2009; Mokashi, et al., 1975; Kipps, et al., 1978; Ablett, 1983). The methods require 
considerable amount of sample; and are prone to sample consumption and 
contamination. Furthermore, they are not available for all body fluids (Bauer, 2007) and 
based on the tests carried out and storage conditions, further tests might be required 
for mixtures and aged samples (Vitali et al., 2012; Myers and Adkins, 2008).  
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1.2.6 RNA suitability in new methods of body fluid identification 
Unlike traditional methods, new techniques using RNA have been reported to be 
suitable, unique and specific for body fluid identification. These include messenger RNA 
(mRNA) profiling (Alvarez, et al., 2004; Juusola, and Ballantyne, 2007; Haas, et al., 2009; 
Bowden, et al., 2011; Haas, et al., 2011; Roeder and Haas, 2013), micro RNA (miRNA) 
profiling (Hanson, et al., 2009; Bentwich, et al., 2005; Berezikov, et al., 2005) and 
techniques such as cDNA next generation sequencing (Ogawa, et al., 2013), multiplex 
high resolution melt analysis (HRM) (Hanson and Ballantyne, 2014), RNA Suspension 
Fluorescent in situ hybridization (RNA S-FISH) (Williams, et al., 2013), Matrix-assisted 
laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF MS) (Donfack 
and Willey, 2015), and massively parallel sequencing (MPS) (Lin et al. 2015) have been 
described in the literature. These have gained popularity due to the specificity of the 
molecular markers used, ability to multiplex such markers in a PCR assay and the 
potential for distinguishing the components of a heterogeneous mixture of human body 
fluids in a single assay (Alvarez, et al., 2004; Juusola, and Ballantyne, 2003; Juusola and 
Ballantyne, 2005; Zubakov, et al., 2010; Vandewoestyne et al., 2009; Robertson, et al., 
2009). 
1.3 Ribonucleic acid (RNA) 
Ribonucleic Acid (RNA) is present in all living cells playing an essential role in protein 
synthesis.  Numerous RNA families have been reported (Vennemann and Koppelkamm, 
2010). They are not only distinguishable by their configuration and secondary structure; 
they also have different half-lives and carry out distinctive functions. While most RNAs 
regulate the process of gene expression, messenger RNA (mRNA), transfer RNA (tRNA) 
and ribosomal RNA (rRNA) are all directly involved in protein biosynthesis. The transfer 
of genetic information from DNA to RNA and protein synthesis is shown in Figure 1.1. 
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Figure 1.1: Schematic representation of the Centra Dogma showing the flow of genetic 
information from DNA through RNA to protein synthesis (Taken from Saxena and Chitti, 2016). 
Oehmichen and Zilles, (1984) first reported the use of RNA in forensic science, describing 
post-mortem RNA synthesis. It was nearly another decade before a new report of RNA 
use in this research area was published (Phang, et al., 1994). Subsequently, there was 
no significant advancement until another six years when the Reverse Transcriptase PCR 
(RT-PCR) technique was described (Bauer, 2007). Following this report, there has been 
a steady growth in the practical use of mRNA techniques in forensic science. These 
include determinations of age of wound, stains, post-mortem interval and body fluid 
identification. 
The stability of RNA remains a major concern in forensic science because of the 
ubiquitous ribonucleases, which rapidly degrade RNA (Bauer, 2007). A number of 
reports have established the stability of mRNA under various environmental conditions 
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thereby indicating their suitability for use in gene expression studies (Bauer, et al., 2003; 
Setzer, et al., 2008; Zubakov, et al., 2009). Bauer et al., (2003) could detect 106 tested 
bloodstains stored up to 15 years at room temperature and protected from sunlight. 
More body fluids were assayed in a similar study by Setzer, et al., (2008). The authors 
reported the stability of RNA prepared from blood, semen, saliva and vaginal secretion 
that were exposed to a range of environmental conditions (light sources, temperature, 
and exposure to rain) over a period of 1-547 days. For each type of body fluid, total RNA 
quantitation and reverse transcriptase polymerase chain reaction (RT-PCR) using seven 
different tissue-specific and a reference gene mRNA transcript monitored the stability 
of RNA. mRNA detection varied across each sample based on the effect of 
environmental conditions. Samples protected from direct rain impact displayed 
detection up to 180 days; those exposed to direct rain were only detected up to 7 days 
while mRNA was detected in only a few samples stored at room temperature for at least 
547 days. In a similar study using different sets of markers, Zubakov, et al., (2009) also 
reported identification of blood and saliva stains stored under ambient temperature 
(away from dust and humidity), for up to 16 years and saliva samples stored up to 6 
years.  
1.4 Applications of RNA in Forensic Science 
Gene expression patterns of mRNA have also been utilised in forensic science in many 
areas that are discussed below.  
1.4.1. Determination of circumstances leading to death 
It is essential to diagnose the cause of death by careful examination of both functional 
and morphological variations that occurred in cells shortly before the time of death. 
Bauer, (2007) reported that though most circumstances leading to death do not reveal 
morphological changes within the cells of a tissue; the functional quality in the cell’s 
mRNA pattern is, however, affected. Consequently, the cell responds rapidly, thus 
leading to a change in proportions of specific mRNAs due to the effects of external 
factors on the body (Vennemann, and Koppelkamm, 2010). Different gene expression 
patterns were observed in various types of death depending on the markers evaluated 
(Matsuo et al., 2009; Takahashi, 2008). Ikematsu et al., (2006) established that post-
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mortem gene expression activities continue for at least 30 minutes after death. In their 
study, the authors investigated gene expression patterns of four candidate markers in 
mouse skin cells that were killed by either decapitation or compression of the neck. The 
markers in these two groups could differentiate the nature of death in the experimental 
rats, which indicated their possibility of use in decapitation or compression of neck-
related deaths. Also, Takahashi, (2008) described mRNAs for catecholamine biosynthetic 
markers in adrenals and anterocervical ganglia of mice as potential candidates to 
determine acute response to contusion stress. Furthermore, methamphetamine-
related-deaths were investigated by Matsuo et al., (2009) where the authors studied 
immediate early genes (IEGs) which are expressed almost immediately after death in the 
mouse heart over a period of 4 weeks. Similarly, hypoxia-inducible factor 1 (HIF-1), 
erythropoietin (EPO) and vascular endothelial growth factor (VEGF) have been described 
by Zhao et al., (2006) as robust mRNA transcripts in the kidney which could predict cause 
of death due to hypoxia. All these studies have established the possibility of determining 
the nature of death by monitoring the expression patterns of various gene transcripts.  
1.4.2 Biological stain age determination of samples 
The ability to determine the age of a biological stain can give an indication of the time a 
crime was perpetrated. Many studies have been carried out on approximate age of stain 
determination. Early methods included the use of HPLC chromatographs to measure 
alpha chain area relative to heme area in blood (Inoue et al., 1991; Inoue et al. 1992). 
These studies displayed a linear decrease in the alpha/heme area ratio as the stain age 
increased. Although the results obtained indicated a direct correlation between the age 
of stain and haemoglobin deterioration, no similar sets of markers have been found for 
other forensically relevant body fluids. However, recent studies have focused on 
monitoring mRNA degradation to determine the approximate age of a biological stain. 
Bauer et al., (2003) reported the identification of dried bloodstains using semi-
quantitative duplex and competitive RT-PCR. In their experiment, blood samples were 
stored protected from sunlight at room temperature for up to 5 years. The effect of 
storage condition was examined in samples exposed to direct light, humidity and tubes 
containing EDTA over a period of 2 months to 2 years (Bauer et al., 2003; Anderson et 
al., 2005). They observed a significant correlation between RNA degradation and storage 
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interval; and this was reported for use as a possible indicator of age of stains. 
Subsequently, Anderson et al., (2005) further described age of bloodstains identification 
using real-time RT-PCR. The authors showed that β-actin mRNA and 18S rRNA exhibited 
a linear change in ratio in dried human blood samples analysed over a period of 150 days 
under controlled conditions. These two transcripts were selected as they were widely 
acknowledged reference genes, and their RNA transcripts were likely recovered from 
any cellular material deposited at crime scenes. During the time course, a significant 
change in cycle threshold -Ct (cycle at which florescence signal crosses the threshold) 
value of β-actin but not 18 S was observed. Thus, there was an increase in relative ratio 
of 18S to β-actin over time. Using this phenomenon, the authors hypothesised that 
careful study of relative RNA ratios, which were consistent and predictable, could be 
used to determine the approximate age of bloodstains. In addition, since 18S and β-actin 
were broadly recognized as reference genes, the approach and analysis in this study 
might be useful for determining the approximate age of stains of other body fluids too. 
1.4.3 Wound age determination 
Wound-age determination is one of the key aspects in forensic pathology, especially in 
wound-related deaths. In humans and other animals, the skin shields the body against 
invasion from the surrounding environment, thereby making it susceptible to injuries 
(Masataka et al., 2008). In order to determine the approximate age of wounds, a 
detailed knowledge of heterogeneous composition of cutaneous repair is important 
(Guler et al., 2011). The mechanism of skin repair starts upon infliction of injury and this 
comprises three main phases viz inflammation, proliferation and maturation of newly 
formed tissues (Kondo, 2007). Early methods are still currently used to determine age 
of wounds include enzyme (phosphatase) activities and inflammatory cell dynamics 
(Betz, 1994; Hernandez-Cueto et al. 2000). However, with increased research and 
advance in technology, the use of mRNA markers has been reported (Masataka et al., 
2008; Guler et al., 2011; Takamiya et al., 2009; Palagummi et al., 2013). Takamiya et al., 
(2008) described the use of eight cytokines (interleukin (IL) 2, IL 4, IL 6, IL 8, IL 10, GM-
CSF, IFN γ, and TNF α) to assess wound age in human dermal wounds. The expression of 
these cytokines was monitored at the early, middle and late stages of wound healing 
and the results analysed using quantitative multiplex bead-based immunoassay. IL 6, IL 
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8, IFN γ, and TNF α were reported to be significantly expressed during wound healing 
and thus recommended as candidate markers in wound age determination. Further 
study carried out by Takamiya et al., in 2009 included nine more markers such as 
interleukin 1b (IL 1b), IL 5, IL 7, IL 12 p 70, IL 13, IL 17, granulocyte colony-stimulating 
factor (G-CSF), monocyte chemoattractant protein 1 (MCP 1), and macrophage 
inflammatory protein 1b (MIP 1b) which were together quantitatively monitored with 
the former eight cytokines. In this study, MCP1 was found to be most widely expressed. 
However, the authors proposed that quantitative analysis of all these markers combined 
could enhance the precision of age of wound determination. The relevance of tenascin 
and ubiquitin in wound age estimation have also been reported in wound age over 40 
days (Guler et al., 2011). Various types of wounds ranging between gunshot, blunt 
injuries, sharp weapon injuries and medical incisions were studied. While tenascin was 
negative in wounds over 40 days, ubiquitin was still observed in the fibroblasts. The 
expression of tenascin & ubiquitin was consistent irrespective of wound types. The 
authors concluded that semi-quantitative evaluation of both markers together would 
aid in estimating the age of the wound. 
1.5 Environmental insults on sample degradation 
Most forensic samples are usually recovered in environmentally compromised state. 
These are due to the effects of temperature, humidity and ultraviolet radiation (Barbaro 
et al., 2008; Lund and Dissing, 2004; McNally et al., 1989). In theory, DNA degrades 
rapidly, especially when exposed to extreme temperatures and absolute humidity. 
However, Lund and Dissing (2004) reported the stability of DNA in stains after they were 
exposed to 35 0C - 65 0C and 100% relative humidity. Although, the authors noticed a 
decrease in amplification of a few stains, which they reported to be because of microbial 
growth. Most of the samples, especially long DNA fragments were still reported to be 
amplifiable after being exposed over a month. A similar study was reported by Barbaro 
et al., (2008) where the effects of high temperature was investigated on DNA typing 
from blood, saliva and semen. The temperature range included 50 0C - 200 0C. The 
authors established that it is possible to type these three body fluids with success after 
exposure to harsh conditions, although, they recommended analysis of mini STRs for an 
improved result. Fordyce et al., (2013) in a recent study further explained the changes 
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in cell activities that could be a factor to their stability upon exposure to environmental 
insults. They stated that cells are usually dehydrated because of high temperature and 
humidity. During this process, microorganisms’ and RNases’ activities are inhibited, 
which in turn shields the nucleic acids from degradation. Furthermore, the presence of 
stronger N-glycosidic bonds and depyrimidation process in RNA molecules enables them 
resist hydrolytic depurination and prevention of phosphodiester bond hydrolysis. These 
were reported to be possible reasons why successful RNA/DNA typing could still be 
achieved upon sample degradation due to exposure to environmental insults. 
1.6 Micro RNAs (miRNA) 
MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules (usually 18-24 
nucleotides) which play an essential regulatory role for many cellular processes.  Due to 
their relatively small size, they have been reported to be invaluable in molecular studies, 
especially in forensic body fluid identification where recovery of aged and 
environmentally compromised samples are common occurrence. These molecules were 
first described by Lee et al., (1993) and to date, more than 700 miRNA markers have 
been discovered (Bentwich et al., 2005; Berezikov et al., 2005). miRNAs have been 
reported in embryonic development, cell proliferation and tumorigenesis and human 
disease studies such as cancer and viral infections (DeVincenzo et al., 2010; Aten et al., 
2008). Hanson et al., (2009) assessed the expression of 452 human miRNAs in dry 
semen, blood, saliva, vaginal secretion and menstrual blood. They reported most of the 
452-human miRNA to be expressed in more than one body fluid or not expressed at all. 
This led to further screening of the miRNA transcripts and development of a 9-marker 
assay (miR451, miR16, miR135b, miR10b, miR658, miR205, miR124a, miR372, and 
miR412). The assay was reported to be highly sensitive and allowed the identification of 
blood, semen, saliva, vaginal secretions, and menstrual blood— with a minimum of 50pg 
total RNA input (Hanson et al., 2009). Furthermore, specificity of the panel was studied 
and the researchers were able to distinguish each body fluid from other human tissues. 
Following the initial screening and enhancement of the specificity and sensitivity of the 
assay, the authors further assessed more miRNA (1198) transcripts and their expression 
in blood, semen, saliva, vaginal secretion and menstrual blood. Thirteen novel miRNA 
markers were identified with five from the initial assay, bringing the total number of 
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markers in the new assay to 18. In addition, a binary logistic regression statistical model 
that could provide exact indication of the presence of a forensic body fluid was 
developed. This assay, together with the statistical model, was reported to be specific 
in distinguishing forensically relevant body fluids of interest from other human tissues 
tested.  
1.7 mRNA Based Identification of Body Fluids  
Body fluids commonly encountered at crime scenes include blood, saliva, menstrual 
blood, vaginal secretion, and semen. Each body fluid is made up of unique cell types 
(Gaensslen, 1983; Greenfield and Sloan, 2003; Li, 2008) that have distinctive 
transcription and gene expression profiles. These distinctions are used to identify 
forensically relevant body fluids, especially in casework samples. Previously, studies of 
body fluid identification techniques have been limited on casework samples possibly 
due to limited sample recovery, lack of definitive assay to identify the body fluids and 
the impression that tissue identification might not be important to the case (Hanson and 
Ballantyne, 2013). Nonetheless, with advance in technology and ability to co-extract 
DNA and RNA, a few of these challenges have been curtailed (Alvarez et al., 2004; Bauer 
and Patzelt, 2003). 
Currently, body fluid identification is still being carried out using traditional serological 
methods; Saliva Phadebas amylase test, semenogelin test for semen (which involve the 
use of membrane strip test to identify human semenogelin), and 
tetramethylbenzinidine, Rapid Stain Identification (RSID) test for blood (Hedman et al., 
2008; Pang et al., 2007; Garner, et al., 1976). These methods are non-specific for human 
samples, presumptive and enzyme based.  The techniques rely on basic colour change, 
which further requires a confirmatory test to analyse. Although they are still being used, 
their robustness is compromised when body fluids are mixed and contaminated – a 
scenario in which most forensic samples are recovered.  
In addition to body fluids, skin cells are mostly left by the unsuspecting perpetrator of a 
crime and by the victims as well on various substrates. The recovery of skin cells from a 
crime scene could indicate the perpetrator’s presence or contact with the crime scene. 
Previously used methods to identify skin cells include dactyloscopic fingerprint analysis 
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and other microscopic and immunological techniques (Lindenbergh et al., 2012). These 
methods were not ideal as they were not applicable to all cell types (Schulz, et al., 2010); 
could introduce contamination into the reaction (Van Hoofstat et al., 1999) and were 
reported to have adverse effects on the nucleic acids in the skin cells (Grubwieser et al., 
2003). 
Modern and alternative methods used to identify body fluids and skin cells have been 
reported and they include immuno-histochemical methods, Raman spectroscopy 
(Virkler and Lednev, 2008; Virkler and Lednev, 2010), miRNA and mRNA analysis 
(Alvarez, et al., 2004; Hanson et al., 2009; Haas et al., 2015). 
Recently, there has been increased research into the use of mRNA which could usher an 
era of replacement of traditional methods of body fluid identification with such methods 
(Courts and Madea, 2010; Mara et al., 2012). This is due to the advent of automated 
technologies, ability of mRNA markers to identify broad spectrum of body fluids and also 
to simultaneously detect different body fluids through multiplex PCR systems 
comprising of mRNA markers (Juusola and Ballantyne, 2007; Haas et al., 2009; Juusola 
and Ballantyne, 2005). 
mRNA techniques also  offer the potential of  co-extraction of both DNA and RNA 
(Alvarez et al., 2004; Bowden et al., 2011; Chevillard, 1993; Triant and Whitehead, 2009; 
Xu et al., 2008), thus increasing the possibility to independently carry out DNA and RNA 
profiling, especially when samples with limited biological materials are recovered 
(Alvarez et al., 2004; Bauer et al., 2003). Most importantly, decreased sample 
consumption and higher body fluid specificity give mRNA body fluid identification 
techniques an advantage over traditional methods (Juusola and Ballantyne, 2003). 
Sufficient quality and quantity of mRNA have been recovered in samples stored up to 15 
years (Bauer et al., 2003), 16 years (Zubakov et al., 2009) and 23 years (Kohlmeier and 
Schneider, 2012), despite the challenging presence of RNAses’ in the environment and 
storage conditions. Until multiplex PCR assays were developed, single-gene-based 
assays were used to study body fluid specific mRNA markers (Bauer, 2007; Juusola, and 
Ballantyne, 2005; Setzer et al.,  2008; Bauer and Patzelt, 2003; Ferri et al., 2004). 
Subsequently, more markers were discovered and multiplex PCR assays were enhanced 
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(Haas et al., 2011; Haas, et al., 2012). Roeder and Haas, (2013) also reported a recent 
and comprehensive study, where the authors investigated the detection of body fluids 
utilising a minimum of five mRNA markers for each body fluid. 
In all the above-mentioned mRNA body fluid identification studies, the markers reported 
were selected based on high expression in specific body fluids. Ideally, a single marker 
should detect the presence of a body fluid. However, physiological conditions, as well as 
the impact of environmental factors, could lead to significant variations in mRNA 
expression patterns. With much variability, false positive and negative results, including 
the possibility of one of the markers dropping out, cross reactivity with body fluids other 
than the target body fluid, the use of multiple markers have been recommended for 
forensic body fluid identification (Lindenbergh et al., 2012; Juusola and Ballantyne, 
2005). 
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Table 1.2: Body fluids and tissues based mRNA markers currently used for their 
identification in human materials 
Blood Saliva Vaginal 
secretion 
Semen Menstrual 
blood 
Skin Mucosa 
HBB  
CD93 
AMICA1 
β- 
Spectrin 
SPTB  
ALAS2 
PPBP 
 HBA  
PBGD 
 CD3G 
ANK1 
AQP9 
GlycoA 
PRF1 
PF4 
 
FDCSP 
PRB1 
PRB2 
PRB3 
STATH 
HTN3 
SMR3B 
PRB4 
MUC7 
HBD1 
MUC4 
MSLN 
SFTA2 
FUT6 
DKK4 
MYOZ1 
CRYP2B7P1 
Lactobacillus 
gasseri 
Lactobacillus 
crispatus 
     ESR1 
L. jen 
 
SEMG1  
PRM1 
 PRM2 
 TGM 4 
 MSMB 
 KLK3  
MCSP 
MMP7  
MMP11 
 MMP10 
MSX1 
SFRP4 
LEFTY2 
Hs202072e 
LOR 
 CDSN 
 KRT 9 
KRT4 
SPRR2A 
KRT13 
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1.8 New techniques to identify forensic body fluids  
Unlike the traditional methods of body fluid identification, several new techniques have 
emerged recently. Although, many of these are still in their early stages of use, however, 
they have been reported to be robust in unambiguous identification of forensic body 
fluids. 
1.8.1 RNA Suspension Fluorescent in Situ Hybridization (RNA S-FISH) 
RNA Suspension Fluorescent in situ hybridization, a technology that aids specific regions 
of nucleic acids to be detected in situ, is a new method of body fluid identification 
proposed by Williams et al., (2013) and Williams et al., (2014) using locked nucleic acid 
probes (LNA). The method had been earlier reported by Vandewoestyne et al., (2009) 
to distinguish male cells in male and female sample mixtures. FISH has also been 
described in embryo development (Arvey et al., 2010), and molecular cytogenetic 
studies (Lourov et al., 2005). Williams et al., (2013) described a RNA suspension FISH 
(RNA S-FISH) to label epithelial cells. The authors designed and optimised locked nucleic 
acid probes (LNA) for KRT10 mRNA (present in vaginal and buccal epithelial cells) in fresh 
and aged samples. Leucocytes were utilised as a control for the KRT10 specific probes. 
As expected, fluorescent signals were observed for the KRT10 transcript and were 
reported to be expressed in buccal and vaginal epithelial cells but not in leucocytes 
(control). In addition, KRT10 signals were detected in their 10-month-old samples stored 
at room temperature. Furthermore, the authors investigated the possibility of 
generating DNA profiles from 150 buccal and vaginal RNA S-FISH labelled cells. Full DNA 
profiles were reported for the 150 fresh cells that were RNA S-FISH labelled. However, 
there was a significant decrease in peak heights between RNA S-FISH treated and 
untreated cells in both aged and fresh samples. This was suggested and it was due to 
likely degradation of DNA or PCR inhibition. To circumvent this, the authors 
recommended the use of more epithelial cells to generate a full DNA profile, whenever 
casework samples are to be analysed.  
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1.8.2 Next generation sequencing (NGS) 
Next generation sequencing (NGS) is gradually gaining popularity in forensic science, 
especially in body fluid identification. With this new technology, Ogawa et al., (2013) 
reported detection of miRNA markers in two different exosomes found in whole human 
saliva. Exosomes are membrane bound vesicles, originating from most living cells. They 
have been described to comprise proteins, lipids, RNAs, non-transcribed RNAs, 
microRNAs and small RNAs, which are peculiar to their cells of origin and thus can be 
used in their identification. Exosomes and markers derived from them have been 
reported to be viable in oral cancer (Li et al., 2004) and ovarian cancer diagnoses (Beach 
et al., 2014), although this was not done with NGS. With saliva being among body fluids 
commonly encountered at crime scenes, Ogawa et al., (2013) described using NGS, the 
identification of 81 novel miRNA markers from exosomes I, II and whole human saliva. 
RNA was isolated from exosomes I, II and whole saliva and transcribed to cDNA. The 
cDNA was then sequenced using NGS; and 143 miRNA markers and other RNAs (piRNA, 
snoRNA) were discovered from both exosomes and whole saliva. Eighty-one miRNA out 
of these were reported to be novel, with 10 found to be mostly expressed in whole saliva 
and both exosomes II and I. These markers were proposed to be useful in biomarker 
research. Though there has been no report of a similar study with other body fluids, 
further optimization and validation of these miRNA markers could be a gold standard in 
saliva identification, especially when most importantly, when degraded samples are 
encountered (Harbison and Fleming, 2010; Roeder and Haas, 2013; Fleming et al., 2013; 
Paterson et al., 2006; Jakubowska et al., 2013).  
Lin et al., (2015) described NGS methods as a useful technique to identify degraded 
forensic body fluids. Whole transcriptome sequencing (cDNA) of four body fluids 
(menstrual blood, vaginal secretion, oral mucosa/saliva and circulatory blood) that were 
aged two to six weeks was carried out. The RNA integrity was measured based on RNA 
integrity (RIN) score that was assessed throughout the time course of the experiment. 
In order to distinguish the body fluids, specificity and sensitivity was determined using 
fragments per kilobase of exon per million fragments mapped (FPKMs) values of the 
RNA transcripts (GYPA, MMP11, STATH, HTN3, UBE 2D2, TCEA1, G6PD) assayed. TopHat 
and Cufflinks analysis software (a tool for gene discovery and comprehensive analysis) 
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were used to generate FPKM values (Trapnell et al., 2012). The authors reported that 
the FPKM values for body fluid specific markers corresponds to the target body fluid 
thus leading to their identification.  
1.8.3 Multiplex high resolution melt (HRM) mRNA analysis 
Another new and promising technique using a molecular approach (mRNA) to identify 
forensically relevant body fluids is the multiplex high resolution melt (HRM) analysis 
proposed by Hanson and Ballantyne in 2014. As current body fluid identification assays 
are capillary electrophoresis (CE) or quantitative RT-PCR (qRT-PCR) based. These authors 
were prompted to design a better analysis technique that is aimed at reducing the cost 
and time of analysis, which are both fundamental factors in CE and qRT-PCR, based 
assays. Previously, HRM has been reported for single nucleotide polymorphism (SNP) 
typing (Reed et al., 2004), mutation and methylation analysis (Worm et al., 2001), and 
copy number variant confirmation (Aten et al., 2008). Post RNA isolation and cDNA 
synthesis, the technique was reported by the authors to require unlabelled PCR primers 
in addition to intercalating fluorescent dye (Eva green). The amplimers were slowly 
melted after amplification by increasing the temperature of the reaction medium. This 
generated fluorescent signals with the release of the bound dye into the solution.  Each 
marker was thus identified based on the unique melt curve (peak) generated. In this 
study, single and multiplex assays were developed for forensically relevant body fluids -
vaginal secretion, blood, menstrual blood, and semen. The assay had the capacity to 
distinguish each body fluid. However, some artefacts were reported for the 
semen/saliva assay. The authors suggested further optimization and/or replacement of 
these primers with more specific ones that would thus lead to unambiguous 
identification of the body fluids. Upon adequate validation and optimisation, the 
authors recommended the assay was a robust mRNA-based identification of body fluids, 
and a relatively cheaper alternative to CE and qRT-PCR based techniques.  
1.8.4 Matrix-assisted laser desorption/ionization-time of flight mass 
spectrometry (MALDI-TOF MS) 
This technique had been successfully utilised in nucleic acid research ranging from short 
tandem repeats analysis (STRs) (Krebs et al., 2001); single nucleotide polymorphisms 
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(SNPs) detection; pharmacogenomics (Pusch et al., 2002); and DNA/RNA sequencing 
(Edwards et al., 2005). In order to establish an alternative method of mRNA/cDNA 
analysis of body fluid, while conserving time and cost of analysis, specifically in CE and 
qRT-PCR based methods where fluorescent dyes are used; Donfack and Willey, (2015) 
proposed a mass spectrometry based method (MALDI-TOF MS) which is useful in 
identifying body fluids. This is the first study that investigated the use of MALDI-TOF-MS 
to identify body fluids. The authors reported the technique to be based on the principles 
of single base primer extension assay with modified terminators as described by Oeth 
et al., (2006). Primer (ALAS2, HBB, SPTB, HTN3, STATH, KRT16, KLK3, SEMG1, TGM4, 
B2M, GAPDH, and HMBS) specificity and sensitivity were tested in venous blood; semen 
and saliva with the body fluids were accurately identified with no cross reactivity 
observed. In addition, B2M (a reference gene used as a positive control) displayed a 
stable expression across the three body fluids tested. With 19 assays designed for this 
study, the authors recommended further study on other forensically relevant body 
fluids with adequate optimization, and validation of the assays. Besides, inclusion of 
more body fluid specific markers as proposed by the authors would likely increase the 
suitability of the assay as it could accommodate up to 36 plex. 
1.9 Use of Reference Genes in mRNA Based Body Fluid Identification 
Reference genes are constitutive genes that carry out maintenance of basic metabolic 
functions in a cell. Irrespective of the cells patho-physiological conditions (Butte, 2001; 
Pfaffl et al., 2004). They were expected to be uniformly expressed. These unique 
characteristics make them ideal for use in calibration and normalization studies 
(Vandesompele et al., 2002). Similarly, they were utilised as internal controls for some 
experimental studies (Robinson and Oshlack, 2010; Dheda et al., 2004; Rubie, 2005). The 
use of reference genes has been extensively described in studies that involve qRT-PCR 
and capillary electrophoresis (CE) (Lindenbergh et al., 2012; Roeder and Haas, 2013).  
Most body fluid identification assays using miRNA/mRNA attempt to incorporate them, 
as they were required as endogenous controls and for adequate normalisation of non-
biological variances, which may include variations in sample loading, sample-to-sample 
variation and PCR efficiency. Their use could ascertain whether mRNA/miRNA had been 
successfully isolated from samples and validate true negatives. Usually the expression 
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of the target gene is compared to the reference gene, which thus aids the normalisation 
of data generated. Sauer et al., (2014) in a recent study, assessed a panel of 13 reference 
genes (hsa-miR-93-5p, hsa-miR-191-5p, RNU6-1, RNU6-2, SNORA66, SNORA74A, 
SNORD7, SNORD24, SNORD38B, SNORD43, SNORD44, SNORD48 and SNORD49A) and 
investigated their suitability for use on saliva, venous blood, vaginal secretion, menstrual 
blood and semen. Expression of the markers in dry samples, mixtures was assayed, in 
addition to examining biological variation using five individual samples for each body 
fluid. GenEx software, which comprises geNORM and Normfinder algorithms, was used 
to select the reference genes. The authors reported SNORD24, SNORD38B and SNORD43 
to be most stable across all the body fluids and, thus, recommended them for 
normalisation of qRT-PCR data analysis of forensic body fluids. Other reference genes of 
mRNA transcripts have also been reported (Dheda et al., 2004, Pohjanvirta, et al., 2006). 
Different researchers have outlined fundamental criteria in their choice of reference 
genes, based on their reported use in other studies. Though most experiments involving 
CE or qRT-PCR tend to have an identical sequence of workflow, however, the 
characteristics being investigated vary. With this in mind, it is worthy to note that the 
choice of a reference gene for any study should not be based on its traditional use in 
other studies but on adequate validation for the intended study (Meller et al., 2005). 
Furthermore, since an ideal  single reference gene capable of possessing all the required 
characteristics does not exist (Vandesompele et al., 2002; Pohjanvirta et al., 2006), and 
use of multiple reference genes has been proposed for normalization of mRNA/miRNA 
expression studies such as in body fluid identification (Sijen, 2015). Commonly used 
reference genes in forensic body fluid identification are listed in Table 1.3. 
1.10 Contact Traces 
Skin cells are mostly left by unsuspecting perpetrators of a crime and by the victims. The 
recovery of skin cells from a crime scene can give an indication of the presence of 
contact DNA. Previously, used methods to identify skin cells include dactyloscopic 
fingerprint analysis and other microscopical and immunological techniques 
(Lindenbergh et al., 2012). These methods were not ideal as they do not apply to all cell 
types (Schulz et al., 2010). However, they can introduce contamination into the reaction 
(Van Hoofstat et al., 1999) and they were reported to have a degradative effect on the 
24 
 
nucleic acids in the skin (Grubwieser et al., 2003).  A recent development to circumvent 
this was reported by Visser et al., (2011), Lindenbergh et al., (2012) and Hall et al., 
(2013). These authors reported the use of mRNA markers in multiplex reactions to 
identify skin cells. 
Table 1.3: Names of markers and sequences of PCR primers for currently used 
reference genes for forensic body fluid identification 
Marker 
names 
Forward primers (5’-3’) Reverse primers 5’-3’ References  
18S 
rRNA 
CTC AAC ACG GGA AAC CTC AC CGCTCC ACC AAC TAA GAA CG (Lindenbergh 
et al., 2012; 
Fleming, 
2010) 
ACTB TGA CCC AGA TCA TGT TTG AG CGT ACA GGG ATA GCA CAG (Lindenbergh 
et al., 2012; 
Ghani et al., 
2013) 
B2M GGCATTCCTGAAGCTGACA AAACCTGAATCTTTGGAGTACG (Hanson and 
Ballantyne, 
2013a; Ghani 
et al., 2013) 
OAZ1 GGATCCTCAATAGCCACTGC TACAGCAGTGGAGGGAGACC 
 
(Hendrik et 
al., 2007) 
RPS29 GCACTGCTGAGAGCAAGATG 
 
ATAGGCAGTGCCAAGGAAGA  
S-15 TTC CGC AAG TTC ACC TAC C CGG GCC GGC CAT GCT TTA CG (Juusola and 
Ballantyne, 
2003) 
β-Actin TGA CGG GGT CAC CCA CAC 
TGT GCC CAT CTA 
CTA GAA GCA TTT GCG GTG 
GAC GAT GGA GGG 
 
TEF 
 
TGG GCC ATC AAC TGA GAA 
AGA 
TCT CCC TAC ACT TCA ACT GCA 
CA 
(Fleming, 
2010)  
GAPDH ATC ATC GTG GAG AAG CCC 
TTC 
 
GTT CCA GAT GGG GCC GA 
 
(Lindenbergh 
et al., 2012; 
Park et al., 
2013) 
UCE AAT GAT CTG GCA CGG GAC C ATC GTA GAA TAT CAA GAC AAA 
TGC TGC 
(Fleming, 
2010) 
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1.11 Methods involved in mRNA Profiling 
Messenger RNA profiling follows an identical workflow as DNA profiling. The key stages 
include RNA isolation (Figure 1.2) and purification, quantitation, reverse transcription, 
polymerase chain reaction and capillary electrophoresis. 
1.11.1 RNA extraction 
RNA can be isolated from cell, tissues or organs of living organism. There has been 
reports of RNA isolation from materials that had come in contact with a human e.g. 
cigarette butts, can of drinks, clothing etc. (Zubakov et al., 2009; Bauer et al., 2003, 
Kohlmeier et al., 2012). When isolating RNA, adequate care need to be taken to avoid 
DNA contamination. Few of the available extraction kits in this process include mirVana 
(Thermo Scientific (UK) Ltd), RNeasy mini plus kit (Qiagen Ltd), and guanidine 
isothiocynate-phenol chloroform (Thermo Scientific (UK) Ltd). All these studies are in 
similar manner with tissue lysis and homogenisation, genomic DNA (gDNA) elimination 
and silica membrane binding of RNA from lysed cells. Further purification includes the 
use of Turbo DNA-free kit (Thermo Scientific (UK) Ltd) or on-column DNase treatment 
(Qiagen Ltd). RNA degrades rapidly compared to DNA by ubiquitous ribonucleases 
(Bauer et al., 2003; Setzer et al., 2008). To circumvent this process, the isolated RNA is 
normally stored at -80 0C to stop all enzymatic activities, or converted to complementary 
DNA (cDNA) through reverse transcription and stored at -20 0C for further use. 
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Figure 1.2: Schematic representation of stages involved in RNA isolation from cells and tissues. 
(www.sigmaaldrich.com. Accessed 03/14/16). 
1.11.2 RNA quantitation and reverse transcription 
It is important to know the quantity of RNA present in a given sample, especially where 
the downstream use of RNA involves sample normalisation studies (Vandesompele et 
al., 2002). This is special to prevent overload of samples, which may result in PCR failure. 
Popular quantitation kits and equipment include Quant-IT RNA assay kit (Molecular 
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probes, Eugene); Qubit fluorometer (Thermo Scientific (UK) Ltd) and NanoDrop 2000c 
UV-Vis spectrophotometer (Thermo Scientific, Wilmington, DE). 
Further, RNA can be converted into complementary DNA (cDNA) through reverse 
transcription. cDNA is stable and can be stored at 4 ℃ for further use. 
1.11.3 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is an enzymatic amplification of a specific region (loci) 
of DNA, to produce several million copies of the target region. It was first reported in 
the nineteen-eighties by Saiki et al., (1985) and Mullis and Faloona, (1987). Initially, 
single regions of DNA were targeted but soon, multiplex PCR, which is the enzymatic 
amplification of two or more target sequence (loci) was evolved (Kimpton et al., 1993; 
Edwards and Gibbs, 1994). These suited forensic genetics as minute amounts of 
template DNA could be studied for multiple loci in a single reaction. The technique also 
reduced cost and labour of analysis. PCR amplification takes place in the presence of 
reaction components such as magnesium chloride, DNA polymerase, deoxynucleotide 
triphosphates (dNTPs), PCR primers and template DNA. During a specific thermal cycling 
process that allows the PCR primers to anneal and extend, copy number increases 
exponentially (Garcia and Ma, 2005; Ruijter et al., 2009). Successful amplification 
requires adequate optimisation of the PCR cycling parameters, especially annealing 
temperature as this allows the primer pairs to bind specifically to the complementary 
DNA sequence (Garcia and Ma, 2005) and primer concentrations to compensate for 
varying amplification efficiencies (Butler et al., 2001). In addition, the number of cycles 
is a critical parameter that needs to be optimised; most reactions tend to show optimum 
amplification at 30-33 cycles.  
1.11.3.1 Endpoint PCR and Real-time PCR 
Endpoint PCR is a biochemical technique whereby a single or multiples copies of DNA is 
amplified to generate several thousand or millions of a specific DNA sequence. It is 
carried out either in one-step or two-step. One-step PCR technique combines both cDNA 
synthesis and PCR in a single reaction, thereby simplifying reaction setup, for easy 
processing. In addition, possibility of carry over contamination is minimised, as the tube 
is usually not opened between synthesis and amplification stages. Its usage is slightly 
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limited as it permits only sequence-specific primers (Wacker and Godard, 2005). Two-
step PCR, however, involves reverse transcription of RNA into cDNA in the presence of 
reverse transcriptase, followed by transferring the cDNA into a different tube for PCR. It 
is advantageous over one-step PCR in that it gives the flexibility of both primer (oligo 
(dT), random hexamers or gene-specific primers) and DNA polymerase choice 
(www.thermofisher.com). The final PCR product from both steps can then be visualised 
on gels under UV light (for unlabelled primers) or genetic analysers using fluorescently 
labelled primers (See Figure 1.3) 
 
Figure 1.3: Schematic representation of exponential amplification that occurs during PCR 
(Drawn by hand). 
1.11.3.2 Real-time PCR 
Unlike end product PCR, real-time PCR allows amplification and profile efficiency to be 
studied ‘real-time’ at each cycle of amplification as reaction progresses. This increases 
the possibility of precise measurement of the amount of amplicons at each cycle, which 
in turn enables accurate quantitation of the amount of starting materials in samples 
(Deepak et al., 2007, Real-time PCR handbook, Thermofisher Scientific Ltd). The 
invention of PCR technology by Mullis and Faloona, (1987) led to the discovery of real 
time PCR that has since then witnessed a significant revolution in its usage. Its 
application has cut across many fields of study such as cancer, bacteriology in veterinary 
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and medical science; plant species identification, food microbiology and forensic science 
(Deepak et al., 2007). Due to a rise in Reverse Transcriptase (RT-PCR), studies and data 
generated led to a guideline, which was developed by Bustin et al., (2009). This was 
referred to as the minimum information required for publication of quantitiative real-
time PCR Experiments (MIQE). The main aim of the guideline was to encourage 
consistency between laboratories, increase transparency in the RT-PCR experiments and 
highlight the minimum information that should accompany a RT-PCR experimental data 
to ensure its reliability for publication. These requirements are classified as either 
essential (E) or desirable (D) (see Bustin et al., 2009). 
Real-time PCR  technique makes use of two detection chemistries viz non-specific 
intercalating dyes (SYBR Green) or sequence specific probes (e.g. Hydrolysis/Taqman 
probes) (Monis et al., 2005; Kubista et al., 2006). SYBR Green chemistry due to its non-
specificity binds every double-stranded DNA (dsDNA) molecule in the reaction thereby 
reducing amplification efficiency. Sequence-specific probes, e.g. Taqman probes 
however, binds only specific sequence in the reaction medium, thus increasing 
amplification efficiency (Figure 1.4) 
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Figure 1.4: Schematic representation of SYBR Green and Taqman probes detection systems used 
in real-time PCR experiments. SYBR Green uses intercalating dyes while Taqman uses the probes 
(Adapted from PowerPoint presentation 07/12/2013, Thermofisher Scientific Ltd). 
 
  
31 
 
Reaction efficiency is calculated by the given formula: 
E = 10 (-1/slope) – 1. 
For a reaction slope of -3.32 reaction efficiency becomes 1 and this is given by the 
following equation:  
y = x (1+ E) n. 
When PCR efficiency is 100%, the template doubles after each cycle and the equation 
becomes: 
y = x 2n, 
Where:  
y = number of PCR products; 
x = initial target copy number; 
E = Efficiency and 
n = Number of PCR cycles (See Figure 1.5). 
 
Figure 1.5: A typical A typical graph of Ct values; Log copy number; near 100% efficiency and 
slope of a real-time PCR reaction. A slope of -3.32 signifies an approximate 99.5% efficiency. 
(Taken from Life Technologies training PowerPoint presentation, November, 2013).   
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An amplification plot is generated and captured by a florescent detector in a real-time 
PCR equipment e.g. ABI 7500 (Thermo Scientific (UK) Ltd). Florescent signal increases 
with product. Unlike endpoint PCR, four main phases occur in real-time PCR: lag phase, 
exponential phase, linear and plateau phases. The lag phase is the first in real-time PCR 
amplification. PCR products increases, however, the florescence generated is too low 
for detection by the real-time PCR instrument. Most PCR efficiencies are attained at the 
exponential phase, which is also referred to as the geometric phase. All PCR components 
– dNTPs, primers, polymerase and template DNA are in abundance thus increasing PCR 
products generated, also, a direct proportion in signal to increase in PCR product is 
noticed. At the linear phase, one or more of the PCR components is being used up; this 
in turn decreases reaction amplification. A further decrease in amplification is noticed 
at this phase. The plateau phase is the final phase in real-time PCR where no more 
amplification is noticed because of all reaction components being used up. Florescence 
detection stops at this stage (Figure 1.6).  
 
Figure 1.6: A screenshot of lag, exponential, linear and plateau phases - four main phases of real-
time PCR experiments (as seen on ABI 7500 (Taken from Thermo Scientific (UK) Ltd) compared 
to end-product PCR visualization on agarose gels   
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Ideally, initial cycles 3-15 display an amplification with little or no florescence signal; this 
is referred to as the baseline. For the purpose of clarity, amplification signal needs to be 
differentiated from the ‘background noise’ and therefore, a threshold is set above the 
baseline. This is where signal level is statistically significant. A cycle threshold (Ct) is the 
cycle at which florescence signal crosses the threshold. Rn is the value of reported signal 
divided by reference signal (Figure 1.7). 
 
Figure 1.7: A figure showing various terms used in real-time PCR experiments; Ct values, 
threshold and baseline (Taken from Thermo Scientific (UK) Ltd).  
Cycle threshold is inversely proportional to the amount of template added to the 
reaction. A high amount of template DNA in a reaction will result in low amplification 
cycle and vice versa. This principle enables DNA samples to be effectively quantitated 
using calibration curve of Ct value against the logarithm of initial DNA concentration 
(Kontanis and Reed, 2006; Wong and Medrano, 2005). Standard curves are generated 
from dilution series of known templates and are used to determine the amount of target 
DNA samples. In real time PCR experiments, amplifications are quantified either 
absolutely or relatively. An absolute quantitation makes use of dilution series of known 
templates to generate a standard curve; unknown templates are then quantified based 
on the standard curve generated. Relative quantitation however occurs when the 
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expression of a specific gene of interest (e.g. in treated samples) is compared to the 
same gene in untreated samples.  
The use of taqman probes is preferred to SYBR Green for real time PCR experiments 
because of its specificity, less concerns about primer dimer formation, flexibility of 
multiplexing, and minimal optimization requirement. Also, most manufacturers have 
made available millions of pre-developed assays; however, the overall technique can be 
cost effective. SYBR Green is cheaper compared to Taqman probes but less specific 
thereby creating a need for optimization. It does not have the flexibility of multiplexing 
and they are not pre-developed as found in Taqman probes. In most instances, there is 
always a need to run melt curves in order to increase specificity of reactions (Real-time 
PCR handbook, Thermofisher Scientific Ltd). At the end of PCR cycles, the temperature 
of the reaction is raised, this make the dsDNA molecule dissociate thus releasing the 
incorporated dye. Different PCR products can then be differentiated from common 
artefacts (Figure 1.8). 
 
Figure 1.8: Figure showing derivative view of melt curve without extraneous products and with 
non-specific products which may be artefacts. Melt curves are generated by an additional cycle 
with increase in temperature. This separates the specific and non-specific products. (Taken from 
Life Technologies training PowerPoint presentation, November, 2013). 
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In summary, due to increasing rates of crime which involve body fluids and advancement 
in technology, there has been an urgent need to develop new techniques to identify 
forensic body fluids. As stated earlier, the developed assays consist of markers that were 
reported with cross reactivity with non-target body fluids. This is a major concern in 
forensic body fluid identification study. The unambiguous identification of body fluids 
with no report of cross-reaction of non-target body fluids is a major focus of this study. 
1.12 Working Hypothesis 
An evaluation of genetic markers is of paramount importance for the identification of 
human body fluid. 
1.13 Research aims 
Most research on body fluid identification using mRNA makers have reported the use of 
reference genes and body fluid specific genes for various purposes, which range from 
normalization to calibration etc. However, reports from these experiments have 
indicated various cross-reactions of their assays with non-target body fluids, and did not 
indicate adequate optimization and validation of the genes used.  
Therefore, the aim of this project was to develop and validate a multiplex assay 
consisting of body fluid specific mRNA markers and reference genes, which could be 
used to identify various body fluids unambiguously.  
1.13.1 Research objectives: 
 To evaluate a minimum of 10 reference markers currently used in forensic body 
fluid identification studies. 
 To establish the primer efficiencies using SYBR Green chemistry. 
 To select the robust markers with 95-100% efficiency and analyze the selected 
markers using Hydrolysis/Taqman probes and selecting the best with minimal 
variation across the samples. 
 To validate the selected housekeeping genes using fresh and aged samples. 
 To develop an mRNA multiplex assay for semen, saliva, menstrual blood, vaginal 
secretion, and blood. 
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 To assess the integrity of RNA samples over a period under varying 
environmental conditions such as temperature, and ultraviolet radiations. 
 To validate the developed multiplex assay using SWGDAM guidelines, a criteria 
used in forensic genetics. 
 To assess the efficacy of the developed multiplex assay with the results in 
published literatures. 
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CHAPTER TWO 
 
 
GENERAL MATERIALS AND METHODS 
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2.0 General materials 
This section described the general materials and methods that were used in all 
experiments described in this thesis. Other specific methods peculiar to each study was 
described in relevant chapters. 
2.1 Reagents and consumables suppliers 
RNeasy Mini Plus kit       (Qiagen Ltd) 
Qiagen PCR multiplex mix     (Qiagen Ltd) 
RNase-Zap1       (Ambion, Austin, TX, USA) 
β- Mercapto ethanol (β-ME)     (Thermofisher Scientific 
Ltd) 
RNase-free water      (Thermofisher Scientific 
Ltd) 
Turbo DNA-free kit       (Thermofisher Scientific 
Ltd) 
SuperScript VILO MasterMix      (Thermofisher Scientific 
Ltd) 
XpressRef Universal RNA     (Qiagen Ltd) 
SuperMix Express SYBR GreenER qPCR    (Thermofisher Scientific 
Ltd) 
Taqman Gene Expression assay    (Thermofisher Scientific 
Ltd) 
TaqMan Universal PCR Master Mix    (Thermofisher Scientific 
Ltd) 
RNAse mix       (Thermofisher Scientific 
Ltd) 
Platinum PCR singleplex mix     (Thermofisher Scientific 
Ltd) 
Platinum PCR multiplex mix     (Thermofisher Scientific 
Ltd) 
1.5 ml microcentrifuge tube     (Starlabs (UK Ltd) 
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0.5 ml PCR tubes       (Starlabs (UK Ltd)) 
Propylene seal       (Starlabs (UK Ltd)) 
96-well PCR plate       (Applied Biosystems Ltd) 
2.2 Good Laboratory practice 
Adequate precautions were taken throughout the course of this study in order to 
guarantee quality results. Before commencement of any experiment, workbench and 
pipettes were cleaned with 70% ethanol and RNAse-Zap1  (Ambion, Austin, TX, USA). 
Dedicated lab coats for both pre and post-PCR labs, and disposable gloves were worn 
throughout the procedure.  Dedicated set of pipettes for RNA use and sterile filter tips 
were used to prevent cross-contamination. Unless otherwise stated, each batch of 
reactions was prepared on ice with both positive and negative control samples; all 
samples were run in duplicate. 
2.3 Health and Safety; Ethics 
All risk assessments, COSHH forms were completed before the commencement of lab 
work. Ethical approval was obtained from the Health, Safety and Ethics Committee of 
the University of Central Lancashire prior to sample collection and start of experiments 
(Appendix 1-2). 
2.4 Equipment calibration 
All major instruments used in this research was checked to ensure up-to-date 
calibration. Authorised personnel, usually a laboratory technician or a Field Engineer 
from the manufacturer carried these out regularly. Dedicated set of micropipettes used 
were sent to Star labs for calibration before the start of laboratory work. 
2.5 Sample collection 
Blood, saliva, semen, vaginal secretion and menstrual blood samples were collected 
from voluntary donors (recruited through poster advert) in the University of Central 
Lancashire, Preston, UK after an informed consent was obtained (Appendix 3). Blood 
sample was collected by two methods viz finger prick and by intravenous collection. For 
finger prick collection, the finger was cleaned with disinfectant wipes; a sterilized lancet 
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was then used to prick the finger. Blood was then collected on cotton swabs and left to 
dry at room temperature. Venous blood was collected into EDTA tubes without 
anticoagulant by a qualified phlebotomist within the University. The dry blood on sterile 
cotton swabs and those in EDTA tubes were then stored at -80 oC for further use. Saliva 
samples were collected using sterile cotton swabs and directly into 1.5 ml Eppendorf 
tubes. For cotton swab collection. The donors were encouraged to swab their inner 
cheek for at least 30 seconds before being left to dry at room temperature. A volume of 
20 µL aliquots were prepared for saliva collected in Eppendorf tubes before being stored 
frozen at -80 oC together with those collected on sterile cotton swabs. Semen was 
collected in 1.5 ml Eppendorf tubes and 20 µL aliquots were made before being stored 
frozen at -80 oC. Menstrual blood and vaginal secretion samples were collected on sterile 
cotton swabs. For vaginal secretion, donors were also encouraged to swab the vaginal 
until the cotton swabs becomes damp. Likewise, for menstrual blood, donors were 
encouraged to press the cotton swabs tightly against the sanitary pad that contains the 
menstrual blood. They were then advised to leave the samples to dry at room 
temperature before submission for storage. Both samples upon collection were then 
stored at -80 oC. Further details regarding sample preparation and storage have been 
highlighted in relevant chapters. 
2.5.1 Primer quality control 
Prior to primer order, Basic Local Alignment Search Tool (BLAST) was used to obtain each 
gene sequence in GeneBank® (www.ncbi.nlm.nih.gov) and to check species specificity. 
These were then ordered from Life Technologies (UK) Ltd and Eurofins Genomics Ltd 
(See Tables 2.1 and 2.2) 
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Table 2.1: Primer sequences of 10 reference genes used in Real-time PCR assays 
**Genes selected for Taqman probe design.  
Oligo 
names 
Forward sequences 5’-
3’ 
Reverse sequences 5’-3’ References 
TEF TGGGCCATCAACTGAGAAAG
A 
Hs01896387_g1, 
206bp** 
TCTCCCTACACTTCAACTGCACA (Fleming and 
Harbison, 2010; 
Roeder and 
Haas, 2013) 
ACTB TGA CCC AGA TCA TGT TTG 
AG 
Hs03023943_g1, 
75bp** 
CGT ACA GGG ATA GCA CAG (Ghani et al. 
2013; 
Lindenbergh et 
al., 2012) 
UCE AATGATCTGGCACGGGACC 
Hs00366152_m1, 
241bp** 
ATCGTAGAATATCAAGACAAATGCTGC (Fleming and 
Harbison, 2010; 
Roeder and 
Haas, 2013) 
B2M GGCATTCCTGAAGCTGACA 
Hs00187842_m1, 
120bp** 
AAACCTGAATCTTTGGAGTACG (Ghani et al. 
2013; Hanson 
and Ballantyne, 
2013) 
18S rRNA CTC AAC ACG GGA AAC CTC 
AC 
CGCTCC ACC AAC TAA GAA CG (Fleming and 
Harbison, 2010; 
Lindenbergh et 
al., 2012; Haas 
et al., 2009; 
Haas et al., 
2011).  
OAZ1 GGATCCTCAATAGCCACTGC TACAGCAGTGGAGGGAGACC 
 
(Hendrik et al., 
2007) 
S-15 TTC CGC AAG TTC ACC TAC C CGG GCC GGC CAT GCT TTA CG (Juusola and 
Ballantyne, 
2003) 
GAPDH ATC ATC GTG GAG AAG CCC 
TTC 
 
GTT CCA GAT GGG GCC GA 
 
(Virkler and 
Lednev, 2009; 
Jakubowska et 
al. 2013; 
Nussbaumer et 
al., 2006) 
β-Actin TGA CGG GGT CAC CCA CAC 
TGT GCC CAT CTA 
CTA GAA GCA TTT GCG GTG GAC GAT 
GGA GGG 
(Juusola and 
Ballantyne, 
2003) 
RPS29 GCACTGCTGAGAGCAAGATG 
Hs03004310_g1, 
213bp** 
ATAGGCAGTGCCAAGGAAGA (Heinrich et al., 
2007) 
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Table 2.2: Body fluid specific primer sequences: 
Markers Sequences (5’-3’) Sizes 
(bp) 
References 
PRM1 Fw: AGA CAA AGA AGT CGC AGA C 
Rv: TAC ATC GCG GTC TGT ACC 
91 (Lindenbergh 
et al., 2012) 
TGM4 Fw: TGAGAAAGGCCAGGGCG 
Rv: AATCGAAGCCTGTCACACTGC 
215 (Roeder and 
Haas, 2013) 
MSMB Fw: GGA GTT CCA GGA GAT TCA 
Rv: GTA GCA AGT GCA TGT CTC 
105 (Park et al., 
2013) 
NKX3-1 Fw: GTT GGA CTC TGA AAA CAC TTC 
Rv: GCC GAC AGG TAC TTC TGA 
144 (Park et al., 
2013) 
ALAS2 Fw: GCCAATGACTCTACTCTCTTCACCTTGGC 
Rv: GGAAGCATGGTTGCCTGCGTCTGAG 
81 (Roeder and 
Haas, 2013) 
PF4 Fw: GGTCCGTCCCAGGCACATCACCAGC 
Rv: CAGCGGGGCTTGCAGGTCCAAG 
124 (Roeder and 
Haas, 2013) 
STATH Fw: TTT GCC TTC ATC TTG GCT CT 
Rv: CCC ATA ACC GAA TCT TCC AA 
93 (Roeder and 
Haas, 2013) 
HTN3 Fw: GCA AAG AGA CAT CAT GGG TA 
Rv: GCC AGT CAA ACC TCC ATA ATC 
134 (Roeder and 
Haas, 2013) 
CRYP2B7
P1 
Fw: TCCTTTCTGAGGTTCCGAGA 
Rv: TTTCCATTGGCAAAGAGCAT 
198 (Hanson and 
Ballantyne, 
2013) 
L. 
crispatus 
Fw: GTATCCAGAGCAAGCGGAAGCACAC 
Rv: GCATCTCTGCATTGGGTTCCCCC 
267,30
5 
(Roeder and 
Haas, 2013) 
MUC4 Fw: CTG CTA CAA TCA AGG CCA 
Rv: AAG GGA AGT TCT AGG TTG AC 
141 (Lindenbergh 
et al., 2012) 
SFTA2 Fw: CGGGACTTCAGTGTCTCCTC 
Rv: TTCCAGGAAGCTGGACTCAT 
183 (Hanson and 
Ballantyne, 
2013) 
UCE Fw: AATGATCTGGCACGGGACC 
Rv: ATCGTAGAATATCAAGACAAATGCTGC 
241 
 
(Roeder and 
Haas, 2013) 
ACTB Fw: TGA CCC AGA TCA TGT TTG AG 
Rv: CGT ACA GGG ATA GCA CAG 
75 (Lindenbergh 
et al., 2012) 
 
43 
 
2.5.2 Preparation of RNA standards  
Human XpressRef Universal RNA  (Qiagen Ltd) was used as RNA standard. A 10 ng/µl 
aliquot was prepared from the stock by diluting with RNase free water. For reference 
genes experiment (Chapter 3), 1:10 and 1:5 serial dilutions of the standard (10 ng/µl) 
was prepared over five logs (0.1, 0.01, 0.001, 0.0001, and 0.00001) and (0.2, 0.04, 0.008, 
0.0016, and 0.00032) respectively with RNase-free water. RNA isolated from blood, 
semen, saliva, vaginal secretion and menstrual blood were also prepared in both 1:10 
and 1:5 serial dilutions over five logs. 
2.5.3 Preparation of body fluid samples  
All fresh samples were preserved by storage at -80 0C in order to stop enzymatic 
activities. Ten samples for each body and positive control were prepared for reference 
genes study. A volume of 10 µL of blood, saliva and semen were aliquot onto sterile 
cotton swabs; 10 swabs each of vaginal secretion and menstrual blood were also 
collected from -80 oC storage. All body fluids were placed in a dark cupboard and left 
undisturbed at room temperature for a minimum of six months.  
2.5.4 Preparation of RNA samples for degradation experiments 
RNA samples were degraded using incubator and UV cross linker. More details of 
degradation experiments are stated in relevant sections and chapters in this thesis. 
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Table 2.3: Oligo names and sequences 
Oligo 
names 
Forward primers (5’-3’) Reverse primers 5’-3’ References  
18S 
rRNA 
CTC AAC ACG GGA AAC CTC 
AC 
CGCTCC ACC AAC TAA GAA CG (Lindenbergh 
et al., 2012, 
Fleming and 
Harbison, 
2010, Haas et 
al., 2011, Haas 
et al., 2009). 
ACTB TGA CCC AGA TCA TGT TTG AG CGT ACA GGG ATA GCA CAG (Lindenbergh 
et al., 2012, 
Ghani et al., 
2013) 
B2M GGCATTCCTGAAGCTGACA AAACCTGAATCTTTGGAGTACG (Ghani et al., 
2013, Hanson 
and Ballantyne, 
2013) 
OAZ1 GGATCCTCAATAGCCACTGC TACAGCAGTGGAGGGAGACC 
 
(Hendrik et al., 
2007) 
RPS29 GCACTGCTGAGAGCAAGATG 
 
ATAGGCAGTGCCAAGGAAGA  
S-15 TTC CGC AAG TTC ACC TAC C CGG GCC GGC CAT GCT TTA CG (Juusola and 
Ballantyne, 
2003) 
b-Actin TGA CGG GGT CAC CCA CAC 
TGT GCC CAT CTA 
CTA GAA GCA TTT GCG GTG 
GAC GAT GGA GGG 
 
TEF 
 
TGG GCC ATC AAC TGA GAA 
AGA 
TCT CCC TAC ACT TCA ACT GCA 
CA 
(Fleming and 
Harbison, 
2010)  
GAPDH ATC ATC GTG GAG AAG CCC 
TTC 
 
GTT CCA GAT GGG GCC GA 
 
(Park et al., 
2013, 
Lindenbergh et 
al., 2012, Haas 
et al., 2009, 
Virkler and 
Lednev, 2009, 
Jakubowska et 
al., 2013) 
(Ghani et al., 
2013, 
Nussbaumer et 
al., 2006) 
UCE AAT GAT CTG GCA CGG GAC C ATC GTA GAA TAT CAA GAC 
AAA TGC TGC 
(Fleming and 
Harbison,2010) 
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2.6 Efficiency of RT primers 
The efficiencies of reference genes were evaluated using SYBR Green detection method. 
Genes with 90-110% efficiency and a slope of -3.33±10% were then selected and 
Taqman probes were designed for them (See Figure 3.1). 
2.6.1 SYBR Green 
The efficiency of 10 primers selected (Table 2.3) was determined using SYBR Green 
detection chemistry. Reverse transcribed human XpressRef Universal RNA (Qiagen Ltd) 
was used for efficiency testing. This sample was selected due to its source and industrial 
purification. Also, it reduced the doubts of getting false negative and positive results 
which could arise due to variations in the different body fluids.  
A 10 ng/µL starting input RNA concentration was reverse transcribed. 1:10 and 1:5 serial 
dilution was prepared over 5 logs using 5 µL cDNA. Following manufacturers 
recommendations, a volume of 10 µL SuperMix Express SYBR GreenER qPCR 
(Thermofisher Scientific  Ltd) and  2 µL cDNA from each serial dilution was prepared. 
Primer concentrations and water volumes were varied to make a 20 µL final reaction 
volume. Negative controls were used to assess any possible DNA contamination of the 
primer/enzyme mixes. Standard curve was generated for the samples using a thermal 
cycling condition of 95 oC for 10 min, followed by 40 cycles of 95 oC for 15 sec, 60 oC for 
60 sec. Melting curve stage was added for specificity in the target sample amplification. 
A software default instrument threshold  of 0.133 was used for data analysis. 
2.6.2 Taqman/Hydrolysis probe selection 
Custom Taqman probes were designed for each body fluid markers that passed the qPCR 
efficiency test using SYBR Green detection chemistry. The primer sequences were 
copied into the Basic Local Alignment Search tool (BLAST) to get the gene sequences. 
These were then pasted into the Custom taqman assay design tool (Thermofisher 
Scientific  Ltd) for taqman probe design. The probes were designed to span exon 
junctions so as not to amplify gDNA. The custom taqman assay design tool is a free and 
user-friendly online software (Thermofisher Scientific  Ltd) that enables the user to 
design a custom taqman assay specific for an experiment. It displays the locations of 
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genes on the the chromosome and which makes it easier should a probe redesign be 
necessary (see Figure 2.1). 
 
Figure 2.1: Screenshot of Taqman probe assay design tool (Thermofisher Scientific Ltd). This 
displays the location of specific genes on the chromosomes, should a possible redesign be 
necessary. 
 
Table 2.4: Primer sequences selected for Taqman probe design. 
Oligo 
names 
Forward primers 5’-3’ Reverse primers 5’-3’ 
TEF TGGGCCATCAACTGAGAAAGA TCTCCCTACACTTCAACTGCACA 
ACTB TGA CCC AGA TCA TGT TTG 
AG 
CGT ACA GGG ATA GCA CAG 
UCE AATGATCTGGCACGGGACC ATCGTAGAATATCAAGACAAATGCTGC 
B2M GGCATTCCTGAAGCTGACA AAACCTGAATCTTTGGAGTACG 
RPS29 GCACTGCTGAGAGCAAGATG ATAGGCAGTGCCAAGGAAGA 
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2.7 Limit of detection/ sensitivity testing of RT primers and probes 
According to MIQE guideline (See Bustin et al., 2009), LOD which is the concentration of 
a sample that can be detected with resonable certainty in a given experiment was 
calculated. As a rule, this is also required as one of the essential checklists for RT-qPCR 
experiments.   
All samples that were selected for LOD/sensitivity testing were diluted to 1ng/µL. A 
volume of 2 µL of each sample was then taken and further diluted down to 25 pg and 
reverse transcibed. This was to identify the ideal starting RNA concentration that should 
be added to the realtime PCR experiment without inhibition. A volume of 2 µL cDNA 
from each concentration (25pg – 2ng) was then added to the qRT-PCR sample 
preparation. 
Quantitative PCR (qPCR) reaction was performed using target-specific TaqMan Assays 
and TaqMan Universal PCR Master Mix, No AmpErase UNG (Life Technologies) following 
manufacturer’s protocol. A final reaction volume of 20 µL comprised 10 µL Taqman 
Universal PCR Mastermix, a volume of 1 µL Taqman Gene Expression assay mix (20x), 2 
µL cDNA and 7 µL RNase free water. All samples were run in duplicates for limit of 
detection (LOD) experiments. Standard curve which is the use of dilution series of known 
template concentration to determine the starting amount of target template in 
experimental samples was generated on ABI 7500 SDS software (version 1.4.1) 
(Thermofisher Scientific Ltd). The cycling conditions include the following: UNG 
activation of 2 min at 50 oC; initial step of hold, 10 min at 95 oC followed by 40 cycles of 
denaturation at 95 oC for 15 sec and final annealing/ extension at 60 oC for 1 min. See 
Chapter 2 for more details of statistical analysis. 
2.8 Body fluid specific marker selection and Multiplex design 
Multiplex PCR was first described in Chamberlain et al., (1988). For successful 
amplification to take place, the role of each component – PCR reagents, primer 
concentrations, and cycling conditions must be clearly understood and put into 
consideration (Henegariu et al., 1997). The markers selected (Tables 2.1 and 2.2) were 
aimed to amplify amplicon sizes of 76 bp – 304 bp with predicted annealing temperature 
of 54-62 oC. The G+C contents of each primer was in the range 40-65%.  
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At the start of the experiment, non-fluorescent primers were purchased and each of 
these was optimised in singleplex PCRs. Initially, reference genes were optimised using 
Platinum PCR multiplex mix (Life Technologies Ltd), Tm 54-62 oC, equimolar primer 
concentrations (10 µM) and cDNA (2 ng positive control RNA (Qiagen Ltd), (Table 2.5). 
The primer concentrations were then modified as required throughout the experiment. 
These were optimised at 20, 25, 30, 33 and 35 cycles, with modified extension times 
from 10 min to 8min, 5min and 2 mins, respectively. PCR products were assessed on 
Agarose gels. Subsequent experiments involved PCR optimisation using mRNA isolated 
from each specific body fluid – blood, semen, saliva, vaginal secretion and menstrual 
blood using Qiagen PCR multiplex kit (Qiagen Ltd), (Table 2.6). Following the results 
obtained from PCR optimization using non-florescent primers, markers that displayed 
positive amplification with target body fluids were labelled with fluorescein dye at the 
5’ end (Table 2.12). Again, these were optimized in singleplex PCRs before being 
combined into a multiplex assay. 
The multiplex PCR combinations were carried out at first in five separate multiplexes, 
one for each body fluid. These comprised of four markers (Glyco-A, ALAS2, PF4 and 
SPTB) for blood; three markers (MSX-1, SERP and LEFTY) for menstrual blood; five 
markers (PRM1, PRM2, TGM4, MSMB, and NKX3-1) for semen; four markers (SFTA2, 
MUC4, L. crispatus, and CRYP2B7P1) for vaginal secretion; and three markers (HTN3, 
FDCSP and STATH) for saliva. These five assays were then combined into a single 
multiplex, which was optimised in this chapter and validated (Chapter 5). 
 
Table 2.5: PCR cycling parameters used for Platinum PCR SuperMix for Optimization 
of Reference Gene PCR 
PCR stages Temperatures Times 
Initial denaturation 94 oC 30 s 
Denaturation 94 oC 30 s 
Annealing 58 oC     35 cycles 30 s 
Extension 68 oC 1 min 
Final extension 68 oC 10min 
Final hold 4 oC ∞ 
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Table 2.6: PCR cycling parameters used for Qiagen multiplex kit for Multiplex PCRs of 
mRNA Markers for Blood, Saliva, Semen, Vaginal Fluid and Menstrual Blood 
PCR stages Temperatures Times 
Initial denaturation 95 oC 15 min 
Denaturation 94 oC 15 s 
Annealing 58 oC   33 cycles 1 min 
Extension 72 oC 1 min 
Final extension 72 oC 20min 
Final hold 4 oC ∞ 
 
2.9 Developmental validation sample preparation 
The developmental validation was carried out using well-calibrated instruments and 
micropipettes. These were within the manufacturer’s calibration settings where 
required (Section 2.4). 
Samples used in this study were collected from voluntary donors from the University of 
Central Lancashire, Preston (Section 2.5). Degraded samples were sent in from Saudi 
Arabia to assess the robustness of the developed multiples assay. Unless otherwise 
stated, mRNA was isolated and quantified from human body fluid samples using the 
methods described (Sections 2.10-2.14). 
2.9.1 Reaction components and thermal cycling conditions 
Reaction components such as annealing temperature, cycle number and master mix 
were optimised in this study. For consistent and robust results, two different mastermix, 
Qiagen PCR multiplex mix (Qiagen Ltd) and Platinum supermix (Life technologies Ltd) 
were both optimised at 54 oC, 56 oC, 58 oC and 60 oC. 
2.9.2 Primer titration 
The effect of primer concentration was determined by preparing a primermix as 
outlined in Chapter 4, section 4.4.3. From the primermix, 1 µl, 1.5 µl, and 3.5 µl was 
taken and added to the reaction components 
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2.9.3 Cycle number  
Amplification of cDNA samples were optimised at 28, 30, 33 and 35 cycles. These were 
carried out using the same thermal cycler.  
2.9.4 Species specificity 
For specie specificity study, extracted human DNA samples from blood, saliva and bone 
were collected from storage within the Forensic Genetics Group (FGG) in the university. 
Also, mammalian samples from horse, pig, wood mouse, rat, and rabbit were also 
collected with adequate permission and used for this study. All samples have been used 
previously for studies unrelated to specie identification. 
2.9.5 Reproducibility study 
Following preparation of primermix (See Chapter 4, section 4.4.3), a 350 µl aliquot was 
made and sent to another independent laboratory for use on their prepared mock 
casework samples. The samples were run on 3130 XL Genetic analyser as reported by 
the laboratory. 
2.9.6 Mixture study 
Mixture of all four mRNA body fluid samples were first prepared in equimolar 
concentrations, and then modified in order to obtain a near balanced peak height for 
the overall profile. Further experiments involved preparation of mRNA samples mixtures 
in duplex combinations. These included blood + saliva, semen + vaginal secretion, blood 
+ semen and blood + vaginal secretion with mixture ratios of 1:2, 1:4, 1:9, 1:1, 9:1, 4:1 
and 2:1. For each combination, 1 ng/µl was used, which represents one sample ratio. 
2.9.7 Sensitivity study 
Dilution series was carried out for the sensitivity study with a 5 µl (1ng/µl) starting mRNA 
concentration for each body fluids using the following series: 1:10, 1:50, 1:250, 1:500, 
1:1000, 1:1500, and 1:3000. These were reverse transcribed and amplified in duplicate 
reactions.  
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2.9.8 Degradation experiments 
The degradation experiment was carried out under two conditions viz controlled and 
uncontrolled degradation. For controlled degradation, three different experiments were 
designed.  
2.9.8.1 Controlled degradation 
First, blood samples were prepared on different substrates such as metal scalpel, hand 
gloves, glass slide and facial mask. For each substrate, a volume of 10 µL blood sample 
was spotted. These were left to dry at room temperature and then stored in a cool, dark 
cupboard for six weeks. Samples were taken with sterile and wet cotton swabs every 
two weeks for extraction and downstream analysis. Secondly, a 10 µL blood, semen and 
saliva samples were spotted on glass slides and incubated at 37 0C for six weeks. Samples 
were also taken every two weeks with wet and sterile cotton swabs for downstream 
analysis. The final controlled degradation study involved preparation of extracted mRNA 
samples from blood, saliva, vaginal secretion and semen, following degradation under 
UV crosslinker (X100 µL/cm2) and incubator at 56 0C. Only the last degradation 
experiment with extracted mRNA samples was carried out in parallel between UV cross-
linker and Incubator at 56 0C, others were carried out and analysed independently. For 
UV cross-linker and incubator at 56 0C, 10 µL of each sample was taken at intervals of 5, 
10, 30, 60 and 90 mins for downstream analysis. 
2.9.8.2 Uncontrolled degradation 
Another member of FGG, UCLan (a former PhD student) in Saudi Arabia, prepared Blood, 
saliva and semen used for uncontrolled degradation study. These samples were the 
batches remaining following his degradation study. According to him, the samples were 
prepared in the summer of 2014 and left in a secure place outside, exposed to direct 
sunlight for a total of 51 days. For each body fluid sample, a 5 µl volume was pipetted 
on cloth (100% pure cotton), metal (a large stainless steel kitchen knife) and glass 
(microscopic slides). A metallic grid was placed on the samples to protect them from 
scavengers; otherwise, they were left exposed for the duration of the experiment. 
Samples were taken every 48-72 hours with swabs, the swabs heads were then cut out 
with a sterile scalpel and stored in 1.5 ml Eppendorf tubes at -20 oC for further use. 
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Environmental conditions reported during the sample preparation included maximum 
temperature of 49.5 0C, minimum temperature of 6.3 0C, maximum and minimum 
relative humidity of 95 %, respectively. Following ethical guidelines, the samples were 
requested and brought to the UK by the student in June 2016 on one of his visits to the 
University. These were packaged in a sealed plastic bag. It was picked up from the drop-
off point after 3 days due to communication issues. The samples when opened were 
found in a poor state, considering they have been initially stored frozen and been in 
transit for at least 5 days. From the information that came with the samples, they were 
not in order of sampling as the student used most of the samples for his project. Based 
on the dates on each Eppendorf tube containing the swab heads, samples taken at days 
1, 5, 10, 15, 20, 25, 30, 35, 40, 45, and 51 were selected for this study. 
2.10 RNA extraction 
RNA was extracted from all body fluids using RNeasy Mini Plus kit (Qiagen Ltd) according 
to manufacturers’ instructions. For every sample, 400 µL RLT Plus/βME mixture was 
added to a 1.5 ml microcentrifuge tube. The samples were then transferred (direct 
pipetting/swab head) into the microcentrifuge tube. These were vortexed and 
incubated for 10 min at room temperature. During incubation, the samples were 
vortexed for approximately 2 min, all the stains solubilized after 10 min. The samples 
were briefly centrifuged and the swab head/ cutting was transferred into a spin basket. 
This was later centrifuged at maximum speed for 5 min. The eluates were transferred 
into a genomic DNA (gDNA) eliminator spin column. Care was taken during pipetting to 
avoid air bubbles. Afterwards, the samples were centrifuged for 30 secs at 11, 000 rpm 
(11.2 x g), making sure no fluid remained in the spin column membrane. If any fluid is 
noticed on the membrane, the samples were re-centrifuged. The spin columns were 
discarded and 400 µL of 70% ethanol was added to the eluate and mixed well with 
pipette. While avoiding air bubbles, the eluate/ethanol was transferred to the RNeasy 
spin column and centrifuged for 15 secs at 11, 000 rpm (11.2 x g). The flow through was 
discarded and the spin column placed back in the collection tube. A volume of 700 µL 
RW1 buffer was added and centrifuged at 11, 000 rpm (11.2 x g) for 15 sec. Again, the 
flow through was discarded and the spin column placed back in the collection tube. 
Ethanol was added to the RPE buffer (following manufacturers’ recommendation) and 
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500 µL RPE/ethanol was added to the spin column, centrifuged for 15 secs at 11, 000 
rpm (11.2 x g), the flow-through was discarded and the spin column was placed back in 
the collection tube. A volume of 500 µL RPE buffer/ethanol mix was added again to the 
spin column and centrifuged for 2 min at 11, 000 rpm (11.2 x g). The flow-through and 
the used collection tubes were discarded. While ensuring that ethanol was not carried 
over into the RT-PCR, the spin column was centrifuged for 1 min at maximum speed and 
placed in a new 1.5 ml collection tube. Without touching the spin column membrane 
with the pipette tip, 30 µL RNase-free water was added directly to the membrane. This 
was incubated for 2 min at room temperature and centrifuged for 1 min at 11, 000 rpm 
(11.2 x g) to elute the RNA. For increased yield of RNA, the eluate was placed unto the 
membrane again, incubated for 5 min at room temperature and centrifuged for 1 min 
at 11, 000 rpm (11.2 x g) to elute the RNA (See Figure 2.2). Following final elusion, the 
eluate, which contain RNA, was then purified using Turbo DNA-free kit (Life 
Technologies Corp). 
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Figure 2.2: Schematic representation of RNeasy procedure of RNA isolation (Taken from 
www.qiagen.com on 21/02/2016). 
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2.11 Post RNA purification DNase treatment with TURBO DNA-free 
KitTM (Life Technologies Corp.) 
According to the manufacturer, this RNA purification method using DNase treatment 
allows for thorough removal of contaminating DNA compared to on-column DNase 
treatment. A volume of 30 µL RNA in the final elution stage was transferred into a 0.5 
ml microcentrifuge tube. Similarly, a volume of 3 µL of 10X TURBO DNase buffer and 1 
µL TURBO DNase was added to the sample and incubated for 30 min at 37 oC. Thereafter, 
a volume of 3.4 µL inactivation reagent was added and mixed well. This was incubated 
for 5 min at room temperature, mixing occasionally to re-disperse the inactivation 
reagent. The mixture was centrifuged at 10, 000 rpm (9.2 x g) for 1.5 min. The 
supernatant (about 30-32 µL) was then carefully transferred into a new 0.5 ml tube. 
2.12 RNA Quantitation 
Total RNA was quantified using NanoDrop 2000c UV-Vis spectrophotometer (Thermo 
Scientific, Wilmington, DE) featuring both micro volume pedestal and cuvette 
measurement options. Following manufacturer’s instructions, all samples were 
measured using RNA-40 settings and wavelength monitored at 260 nm and 280 nm. 
Each purified sample was quantitated thrice and the average was taken as the sample 
concentration. A known concentration of standard RNA was quantitated at least twice 
with each batch of samples. 
2.13 Total RNA quality  
Only the samples with absorbance values greater than 1.8 at 260 nm/280 nm when 
quantitated using Nanodrop were selected as this indicated that they were relatively 
free of proteins.  
2.14 cDNA synthesis 
First strand cDNA was synthesized using SuperScript VILO MasterMix (Life Technologies 
(UK) Ltd)) in a total reaction volume of 20 µL. SuperScript VILO mastermix comprises 
SuperScript III reverse transcriptase, RNaseOUT recombinant Ribonuclease inhibitor, a 
proprietary helper protein, random primers, MgCl2 and dNTPs (Life Technologies Ltd). 
Following manufacturer’s instructions, for each sample, a mix of 4 µL SuperScript VILO 
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MasterMix and 6 µL nuclease free-water was prepared on ice. This was added to 10 µL 
(2 ng/µL) extracted RNA sample, gently mixed and incubated at 25 oC for 10 min. Thus, 
prepared sample was then incubated at 42 oC for 60 min and the reaction was 
terminated at 85 oC for 5 min. Negative controls (No Amplification Control (NAC)) were 
processed with the samples by first incubating a 4 µL SuperScript VILO MasterMix and 6 
µL nuclease-free water at 65 oC for 10 min to denature the reverse transcriptase in the 
mastermix. This would detect any genomic DNA co-extracted with mRNA. Similarly, no 
template controls (NTCs) were processed by substituting RNA samples with nuclease 
free water. There was no amplification in both NACs and NTCs. All reverse transcribed 
samples were stored at -20 oC. 
2.15 Real-time PCR cycling conditions 
Real-time PCR was carried out on ABI 7500 system using two detection methods, which 
include SYBR Green and Taqman probes. The cycling parameters are listed in Table 2.7 
and Table 2.8. 
2.15.1 SYBR Green 
Table 2.7: PCR cycling parameters used for SYBR Green experiments 
Temperatures Times  
50 oC 2 min Stage 1 
95 oC 2 min Stage 2  
95 oC 15 s             Stage 3 
60 oC 1 min X 40 cycles 
95 oC 15 s Stage 4 (melt curve) 
60 oC 1 min              X 1 cycle 
95 oC 15 sec  
60 oC 1 min  
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2.15.2 Taqman probes 
Table 2.8: PCR cycling parameters used for Taqman probes experiments 
Temperatures Times  
50 oC 2 min Stage 1 
95 oC 2 min Stage 2  
95 oC 15 s             Stage 3 
60 oC 1 min X 40 cycles 
2.16 End-point PCR cycling conditions 
Similar to real-time PCR, end-point PCR was carried out on the ABI veriti 96 thermal 
cycler (Life Technologies Ltd). Two different mastermix, Qiagen PCR multiplex mix and 
Platinum PCR mastermix were used. The cycling parameters are displayed in Table 2.9, 
for Qiagen multiplex kit and Table 2.10, for Platinum multiplex mix. The primer, 
mastermix and cDNA and water volumes were modified appropriately (See Table 2.11) 
2.16.1 Qiagen PCR multiplex kit 
Table 2.9: PCR cycling parameters used for Qiagen multiplex kit 
PCR stages Temperatures Times 
Initial denaturation 95 oC 15 min 
Denaturation 94 oC 15 s 
Annealing 58 oC     33 cycles 1 min 
Extension 72 oC 1 min 
Final extension 72 oC 20min 
Final hold 4 oC ∞ 
2.16.2 Platinum PCR SuperMix Hifi Mastermix 
Table 2.10: PCR cycling parameters used for Platinum PCR SuperMix 
PCR stages Temperatures Times 
Initial denaturation 94 oC 30 s 
Denaturation 94 oC 30 s 
Annealing 58 oC   33 cycles 30 s 
Extension 68 oC 1 min 
Final extension 68 oC 10min 
Final hold 4 oC ∞ 
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2.16.3 Reaction components for PCR 
Table 2.11: PCR reaction components 
Reagents Reaction volumes (µL) 
Final volume 10 16 
Mastermix 5 10 
Primer mix x 3.5 
cDNA x x 
Water x x 
Primer mix, cDNA and water volumes were varied with each batch of reaction due to 
optimization. A final primer mix used for multiplex reaction was 3.5 µL. 
2.17 Fragment analysis 
The PCR amplicons using unlabelled primers were electrophoresed using AGE. PCR 
amplicons generated using fluorescently labelled primers were analyzed on 3500XL 
Prism Genetic Analyzer (Applied Biosystems Ltd). 
2.17.1 Sample preparation for Agarose gel electrophoresis 
PCR products amplified using unlabeled primers were electrophoresed using AGE. 
Unless otherwise stated, a 1.5% Agarose gel was used throughout the experiments and 
was prepared by adding 1,500 g of Agarose to 100 ml (1X) TAE buffer. This was swirled 
briefly, placed in the microwave and set on low heat until a clear solution was seen. The 
conical flask containing the gel was then left to stand till it was cool to touch. A volume 
of 2 µL safe-view was added to each 100 ml gel. The gel was then gently mixed avoiding 
bubbles and then cast in a gel tray. The gel was allowed to set and then transferred into 
a gel tank containing 1X TAE buffer. Sample were prepared for loading on the gel by 
adding 2 µL tracking dye and 3 µL water to 5 µL PCR product. A volume of 100 bp ladder 
(Thermofisher Scientific) was prepared by adding 3 µL of the ladder to 2 µL tracking dye 
and added to one well of the gel. The prepared samples were added to other designated 
wells. Gel electrophoresis was allowed to run at 100 V for approximately 25 min. The 
gels were viewed using BioDoc-It UVP trans-illuminator (UVP, LLC, CA).  
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2.17.2 Sample preparation for capillary electrophoresis 
PCR samples amplified using fluorescent primers were analyzed using ABI 3500XL Prism 
Genetic Analyzer (Applied Biosystems Ltd). The fluorescent dyes are shown in Table 
2.12. Each PCR sample was prepared by adding 1 µL PCR product to 8.5 µL Hi-Di 
Formamide (Life Technologies, UK) and 0.5 µL GeneScan 500 LIZ size standard (Life 
Technologies, UK). Samples were spun briefly then heated at 95 oC for 5 min and snap-
cooled on ice for at least 10 min. Fragment analysis was carried out on ABI 3500 XL Prism 
Genetic Analyzer in a 50 cm long capillary and POP-6 polymer (Life Technologies, UK) 
using dye set G5 (Table 2.13). 
Table 2.12: Florescent dye labels used for labelling the forward primer of various pairs 
of primers (Eurofins MWG Operon) 
Fluorescent dyes Colors 
ATTO 565 Red 
6-FAM Blue 
Yakima Yellow Green 
ATTO 550 Yellow 
 
 
  
Table 2.13: 3500XL Prism Genetic Analyzer (Applied Biosystems Ltd) fragment analysis 
protocol (Fragment Analysis 50_POP6) 
Dye set: G5 
Parameters Values 
Oven temperature 60 oC 
Run time 2600 s 
Pre-run voltage 15.0 kV 
Run voltage 15.0 kV 
Pre-run time 180 s 
Injection time 15 s 
Injection voltage 3 kV 
Data delay 600 s 
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2.18 Data Analysis (GeneMapper ID-X software) 
ABI 3500 GeneMapper ID-X Software Version 1.2 (Thermofisher Scientific Ltd) was used 
to analyze raw data obtained from capillary electrophoresis (CE). The instrument default 
parameters were left unchanged throughout the course of the experiments (Table 2.14). 
2.19 General statistical Analysis of data 
Statistical analysis to determine primer and PCR efficiencies was carried out using 
Expression suite software (Thermofisher Scientific Ltd) and Microsoft Excel software. 
The expression suite software operates using geNORM analysis, which is the geometric 
mean of multiple carefully selected housekeeping genes validated as an accurate 
normalization factor (Vandesompele et al., 2002). Student’s t-test and Analysis of 
variance (ANOVA) were performed using R studio software (See page 72). R studio is an 
open source statistical analysis software that enables organization of data and 
maintenance of multiple projects using specific codes for various tests. Standard 
deviation was calculated to measure how data were scattered around mean values. 
Where applicable, RNA sample concentration, cycle threshold values (Ct) and peak 
heights (RFU) of samples were used for the statistical analysis. Further details on 
statistical calculation is discussed in relevant chapters. All data are presented as a single 
EPG, gel electrophoresis photos or amplification plot readings from 5-10 of such 
different experiments or as mean ± standard deviation (SD with n and p values where 
possible. 
Table 2.14: Advanced Peak detection Algorithm used for each analysis of PCR 
fragments. 
Parameters Values 
Size calling method Local Southern 
Analysis Range Full Range 
Baseline Window 51 points (pts) 
Peak Detection 50 RFU 
Polynomial Degrees 3 pts 
Minimum Peak Half Width 2 pts 
Peak Window Size 15 pts 
Slope Threshold for peak start/end 0-0 
Size Call Range All sizes 
61 
 
 
 
CHAPTER THREE 
 
 
OPTIMISATION OF REFERENCE 
GENES 
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3.0 Introduction 
Reference genes, otherwise known as housekeeping genes, are constitutive genes that 
carry out the maintenance of basic metabolic functions in a cell. Irrespective of their 
patho-physiological conditions, they are expected to be uniformly expressed in the 
sample type they are found (Butte et al., 2001; Pfaffl et al., 2004). These unique 
characteristics make them ideal for use in calibration and normalization studies 
(Vandesompele et al., 2002). Similarly, they are used as internal controls for some 
experimental studies (Robinson and Oshlack, 2010; Dheda et al., 2004; Rubie et al., 
2005), most importantly, in mRNA profiling, which has been reported to yield good 
results (Wang et al., 2013; Park et al., 2013). Bustin, (2002) reported that validation of 
input RNA required for a reaction without inhibition is time consuming when RNA 
samples are to be compared by controlling the total input RNA. Correspondingly, 
comparison of RNA samples requires precise quantification. In forensic RNA studies, 
endogenous controls, usually housekeeping genes, are required for better normalisation 
of sample-to-sample variation as well as experimentally induced variations 
(Vandesompele et al., 2002). This is achieved by reporting the amount of a target gene 
in reference to a reference gene (Tricarico et al., 2002). Previously, traditional method 
of RNA analysis based on immunological assays such as Northern blots or RNase 
protection assays were used to determine varying amounts of RNA in samples (Thellin 
et al., 1999). Recently, RNA measurement using real time PCR technology as well as 
microarray analysis is able to estimate slight variation in relative quantities for larger 
number of genes  due to their high sensitivity (Yuen et al., 2002). These variations are 
highly significant in any experimental study; therefore, to prevent ambiguity and 
spurious results; such variations must be quantified and minimised whenever possible. 
Equally, the choice of a reference gene for any study should not be based on their 
traditional use in other studies but on adequate validation of their stability in the 
intended experiment (Meller et al., 2005). Although, it is possible for a single reference 
gene to be capable of possessing all the required characteristics, many authors however 
have reported that no single gene is universally stable. Hence, multiple reference genes 
have been proposed for use in normalization data analysis studies (Vandesompele et al., 
2002; Pohjanvirta et al., 2006). For the purpose of this study, endogenous control genes 
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was empirically evaluated for stability and uniformity in expression between many types 
and states of body fluid samples. 
3.1 Reference genes selection 
In this study, 10 reference genes were picked from relevant published literature (Table 
3.1). A thorough literature search showed these reference genes as commonly used in 
Forensic body fluid identification experiments. Chapter 2, Table 2.1 displayed the primer 
sequences that were used to amplify all target loci in this study. All primers were ordered 
from Life Technologies (UK) Ltd and no modification was made to the primer sequences. 
3.2 Aim and objectives 
The aim of this chapter was to evaluate and optimize a total of 10 reference genes 
commonly used in forensic body fluid identification studies for fitness of purpose. 
The chapter has the following objectives: 
To select a total of 10 reference genes commonly used in body fluid identification  
To optimize the reference genes using SYBR Green detection chemistry and establish 
their efficiencies. 
To select the genes with 90-110% efficiency and a slope of -3.33±10% and design 
Taqman probes for them. 
To incorporate the robust reference genes into the multiplex assay that will be 
developed in Chapter 4. 
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3.3 Methods 
Sample preparation for the reference genes study was reported in Chapter 2, sections 
2.5 – 2.7. 
3.4 Results 
This section discussed the results obtained from SYBR Green and Taqman probes 
experiments.  
3.4.1 qPCR efficiency 
A total of 10 reference genes (UCE, TEF, GAPDH, 18S rRNA, ACTB, B2M, B-Actin, OAZ1, 
RPS 29 and S15) were selected from relevant published literatures at the start of the 
study (Table 2.1). Human control RNA (Qiagen) with known RNA concentration was used 
as the sample source.  
The results show that a few of the samples failed amplification using a 1:10 serial dilution 
with varying primer concentrations of 0.1-0.5 µM. This was modified by setting up 
further experiments with a 1:5 serial dilutions, keeping the primer concentrations 
constant. Primer efficiency of 90-110% was tested by generating a standard curve from 
the serial dilutions.  
3.5. SYBR Green 
Cycle threshold (Ct value) is the cycle number at which the florescent signal crosses the 
threshold. Amplification plot was generated, together with the cycle threshold (Ct) 
values. In Microsoft Excel spreadsheet, reaction efficiencies and slope were determined 
by plotting a graph of Ct values against the logarithm of dilutions. All these were in 
accordance to MIQE guidelines. From the data generated, five makers; ACTB, B2M, UCE, 
TEF and RPS29 were found to be 90-110% efficient, having a slope of -3.33 ± 10% (Figures 
3.1-3.5). 
3.6 Taqman probes 
Similar to SYBR Green experiments, Taqman probe assay using the real-time PCR was 
used to evaluate the threshold cycle value (Ct: cycle number at which the fluorescence 
passes the threshold) should the sample extraction and reverse transcription succeed. 
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Real time PCR amplification curves of different amounts of total input RNA (25 pg– 2 ng) 
extracted from blood, saliva, menstrual blood, semen and vaginal secretion was 
obtained. Furthermore, calibration curve was constructed from the Ct values obtained 
in reference to the different RNA concentrations present in each sample. To compare 
the expression levels and normalisation of the target genes among body fluid samples, 
the delta Ct (dCt) value was calculated automatically using the ExpressionSuite Software 
v1.1 for Microsoft® Windows® 7, XP, 10 (Thermofisher Scientific Ltd). The expression 
suite software operates using geNORM analysis, which is the geometric mean of 
multiple carefully selected housekeeping genes validated as an accurate normalization 
factor (Vandesompele et al., 2002). The data obtained from expression suite software 
were used to generate a histogram plot using the Ct values and the samples. This 
showed the frequency of distribution of the data generated (Figures 3.11, 3.12 and 
3.13).  
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Figure 3.1: Melt curve plot of UCE. 0.1-0.5 µM represents UCE primer concentrations/volumes 
optimized. The slope of 0.2, 0.4 and 0.5 µM UCE showed 100% efficiency of -3.33 ± 10%. 0.1 and 
0.3 displayed less than 100% qPCR efficiency; n=5, where n equals the number of repeats of 
experiment. 
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Figure 3.2: Melt curve plot of TEF.  0.1-0.5 µM represents TEF primer concentrations/volumes 
optimized. The slope of 0.1 TEF shows 100% efficiency of -3.33 ± 10%. Other concentrations/ 
slopes did not display 100% qPCR efficiency; n=5, where n equals the number of repeats of 
experiment. 
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Figure 3.3: Melt curve plot of ACTB. 0.1-0.5 µM represents ACTB primer concentrations/volumes 
optimized. The slope of 0.1, 0.4 µM and 0.5 µM B2M shows 100% efficiency of -3.33 ± 10%. 
Other slopes showed less than 100% qPCR efficiency; n=5, where n equals the number of repeats 
of experiment. 
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Figure 3.4: Melt curve plot of B2M.  0.1-0.5 µM represents B2M primer concentrations/volumes 
optimized. The slope of 0.2-0.5 µM B2M shows 100% efficiency of -3.33 ± 10%. 0.1 µM did not 
display 100% qPCR efficiency; n=5, where n equals the number of repeats of experiment. 
 
 
70 
 
 
 
Figure 3.5: Melt curve plot of RPS29. 0.1-0.5 µM represents RPS20 primer 
concentrations/volumes optimized. 0.2-0.5 µM primer volumes showed 100% efficiency of -3.33 
± 10%. 0.1 µM primer volume displayed less than 100% efficiency; n=5, where n equals the 
number of repeats of experiment. 
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3.7 Primer selection for Taqman probes 
The five markers listed (Table 2.4) attained the set efficiency threshold of 90-110% with 
a slope of -3.33±10%. Based on these criteria, they were then selected for Taqman probe 
design and further experiments. 
3.7.1 qRT-PCR efficiency 
Although the manufacturer (Thermofisher Scientific Ltd) suggested that there was no 
need to optimize the taqman probes as these were already carried out before shipment; 
to ascertain the qRT-PCR efficiency using the Taqman probes, a trial experiment was set 
up with UCE  using 25 pg-2 ng of positive control sample (Human XpressRef universal 
total RNA (Qiagen Ltd). The standard curve data generated revealed that all the samples 
were amplified and detected down to 25 pg. 
3.7.2 Sensitivity test/ Limit of detection 
Limit of detection/ sensitivity test was carried out on UCE, TEF, RPS29, ACTB and B2M 
using the designed taqman probes. Fresh samples of blood, saliva, vaginal secretion, 
semen and menstrual blood were analysed. The results indicated that all the body fluids 
were detected up to 0.025 ng input RNA for all the makers except TEF. For semen 
sample, TEF was detected from 0.1 pg while menstrual blood and blood were both 
detected from 0.5 ng. 
3.7.3 Taqman Probes Based Assays 
A fluorescent TaqMan MGB probe (Thermofisher Scientific Ltd) with a non-fluorescent 
quencher at 3’ end was used for attaining a higher specificity. The probes were designed 
to bind the sequences of the mRNA transcripts at exon/exon junctions to avoid the 
detection of DNA contamination. All probes were FAM labelled (as reporter dye) at the 
5’ end and a non-florescent quencher at the 3’ end. The selected genes included: (B2M, 
Hs00187842_m1, 120bp), (ACTB, Hs03023943_g1, 75bp), (UCE, Hs00366152_m1, 
241bp), (TEF, Hs01896387_g1, 206bp), (RPS29, Hs03004310_g1, 213bp). Both positive 
control (Human XpressRef Universal RNA (Qiagen Ltd) and negative controls were 
included in each batch. cDNA was amplified using Taqman probes (Thermofisher 
Scientific Ltd) and Taqman Universal PCR mastermix in a total volume of 20 µL, with 2 µl 
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input cDNA.  For these experiments a range of mRNA were reverse transcribed (25 pg; 
50 pg, 0.1 ng, 0.2 ng, 0.5 ng, 1 ng and 2 ng), to test the sensitivity and the limit of 
detection of the assay. All reactions were prepared in duplicates. Thermal cycling 
conditions were: 2 min at 50 oC; initial step of hold, 10 min at 95 oC followed by 40 cycles 
of denaturation at 95 oC for 15 sec and final annealing/ extension at 60 oC for 1 min. The 
amplification products were detected on a 7500 sequence detection system 
(Thermofisher Scientific Ltd).  
3.8 Data analysis 
The expression of reference genes was evaluated for use as endogenous control. The 
level of expression of each reference gene was assessed by analyzing the cycle threshold 
value (Ct: the cycle number at which fluorescence is detected). The limit of detection 
was assessed in fresh body fluid samples. Amplification curves of different amount of 
input RNA (25 pg- 2 ng) extracted from 30 µl fresh semen, blood, saliva, menstrual blood 
and vaginal secretion samples were generated. The Ct values were determined in the 
range 19-39.  
The reference gene expression data for samples stored for 6 months was analyzed in a 
similar manner. A default instrument threshold of 0.133 was used for the analysis. 
Student’s t test was performed for comparing the gene expression levels for the fresh 
and 6 month old samples. The level of significance was set at 5%. 
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Figure 3.6: Pictorial illustration of  Real-time PCR amplification plot of reference genes on semen 
sample; n=5, where n equals the number of repeats of experiment. 
 
 
Figure 3.7: Pictorial representation of Real-time PCR amplification plot of reference genes on 
saliva sample; n=5, where n equals the number of repeats of experiment. 
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Figure 3.8: Pictorial representation of Real-time PCR amplification plot of reference genes on 
menstrual blood sample; n=5, where n equals the number of repeats of experiment. 
 
 
Figure 3.9: Pictorial representation of Real-time PCR amplification plot of reference genes on 
blood sample; n=5, where n equals the number of repeats of experiment. 
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Figure 3.10: Pictorial representation of Real-time PCR amplification plot of reference genes on 
vaginal secretion sample; n=5, where n equals the number of repeats of experiment. 
Key:  
ACTB  
B2M  
RPS29  
TEF  
UCE  
 
3.9 Six-month old samples 
Samples stored at room temperature over six months were analysed for RNA sensitivity 
and stability. The results are given below. 
3.9.1 Sensitivity  
Four reference genes (UCE, RPS 29, ACTB, B2M) in different body fluids were detected 
down to 25 pg except TEF. TEF was detected at 0.1 ng in semen, and 0.5 ng in blood and 
menstrual blood. 
3.9.2 Stability of RNA in stains over time 
Since most forensic stains are not often recovered in a fresh state, the stability of UCE, 
ACTB, B2M, RPS29 and TEF were examined in samples stored at room temperature for 
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over 6 months. The Ct values of the reference genes were determined. All the markers 
were expressed in at least 4 of 5 different individual samples for each body fluid sample 
except TEF that was amplified in a total 2 individual samples across the 5 body fluids 
(Tables 3.1a, 3.1b). The stability of RPS29 was found to be higher across all the body 
fluids, followed by UCE, ACTB and B2M. TEF was either not expressed (saliva, vaginal 
secretion) or was selectively expressed in blood, semen and menstrual blood. 
Furthermore, the result of Anova test, using the Ct values indicated that the expression 
of each of the reference genes was not significantly different across the five body fluid 
samples (P>0.05) 
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Table 3.1a: Ct values for ACTB, UCE, TEF, RPS29 and B2M in blood, semen, vaginal 
secretion, menstrual blood and saliva samples stored at room temperature for 6 
months, n=10. 
Number of 
samples 
ACTB UCE TEF RPS29 B2M 
Blood 
1 28.4428 24.8423 33.333 23.5240 30.0167 
2 33.9818 34.0654 ND 36.3675 20.1324 
3 29.4415 29.9992 ND 33.3829 20.0917 
4 36.6418 30.9527 ND 33.9107 31.3060 
5 32.6277 28.5818 ND 36.2352 32.7220 
6 21.1790 27.5849 ND 30.7258 25.1986 
7 27.5197 29.6871 ND 29.1299 25.0684 
8 30.0445 26.9511 ND 31.3572 26.9798 
9 31.7106 20.0092 ND 30.0906 25.2114 
10 32.1233 27.0358 ND 19.0231 26.7152 
Semen 
1 32.0857 37.1960 39.9977 32.4851 33.6951 
2 32.7943 37.2625 39.8370 32.5104 33.8875 
3 32.0727 37.0357 39.8261 33.1687 32.9396 
4 31.9274 38.0549 ND 33.1324 34.0133 
5 31.4121 22.2766 ND 33.5893 34.7402 
6 37.9590 37.7419 ND 36.2108 36.3522 
7 35.8241 37.6910 ND 35.2683 22.6165 
8 39.2314 38.5445 ND 32.5896 34.0974 
9 ND ND ND ND ND 
10 ND ND ND ND ND 
Saliva 
1 24.9746 32.4266 ND 28.4760 21.9949 
2 24.6462 32.2880 ND 28.4719 22.0539 
3 24.5889 32.1213 ND 28.1391 21.7412 
4 25.2094 34.2092 ND 29.1876 30.1004 
5 25.0916 32.3652 ND 28.6078 21.7285 
6 25.4542 36.3847 ND 28.8360 22.2883 
7 25.1313 38.7327 ND 33.3331 28.7191 
8 25.2543 39.4030 ND 37.3658 29.0209 
9 25.2673 ND ND 28.8023 22.1194 
10 25.0442 ND ND 28.4509 21.9907 
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ND: Not detected. 
Comparing the Ct values generated from fresh and six-month old samples, it was 
observed that there was no significance difference in the expression of the five markers 
on all the body fluids (See Tables 3.1a and 3.1b).  
  
Table 3.1b: Ct values for ACTB, UCE, TEF, RPS29 and B2M in blood, semen, vaginal 
secretion, menstrual blood and saliva samples stored at room temperature for 
6months, n=10. 
 ACTB UCE TEF RPS29 B2M 
Menstrual blood 
1 29.3250 34.2857 38.0689 33.1929 27.4627 
2 29.2418 35.8603 38.1524 32.5346 27.1493 
3 34.6060 28.8214 34.1209 35.5241 32.5487 
4 38.7505 32.4830 ND 35.4180 32.9574 
5 29.8688 28.3690 ND 31.6119 28.8910 
6 30.6219 36.8748 ND 32.0296 29.6302 
7 32.7020 33.7253 ND 32.1600 27.7370 
8 18.5726 32.1010 ND 36.4235 29.8221 
9 ND 38.9209 ND ND 33.0698 
10 ND ND ND ND 32.5494 
Vaginal secretion 
1 31.7349 35.5805 ND 39.3131 31.1240 
2 30.2438 32.5852 ND 37.0601 31.7799 
3 37.6809 34.6150 ND 34.6686 32.3642 
4 37.9121 30.8288 ND 34.4291 27.9864 
5 36.1747 35.4459 ND 36.7781 28.2896 
6 34.0958 34.5916 ND 38.0804 34.9704 
7 ND 28.0194 ND 34.5791 31.9286 
8 ND 33.3759 ND 34.8006 29.6732 
9 ND 33.7360 ND ND 28.0460 
10 ND 36.1619 ND ND 29.7224 
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Figure.3.11: Histogram plot of Ct values generated from amplification of six-month old body 
fluid samples in duplicate. a) Blood, b) Semen. Data are represented as mean ±SD, n=10, P>0.05. 
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Figure 3.12: Histogram plot of Ct values generated from amplification of six-month old body 
fluid samples in duplicate. c) Saliva, d) menstrual blood, Data are mean ±SD, n=10, P>0.05. 
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Figure 3.13: Histogram plot of Ct values generated from amplification of six-month old body 
fluid samples in duplicate. e) Vaginal secretion. Data are mean ±SD, n=10, P>0.05. 
3.9.3 Result of negative controls 
Although adequate precautions were taken through the whole workflow of each 
experiment to prevent contaminations, both positive (Figure 3.14) and negative controls 
were also prepared and processed along with the main samples to further check 
contamination. Reagent control, reverse transcription negative control (-RT) as well as 
negative control for the extraction, cDNA synthesis and qRT-PCR amplification 
respectively were prepared and processed along the target samples. All negative 
controls were analyzed and the result showed no amplifications (See Figure 3.15) 
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Figure 3.14: Pictorial representation of amplification plot of Human XpressRef positive control 
sample (Qiagen Ltd). 1 ng/µL of positive control sample was used in the reaction; n=10, where 
n represents the number of repeats of experiment. 
 
Figure 3.15: Pictorial representation of amplification plot of negative control sample (1 µL water 
was used in place of body fluid sample); n=10, where n represents the number of repeats of 
experiment. 
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3.10 Discussion 
The data generated in this study were compared to the results reported in similar studies 
by other authors. This is discussed in the Sections 3.10.1 – 3.11. 
3.10.1 Marker selection and analyses 
The study in this chapter has demonstrated that it is possible to recover RNA from body 
fluids in sufficient quantity and quality required for forensic investigations. Using a 
number of relevant literature and database search, ten housekeeping genes were 
chosen and used for normalization in forensic body fluid identification analyses (Table 
2.1). Total RNA, which comprise mRNA, ribosomal RNA and small RNA, was recovered 
from the body fluids in varying quantities. Following the extraction of total RNA, it was 
further determined whether mRNA of interest could be detected in the body fluids as it 
is known that mRNA comprises about 1-3% of total RNA. All the reference genes were 
detected in all the analysed body fluids using SYBR Green and Taqman probe detection 
systems (Figures 3.1-3.10).  
SYBR Green chemistry detection method is less expensive and easy to use. However, it 
is not capable of multiplexing and fluoresces when it binds to any available dsDNA in the 
reaction leading to overestimation of the target amount. Conversely, Taqman probes 
however are more expensive, but with increased specificity, have the ability to multiplex 
and are highly specific (Jelena et al., 2013). 
The use of appropriate controls is important in any experiment. Here, the use of control 
was to confirm that absence of a particular amplification product was not the result of 
sample degradation, but because of absence of that gene. Warrington et al., (2000) 
described reference genes as normally expressed to maintain various cell functions. As 
mentioned earlier, any reference gene should be validated before use for any forensic 
purposes. Among other characteristics, it should be expressed uniformly in all body 
fluids and tissues irrespective of the environmental or experimental conditions; it should 
be free of any known form of pseudogenes and it must be highly sensitive. In qRT-PCR 
experiments, reference genes are used for data normalization. This is to prevent 
variations that may arise from biological and environmentally induced sources 
(Vandesompele et al., 2002; Dheda et al., 2004). 
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A few of the selected reference genes are known to have pseudogenes, which have 
identical properties as real DNA segments. Their difference from real genes arise from 
accumulation of multiple mutations result in them losing some key characteristics that 
their real gene counterparts normally have (Raff et al., 1997). The resulting effect of this 
is that it causes PCR bias leading to reduced reaction efficiency whereby the pseudogene 
might be preferentially expressed rather than the target gene. With this in mind, the 
reference genes were still selected based on other desirable characteristics and reports 
obtained from their use in published literature (Table 2.3). Five markers, namely GAPDH, 
18S rRNA, β-Actin, OAZ1 and S15 failed the qRT-PCR were efficiency tested using SYBR 
Green detection chemistry. While most studies reported the use of these as reference 
genes, it is essential to confirm that the reference genes are adequately validated to 
ensure their suitability for the study type (Ghani et al., 2013). For some reference genes, 
their expression level is affected by a number of factors such as hypoxia (Roberts et al., 
2003); and their involvement in functions other than their basic function of cell 
metabolism (Ishitani et al., 1996).  Due to these reasons, the use of reference genes 
could result in false positive amplification products in both negative, positive control 
and target makers if not adequately validated (Huggett et al., 2005). 
This study tested reference genes and as a result, there were no internal control genes 
to compare them. Microsoft excel statistical software was used to calculate the reaction 
efficiency using the generated Ct values. The premise for the study was because if the 
markers could pass qPCR efficiency using SYBR Green, which is a less specific, sensitive 
method, the use of taqman probes with increased sensitivity and specificity will further 
establish the efficacy of the markers.  
For the SYBR Green experiment, GAPDH, 18S rRNA, β-Actin, OAZ1 and S15 failed the PCR 
efficiency test. Though these markers have been reportedly used as internal controls in 
forensic body fluid identification experiments, 100% efficiency was obtained for them 
during this study. It is envisaged that the markers were binding to all available double 
stranded molecules in the reaction, which is typical of SYBR Green detection system. 18S 
rRNA has the same chemical structure with mRNA. However, they are not in correlation 
as rRNA, a major component of 18S rRNA is not translated into protein like mRNA 
(Meyer et al., 2010) which might be the reason for the efficiency test failure. Contrarily, 
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Lindenbergh et al., (2012), Fleming and Harbison, (2010), Haas et al., 2009, and Bas et 
al., (2004) reportedly utilized 18S- rRNA in their experiment and recommended it for use 
in further studies. S15, b-actin and GAPDH were also reported by Juusola and Ballantyne, 
(2003) to yield positive result in their experiment. This, however, is not in accord with 
the results obtained in this study. The present conclusion for GAPDH failing the 
efficiency test irrespective of the results reported by several authors could be because 
of segmental duplications – a phenomenon whereby a near identical sequence of the 
target is also amplified (Ghani et al., 2013). As reported, segmental duplication covers 
up to 60% of the entire GAPDH length. Thus, the primers will be seen amplifying a near 
identical sequence together with the target sequence. In turn, this can in effect lead to 
a reduction in their efficiency. ACTB was also reported by Ghani et al., (2013) to possess 
segmental duplication characteristic property. However, it showed 100% efficiency in 
our study and this made us select it amongst others for taqman probe design. Meller et 
al., (2005) reported OAZ1 and RPS 29 to be novel and promising candidate markers to 
be used in qPCR experiments. While RPS 29 passed the efficiency test, OAZ1 failed. 
These are still worthy of further research as they have not been validated for forensic 
body fluid identification and casework samples. 
Likewise, for the taqman probe detection system, the five candidate markers - ACTB, 
B2M, RPS29, TEF and UCE that passed the efficiency test using SYBR Green detection 
system were selected for taqman probe design. Sensitivity test was carried out on them 
and all the markers were detected down to 25 pg of total input RNA with the exception 
of TEF which was detected from 100 pg in semen; and 500 pg in menstrual blood and 
venous blood, respectively. This result proves the markers as gold standard in qRT-PCR 
normalization studies, especially in a scenario where the perpetrator of a crime tries to 
conceal the evidential material by washing or cleaning up stains that can be recovered 
and used as evidence. As mentioned earlier, there was no internal control to compare 
the results since the study was centred on reference genes. Nonetheless, expression 
suite software (Life Technologies) was used for statistical analyses. This software makes 
use of geNORM algorithm as recommended by Vandesompele et al., (2002). A histogram 
plot was generated for all the five reference genes on each body fluid (Figures 3.11-
3.13). This reveals the spread of the data set from the minimum  to maximum RNA 
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concentrations that was added to the reaction system. Since each RNA concentration 
was added in duplicates, the histogram plot showed the mean of each duplicate as well 
as the median. From the range of the data set obtained, the reference genes were seen 
to be expressed evenly across each body fluid except for TEF that showed a slight 
variation. 
3.10.2 Six-month old samples 
RNA was seen to be stable in the six-month old body fluid samples analysed. With 
samples from five different individual for each body fluid, expressions were detected in 
at least four individuals for each body fluid with ACTB, RPS29 and UCE being fairly stable 
across the five body fluids, (Figure 3.1). However, TEF was detected in a total of 2 
individuals across the five body fluids. This result supports reports from other studies 
that no single reference gene is universally stable (Vandesompele et al., 2002; 
Pohjanvirta et al., 2006); hence, multiple reference genes have been proposed for use 
in normalization data analysis studies. 
3.11 Conclusion  
There have been several reports of reference genes being used as normalizers in body 
fluid identification experiments (Table 2.3). This study has demonstrated a novel 
approach to establish the efficiency of reference genes for use in forensic body fluid 
identification on five different body fluids – semen, saliva, vaginal secretion, blood and 
menstrual blood on the real time PCR using SYBR Green and Taqman probe detection 
systems. The genes selected include GAPDH, 18S rRNA, β-Actin, OAZ1, S15, ACTB, B2M, 
RPS29, TEF and UCE. The results showed that ACTB, B2M, RPS29, TEF and UCE passed 
the reaction efficiency test using SYBR Green and were further detectable in all the body 
fluids up to 25 pg using Taqman probes (Afolabi et al., 2015). However, as shown in the 
present study, TEF did not demonstrate high sensitivity as other markers, especially on 
semen, blood and menstrual blood. So far, the high sensitivity of any marker is of high 
significance, particularly when stains with minimal amount of nucleated cells are 
encountered on crime scenes, which could be due to the perpetrator of a crime trying 
to conceal the evidentiary materials. Though TEF amongst the five markers tested 
showed no high sensitivity with semen, blood and menstrual blood, it will not be 
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discarded at this time. Meller et al., (2005) and Pohjanvirta et al., (2006) reported that 
since no single reference gene is universally stable, the use of more than one is highly 
recommended to be validated for any normalization experiment.  
In summary, the results obtained from the study carried out in this chapter showed that 
SYBR Green chemistry is cost effective and are ideal to detect efficiencies of reference 
genes. In addition, all five-reference genes that passed the efficiency test and labelled 
with Taqman probes were all expressed in the six-month old samples tested. The 
approach outlined in this chapter is of high relevance as it established the suitability of 
the evaluated reference genes in both fresh and aged samples for forensic body fluid 
identification. More experiments would be carried out on the body fluids using TEF to 
further test its sensitivity.  
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CHAPTER FOUR 
 
 
DESIGN, DEVELOPMENT AND      
OPTIMIZATION OF A MULTIPLEX 
PCR-BASED mRNA ASSAY FOR BODY 
FLUID IDENTIFICATION 
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4.1 Introduction 
Currently, there are no mRNA assay kits commercially available for unambiguous 
identification of forensic body fluids. Each published multiplex assay kit has been 
developed in-house by research groups (Juusola and Ballantyne, 2005; Lindenbergh et 
al., 2012; Roeder and Haas, 2013). Although many authors have reported successful 
development of multiplex assays for forensic body fluid identification using various 
techniques, a large number of markers in these assays are reported to display cross 
reactivity with non-target body fluids (Song et al., 2015; Roeder and Haas, 2013). Most 
forensic samples are usually recovered from the crime scene in a compromised state; all 
these factors necessitated the development of a multiplex PCR-based assay, which can 
unambiguously identify forensic body fluids in this study. Different marker sizes have 
been reported by several authors for the same mRNA PCR amplicons; an example of 
which could be seen in MUC4, a vaginal mucosal marker that is 141 bp (Lindenbergh et 
al., 2012) and 235 bp (Roeder and Haas, 2013). mRNA markers used in this study were 
selected from relevant publications (See Chapter 2, Tables 2.1, 2.2).  
4.2 Aim and objectives of the study 
The aim of this study was to select and evaluate body fluid specific markers from 
relevant literature, employing two approaches, which include minimal cross-reactivity 
with non-target body fluids and smaller amplicon sizes as most forensic samples are 
commonly recovered in environmentally compromised form 
The objectives were: 
 To select body fluid specific markers with small amplicon sizes from relevant 
publications. 
 To optimise the selected primer pairs and PCR conditions using non-labelled and 
florescent-labelled primers. 
 To develop a specific multiplex for each of the five body fluids including blood, 
saliva, semen, vaginal fluid and menstrual blood. 
 To combine the five multiplexes into a single multiplex assay, capable of 
identifying all the five body fluids. 
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4.3 Methods 
Sample preparation and reaction conditions for assay development was highlighted in 
Chapter 2, section 2.8. 
4.4 Results 
This section shows the results generated in this study using gel electrophoresis and 
capillary electrophoresis. A comprehensive discussion of each result detailed in Section 
4.5.  
4.4.1 Gel electrophoresis 
The following results showed gel electrophoresis of body fluid samples amplified using 
Platinum PCR multiplex kit and Qiagen PCR multiplex kit 
4.4.1.1 PCR optimizations using Platinum PCR multiplex kit  
 
Figure.4.1: A pictorial representation of gel electrophoresis of positive control PCR product and 
reference genes stained with safeview. UCE – 241bp; ACTB – 75 bp; B2M – 120 bp; TEF – 206 
bp; RPS29 – 213 bp; L: 100 bp ladder, A: 54 0C, B: 56 0C, C: 58 0C, D: Negative control sample; 
Number of cycles: 35, n=5; where n is the number of repeats of experiment. 
Positive control RNA samples were amplified using Platinum PCR mastermix. All five 
reference genes (UCE, B2M, RPS 29, TEF and ACTB) were expressed with expected sizes 
(Figure 4.1). Although, non-specific amplification was noticed, this was further 
optimised using Qiagen PCR mastermix.
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4.4.1.2 PCR optimization using Qiagen PCR multiplex kit  
PCR amplification using Platinum PCR multiplex kit displayed non-specific amplification 
across all tested samples. Further optimization was carried out using modified cycling 
parameters, primer concentrations and a different mastermix (Qiagen multiplex PCR 
mastermix). The results show that all reference genes were fully expressed in vaginal 
secretion samples and reference genes (Figure 4.2).  
 
Figure 4.2: Pictorial representation of gel electrophoresis of vaginal secretion PCR product and 
reference genes stained with safeview. 1: B2M – 120 bp, 2: ACTB – 75 bp, 3: TEF – 206 bp; 4: 
UCE – 241 bp, 5: RPS29 – 231 bp. L: 100 bp ladder, A: 58 0C, B: 60 0C, C: 62 0C, D: Positive control, 
E: Negative control; Number of cycles: 33. B2M: A: 54 0C, B: 56 0C, C: 58 0C, D: 60 oC, E: Positive 
control, F: Negative control. n=5; where n is the number of repeats of experiment. 
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Figure 4.3: Pictorial representation of gel electrophoresis of vaginal secretion PCR product 
stained with safeview. 1: L. gasseri – 273 bp; 2: MUC4 – 141 bp; 3: L. crispatus – 267, 305 bp; 4: 
HBD1 – 101 bp; 5: CRYP2B7P1 – 198 bp, 6: SFTA2 – 183 bp. L: 100 bp ladder, A: 56 0C, B: 58 0C, 
C: 60 0C, D: Positive control, E: Negative control; Number of cycles: 33. n=5; where n is the 
number of repeats of experiment. 
Figure 4.3 shows amplifications and gel electrophoresis of all vaginal secretion body fluid 
specific markers, positive and negative control samples at 56 0C – 60 0C. All markers were 
expressed at the three annealing temperatures optimised except for HBD1 which 
showed amplification with positive control sample only. There was no amplification in 
the negative control samples.  
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Figure.4.4: Pictorial representation of gel electrophoresis of semen PCR product stained with 
safeview. 1: PRM1 – 91 bp, 2: PRM2 – 294 bp, 3: TGM4 – 215 bp; 4: MSMB – 105 bp, 5: NKX3-1 
– 144 bp, 6: SEMG – 183 bp L: 100 bp ladder, A: 56 0C, B: 58 0C, C: 60 0C, D: Positive control, E: 
Negative control; Number of cycles: 33. n=5; where n is the number of repeats of experiment. 
Semen markers were all expressed in semen samples tested. PRM1, PRM2 and NKX3-1 
displayed a good amplification at all the three annealing temperatures optimised. 
However, TGM4, MSMB and SEMG showed amplification with smeary bands. The 
smeary bands were more noticeable in MSMB at 60 0C (Figure 4.4) 
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Figure 4.5: Pictorial representation of gel electrophoresis of blood PCR product stained with 
safeview. 1: CCL5 – 134 bp; 2: HBB1 – 61 bp; 3: β-SPECTRIN – 150 bp; 4: PPBP – 146 bp; 5: ALAS2 
– 81 bp; L: 100 bp ladder; A: 56 0C, B: 58 0C, C: 60 0C, D: Positive control, E: Negative control; 
Number of cycles: 35. n=5; where n is the number of repeats of experiment. 
Figure 4.5 shows amplification of blood specific markers at 56 0C, 58 0C and 60 0C with 
smeary bands. HBB1 appeared to display optimal amplification at all annealing 
temperatures. Smeary bands were prominent in CCL5, β-Spectrin and ALAS2, and all 
markers were expressed in the positive control sample.  
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Figure.4.6: Pictorial representation of gel electrophoresis of saliva PCR product stained with 
safeview. 1: HTN3 – 134 bp, 2: FDCSP – 115 bp, 3: STATH – 93 bp; L: 100 bp ladder, A: 56 0C, B: 
58 0C, C: 60 0C, D: Positive control, E: Negative control; Number of cycles: 35. n=5; where n is the 
number of repeats of experiment. 
Three saliva markers were all expressed in saliva samples at the annealing temperatures. 
Brightest band was noticed in HTN3, which decreased across FDCSP and STATH 
respectively. None of the markers was expressed in the in the positive control samples 
(Figure 4.6). 
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Figure.4.7: Pictorial representation of gel electrophoresis of menstrual blood PCR product 
stained with safeview. 1: MSX1 – 96 bp; 2: SFRP – 136 bp; 3: MMP11 – 96 bp; L: 100 bp ladder; 
A: 56 0C, B: 58 0C, C: 60 0C; D: Positive control; E: Negative control; Number of cycles: 35. n=5; 
where n is the number of repeats of experiment. 
Figure 4.7 shows amplification and gel electrophoresis of menstrual blood markers. 
MSX1 was expressed in menstrual blood sample at all annealing temperatures while 
SFRP and MMP11 were only expressed in the positive control sample. There was no 
amplification noticed in the negative control samples. 
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4.4.2 Optimisation of Multiplex PCRs using Capillary Electrophoresis 
(CE) 
Capillary electrophoresis was carried out on the ABI 3500 genetic analyser. The results 
are reported in the sections below. 
4.4.2.1 Five-plex multiplex PCR 
Capillary electrophoresis experiment resulted in the development of a five-plex 
multiplex assay which consist of saliva-plex, semen-plex, vaginal secretion-plex and 
blood plex. All the markers were fully expressed in their respective body fluids, which 
indicated specificity of the body fluid markers (Figures 4.9 – 4.13). This implied no 
expression of the specific body fluid markers in non-target body fluids. A schematic 
representation of all the five-plex combined is represented in Figure 4.8.  
 
Figure 4.8: Schematic representation of developed and modified body fluid-specific multiplex 
assay. The following dye colours indicate markers for each body fluid: Blue: blood, menstrual 
blood and semen, Red: saliva, Yellow: vaginal secretion, Green: reference genes, Orange: Size 
standards.  
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 Table 4.3: Final primer concentrations in the five-plex multiplex reactions. An initial 
equimolar concentration of 0.5 µM was used and modified based on the RFUs 
generated in the first rounds of multiplex optimisation. 
Body fluid markers Primer concentrations (F/R) µM 
GLYCOA 2.0 
ALAS2 0.11 
PF4 0.11 
SPTB 1.40 
MSX-1 0.86 
SERP4 1.44 
LEFTY 1.44 
PRM1 0.10 
PRM2 0.35 
TGM4 0.87 
MSMB 0.10 
NKX3-1 0.07 
CRYP2B7P1 0.46 
L. crispatus 0.03 
SFTA2 0.08 
MUC4 0.93 
HTN3 0.18 
FDCSP 1.22 
STATH 0.09 
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4.4.2.1.1 Blood-plex 
The EPG below shows a multiplex panel of all the blood markers. Three blood markers 
were successfully amplified out of four that were optimised (Figure 4.9). SPTB dropped 
out during amplification. An artefact was noticed just before ALAS2, with amplicon size 
of 70 bp. This would not be an issue in profile interpretation due to the sensitivity of the 
genetic analyser used – this is capable of detecting amplicon sizes of a single base-pair 
difference. In addition, ALAS2 is the marker with the smallest amplicon size in the overall 
multiplex panel; therefore, any artefact below this range could be disregarded. 
  
Figure 4.9: EPG showing multiplex panel of blood markers ALAS2: 76 bp; GLYCOA: 110 bp; PF4: 
119 bp. (A) and (B) indicates duplicate PCR of the same sample, n=5; where n is the number of 
repeats of experiment. 
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4.4.2.1.2 Saliva-plex 
All three saliva markers were successfully expressed in the saliva-plex assay. Unlike 
blood-plex that displayed an artefact, none was observed in the saliva-plex. Also as 
expected, the three markers were expressed at different proportions (Figure 4.10). 
 
Figure 4.10: EPG showing multiplex panel of saliva markers STATH: 95bp; FDCSP: 115 bp; HTN3: 
134 bp. (A) and (B) indicates duplicate PCR of the same sample, n=5; where n is the number of 
repeats of experiment. 
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4.4.2.1.3 Semen-plex 
Four markers out of five was expressed in the semen-plex (Figure 4.11). PRM2 dropped 
out in the multiplex. Further modifications were made to the primer concentration, 
which yielded no positive results. 
 
Figure 4.11: EPG showing multiplex panel of semen markers PRM1: 86 bp; MSMB: 100 bp; NKX3-
1: 140 bp; TGM4: 213 bp. (A) and (B) indicates duplicate PCR of same sample, n=5; where n is 
the number of repeats of experiment. 
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4.4.2.1.4 Vaginal secretion-plex 
Four markers were optimised for vaginal secretion detection; however, three markers 
were amplified with MUC4 dropping out of the multiplex. Several attempts made to 
modify the primer concentration yielded no result (See Figure 4.12). 
  
Figure 4.12: EPG showing multiplex panel of vaginal secretion markers SFTA2: 183 bp; 
CRYP2B7P1: 199 bp; L. cris: 304 bp. (A) and (B) indicates duplicate PCR of the same sample, n=5; 
where n is the number of repeats of experiment. 
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4.4.2.1.5 Menstrual blood-plex 
Three markers were initially optimised for menstrual blood detection. SFRP4 and MSX-
1 were expressed with LEFTY dropping out of the multiplex. Further increase in LEFTY 
primer concentration yielded no result (Figure 4.13) 
  
Figure 4.13: EPG showing multiplex panel of menstrual blood markers MSX-1: 79bp; SFRP4: 134 
bp. (A) and (B) indicates duplicate PCR of the same sample, n=5; where n is the number of 
repeats of experiment. 
4.4.2.1.6 Reference genes-plex 
Human XpressRef Universal mRNA sample was used initially to optimise the five 
reference genes. Donated body fluids were then used in the combined multiplex. In the 
EPG (Figure 4.14), TEF and B2M dropped out of the multiplex.  
 
Figure 4.14: EPG showing multiplex panel of reference gene markers ACTB: 75 bp; UCE: 241 bp; 
RPS29: 213 bp for positive control sample (Human XpressRef universal RNA). (A) and (B) 
indicates duplicate PCR of the same sample, n=5; where n is the number of repeats of 
experiment. 
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4.4.2.1.7 Negative controls 
Figure 4.15 shows EPG of negative control samples. These were cDNA prepared from 
original negative control with water. No amplification was seen in any of the four panels. 
This infers there was no form of contamination in any of the reactions. 
 
Figure.4.15: EPG showing negative controls of all the panels utilised in the multiplex reactions 
of each body fluid. (A), (B) and (C) represents blood, menstrual blood and semen panels; vaginal 
secretion panel; and saliva panel respectively, n=5; where n is the number of repeats of 
experiment. 
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4.4.3 Combination of five-plex assay into a single multiplex 
Final primer concentrations used in the combined 5-plex are shown Table 4.4. The 
results displayed expression of all the body fluid markers in their target body fluids with 
no cross-reaction with non-target body fluids (See Figure 4.16). 
Table.4.4: Final primer concentration in the combined multiplex reaction. This include 
primers for blood, saliva, semen, vaginal secretion and reference genes. 
Body fluid specific markers Final primer concentration (F/R) * µM 
ALAS2 0.26 
PF4 0.92 
HTN3 0.19 
STATH 0.19 
PRM1 0.16 
TGM4 0.46 
MSMB 0.28 
NKX3-1 0.18 
UCE 0.92 
ACTB 0.16 
L. crispatus 0.19 
CRYP2B7P1 0.92 
MUC4 0.92 
SFTA2 0.92 
 
F/R* indicates forward and reverse primer 
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The result in Figure 4.16 shows the EPG generated from cDNA mixture of all body fluids. 
These were amplified using equimolar concentration of primers (0.5 µL). Menstrual 
blood markers dropped out of the combined multiplex. In addition, two blood markers, 
four semen markers, two saliva markers, two vaginal secretion markers and 2 reference 
gene markers were expressed. There was a pull-up noticed in both blue and red panels 
with ACTB. This remained persistent despite reducing ACTB primer concentration. As 
shown in Figure 4.16, all body fluid markers were displayed varied expression.  
 
 
Figure 4.16: EPG showing the combined 5-plex into a single multiplex panel using equimolar 
primer concentration. A: Blue panel displays blood and semen markers; B: red panel displays 
saliva markers; C: Green panel displays reference gene markers; D: Yellow panel displays vaginal 
secretion markers. Reference gene ACTB is expressed in all the body fluids while UCE was 
expressed in only the reference genes panel, n=5; where n is the number of repeats of 
experiment. 
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A modified primer concentration was used to generate the EPG in Figure 4.17. A better 
EPG was obtained and the samples did not display over-amplification as noticed in 
Figure 4.16. CRYP2B7PI vaginal secretion marker was expressed this time. The primer 
concentration of UCE was increased due to low expression noticed in Figure 4.16. 
However, this increase did not seem to make any significant difference in the markers 
expression. In addition, pull-ups were still noticed for ACTB in both blue and red panels. 
Most importantly, all markers displayed high specificity with no record of non-specific 
amplification to non-target body fluids noticed. 
 
Figure 4.17: EPG showing the combined 5-plex into a single multiplex panel using modified 
primer concentrations in Fig. 4.4 above. A: Blue panel displays blood and semen markers; B: 
Green panel displays reference gene markers; Yellow panel displays vaginal secretion markers. 
D: red panel displays saliva markers; D: Reference gene ACTB was expressed in all the body fluids 
while UCE was expressed in only the reference genes assay, n=5; where n is the number of 
repeats of experiment. 
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4.5 Discussion 
Multiplex PCR, which offers the flexibility to combine two or more primer pairs in a single 
reaction, has remained an indispensable tool in the forensic science field. Since its first 
description by Chamberlain et al., (1988.), its application has witnessed a significant 
increase across various biochemical fields of study, especially in areas of forensic DNA 
study. It is specifically important in forensic area of body fluid identification as most body 
fluid stains comprise of heterogeneous mixture of cellular materials and are mostly 
recovered with other body fluids (Juusola and Ballantyne, 2003). Multiplex PCR is made 
up of critical parameters, which must be adequately optimised in order to establish its 
success. These include primer concentration, cycling parameters, and role of various 
reagents involved in the reaction (Saiki, 1989). 
In this study, a mRNA multiplex assay for forensic body fluid identification was 
developed and adequately optimised for unambiguous identification of human body 
fluids (Figures 4.1-4.17). Unlike various human identification multiplex assays that are 
commercially available (Applied Biosystems Ltd, Promega Corporation, and Qiagen Ltd), 
there is no known commercial body fluid identification assay till to date. All reported 
different research groups have developed body fluid identification assays in-house, 
which is intended for use in their respective laboratories.  
Initially, 32 markers were selected from relevant literature for the mRNA assay 
development. These include six markers each for vaginal secretion and semen 
respectively, five markers for blood, three markers each for saliva and menstrual blood, 
and five markers for reference genes (Table 2.2). The first phase of the study evaluated 
the reference genes that were initially screened in chapter 3, but in this case, they were 
fluorescently labelled and analysed with body fluid specific markers on the genetic 
analyser. This was optimised using Platinum PCR supermix (Life Technologies Ltd) and 
Qiagen PCR mastermix (Qiagen Ltd) using manufacturers recommended protocols. 
Upon amplification with Platinum PCR supermix, Agarose gel electrophoresis displayed 
the expected sizes for each marker, however, with non-specific amplifications (Figure 
4.1). Although, the use of Platinum PCR mastermix has not been reported in any body 
fluid identification study, it was considered and used in this project because of its 
reported higher specificity and fidelity (Life Technologies Ltd). Further optimization was 
109 
 
carried out to detect the source of the non-specific binding (See Tables 4.1, 4.2 for 
modified cycling parameters). This included optimization of reaction cycles (20–35), 
annealing temperatures (54 oC – 64 oC) and most importantly, the cDNA (Kapley et al., 
2000). In addition, since the non-specific amplifications were noticed above the 
expected amplicon sizes (See Fig. 4.1), attempts were made to reduce the final extension 
time from 10 min to 8 min, 5 min, and 2 min, respectively. The reduction in final 
extension time was targeted at terminating the PCR reaction just shortly after the target 
product has been amplified. These modifications did not yield significant change in 
amplification products obtained as all the reactions produced similar result with the 
presence of non-specific amplifications. Having established this, Qiagen PCR master mix 
was then used for further optimisation with both positive control and vaginal secretion 
samples. This was done as a blind test to check if there would be any difference in cDNA 
amplification using Qiagen PCR multiplex mix, compared to the results obtained using 
Platinum PCR multiplex mix. The amplification produced similar results with Platinum 
mastermix; however, there were no non-specific amplifications (See Figure 4.2). Similar 
studies have reported amplification success using Qiagen PCR mastermix (Lindenbergh 
et al., 2012; Roeder and Haas, 2013; Jakubowska et al., 2013).  
Figure 4.3 shows the result obtained from optimization of all vaginal secretion markers. 
Optimal amplification was recorded at 33 cycles for all markers except HBD1. All markers 
displayed expected sizes as reported in the literature (See Chapter 2, Table 2.2; Figure 
4.3). Positive control sample was only expressed in CRYP2B7P1 marker. HBD1 was not 
expressed in vaginal secretion sample other than in the positive control. This was found 
to be in agreement with a study by Lindenbergh et al., (2012). These authors reported 
no expression of this marker in their developed 19-plex assay. In addition, cross-reaction 
of the marker with saliva was reported by Roeder and Haas, (2013) and Jakubowska et 
al. (2013); and menstrual blood (Juusola and Ballantyne, 2005). This result coupled with 
other authors’ reports could infer the marker might not be ideal in unambiguous 
identification of vaginal secretion.  
PCR optimisation optimization strategy proposed by Chamberlain et al., (1988) and Saiki, 
(1989) was adopted in this project. This include basic PCR cycle (Tables 4.1 and 4.2), and 
annealing temperatures were first tested. Optimised annealing temperature was 58 oC 
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for all samples. This was found to be consistent with the reports of Lindenbergh et al., 
(2012). However, for semen and vaginal secretion specific markers, 33 cycles appeared 
to be optimal whereas 35 cycles were optimal for blood, saliva and menstrual blood 
markers. The 35 cycles for menstrual blood amplification was again consistent with the 
reports of Roeder and Haas, (2013). The variations in PCR primer concentrations 
appeared to have a limited effect after the initial optimisation so these were kept 
constant.  
Semen specific markers displayed optimal amplification and sizes at 33 cycles using 
semen samples. However, positive control samples were not expressed in any of the 
markers (Figure 4.4). Unlike, vaginal secretion and semen markers, blood markers were 
optimally expressed at 35 cycles (Figure 4.5). HBB1 was expressed at all optimized 
annealing temperatures. A smeary band was observed in β-Spectrin and ALAS2, and 
positive control was constantly expressed in all the markers. Although CCL5 and PPBP 
was reported by Park, et al., (2013) to be a robust candidate marker for the identification 
of blood, both markers displayed no expression in this study. Most of the discrepancies 
noticed in the results in comparison to other authors’ reports could be due to using 
different equipment, amplification platforms and reagents (Roeder and Haas, 2013; 
Lindenbergh et al., 2012). 
The three saliva markers displayed expected size expression at 35 cycles (Figure 4.6) 
which further validates the reports of Lindenbergh et al., (2012) and Park et al., (2013). 
All menstrual blood markers were expressed in positive control samples, however, only 
MSX1 was expressed in menstrual blood sample (Figure 4.7). SFRP4 and MMP11 were 
both reported to display specificity for menstrual blood by Roeder and Haas, (2013) and 
Lindenbergh et al. (2012), respectively; however, these were not expressed in this study. 
The reason for this could be because of the nature of sample used. Menstrual blood is 
made up of complex composition (Divall and Ismail, 1983), and expression of its markers 
are dependent on the time of the month the sample was taken. As no specific time of 
menstrual flow was given to the participants regarding the sample collection, this could 
be a main reason some of the markers were not expressed. 
The results of PCR optimization obtained using the non-florescent primers was used for 
fluorescent labelling of primers with high specificity. Four different florescent dyes were 
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selected and these include ATT0 565(Red), 6-FAM (Blue), Yakima Yellow (Green) and 
ATT0 550 (Yellow) (Table 2.8). The use of four different florescent dyes was necessary 
due to some markers having similar sizes as well as to prevent overlap of sizes (Figure 
4.8). The florescent markers were optimised in singleplex PCR to establish their sizes 
using capillary electrophoresis, a platform with vastly increased sensitivity compared to 
gel electrophoresis.  
Further attempts made to develop a 5-plex multiplex panel for all the five body fluids 
resulted in three markers each for blood and saliva, four markers each for semen and 
vaginal secretion and two markers for menstrual blood (See Table 4.3). An initial 
approach was to use equimolar primer concentrations for all the primers in each 
multiplex as recommended by Chamberlain et al., (1988) and Saiki, (1989). These were 
then modified based on the result obtained (RFU) on the electropherogram (EPG). 
Primer pairs with low RFU were increased while those with very high RFUs were reduced 
in order to obtain a nearly balanced peak height (Henegariu et al., 1997). A Tm of 58 0C 
and 33 cycles produced better amplification (Lindenbergh et al., 2012). Magnesium 
Chloride (MgCl2) and dNTP concentrations as recommended by Henegariu et al., (1997) 
did not alter the results as a ready-made multiplex mix (Qiagen PCR multiplex mix) was 
used.  
In this study, blood-plex assay displayed three markers from a total of four (Figure 4.9), 
excluding SPTB. This was expected as many studies that focused on blood identification 
have reported this marker as either not specific or not optimal for mRNA profiling of 
blood (Kohlmeier and Schneider, 2012). MUC4 expression for vaginal secretion in this 
study displayed a very low RFU of 183 and could not be shown on the vaginal secretion-
plex (Figure 4.12). Mara et al., (2012); Nussbaumer et al., (2006); Haas et al., (2009); and 
Cossu et al., (2009), have all reported this marker to exhibit cross reactivity with saliva. 
The results obtained from saliva-plex (Figure 4.10) and semen-plex (Figure 4.11) were 
consistent with all the studies where these markers were used (Lindenbergh et al., 2012; 
Roeder and Haas, 2013; Park et al.,2013; Mara et al., 2012). LEFTY2 was not detected in 
menstrual blood-plex in this study (Figure 4.13). This was less of a concern as Roeder 
and Haas, (2013) reported this marker coupled with other menstrual blood specific 
markers to be non-specific as they were all detected in the non-target body fluids.  
112 
 
Reference genes-plex displayed three markers out of five in the multiplex assay (Figure 
4.14). Although B2M was one of the markers that was expressed across all body fluids 
in previous experiments (Chapter 3), it was not detected in this study. While the primer 
concentration and other cycling parameters were modified to enhance this with no 
positive result, a less concern was placed on the non-expression of TEF as this displayed 
the least expression profile in the previous experiments (Chapter 3). This contrasted 
with the reports of Roeder and Haas, (2013) as the authors reported full expression of 
this marker in their developed assay. In order to keep in check the presence of 
contamination in this study, negative control samples were prepared with each batch of 
reactions. No amplification was observed in any of the negative control samples (Figure 
4.15). 
The developed five-plex multiplex assay displayed unambiguous identification of the 
target body fluids with increase in time and reagents used for the experiments. In 
addition, cross contamination may not be ruled out in the preparation of separate 
multiplex if the analyst does not take adequate care (Ghani et al., 2013). This 
necessitated the need to attempt a single multiplex assay, which will incorporate all the 
markers expressed in the five-plex multiplex assay and reference genes. 
A few modifications in the reaction components were made at the initial stage of the 
multiplex development. A total of 10 µL of mastermix was used in each reaction instead 
of the initial 5 µL in the five-plex reactions. This increased the total reaction volume to 
17 µL as against 10 µL in the five-plex. All the markers that were expressed in the five-
plex reactions were included in the multiplex development. Starting with equimolar 
primer concentrations (Table 4.4), ALAS2 and PF4 (blood), STATH and HTN3 (saliva), 
SFTA2 and L. crispatus (vaginal secretion), PRM1, TGM4, MSMB, NKX3-1 (semen), ACTB 
and UCE (reference genes) were expressed leaving GLYCOA (blood), FDCSP (saliva), 
MUC4, CRYP2B7P1 (vaginal secretion), MSX-1, SFRP4 (menstrual blood) and RPS29, B2M 
(reference genes) unexpressed in the final assay. A minimum of two markers were 
expressed for each target body fluids other than menstrual blood markers that were not 
expressed at all (Figure 4.16).  
Further attempts were made to balance out the peak heights of the markers in the final 
multiplex assay. Markers that displayed relatively high RFUs were decreased and those 
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that were unexpressed or displayed relatively low RFUs were increased (Table 4.4). An 
improved assay was developed with these further optimisations (Figure 4.17). The final 
multiplex assay comprises the following markers: ALAS2 and PF4 (blood), STATH and 
HTN3 (saliva), PRM1, TGM4, MSMB, NKX3-1 (semen), ACTB and UCE (reference genes), 
CRYP2B7P1, SFTA2, and L. crispatus (vaginal secretion). Menstrual blood markers were 
not expressed in the final multiplex assay despite increase in primer and cDNA 
concentrations. This led to the exclusion of these markers in the final multiplex assay. In 
addition, ACTB was consistently expressed in all the four panels representing the body 
fluids while UCE was only expressed in the reference genes panel (Figure 4.17b). Despite 
all optimisations made to UCE, it was either consistently low in expression or not 
expressed at all in the assay. The consistent expression of ACTB across all body fluid 
panels further validates the marker as a robust reference gene marker for forensic body 
fluid identification (Lindenbergh et al., 2012; Ghani et al., 2013). 
In conclusion, body fluid specific markers have been adequately optimised using both 
gel and capillary electrophoresis technique. The results led to the development of a 14-
marker multiplex assay, which was used for the identification of semen, saliva, vaginal 
secretion and blood. For each tested sample, there was no expression of non-target 
body fluid by the assay. Validation experiments were carried out (See Chapter 5) using 
degraded samples, mixtures, mock casework and aged samples. Sensitivity experiments 
were also undertaken in order to establish the overall efficacy of the 14-plex assay.  
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CHAPTER FIVE 
 
 
DEVELOPMENTAL VALIDATION OF A 
14-mRNA MARKER MULTIPLEX PCR-
BASED ASSAY FOR BODY FLUID 
IDENTIFICATION 
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5.1 Introduction 
The drive to unambiguously identify body fluids deposited at the crime scene has been 
a major concern for forensic investigators. Use of RNA markers for body fluid 
identification has been researched in recent years. The multiplexes based on RNA 
markers follow the same principles as the commercial STR based multiplex kits for 
human identification.  
Validation of methods in Forensic field is a key factor that cannot be overemphasized. It 
is used to establish ‘fitness of purpose’ for methods involved in conducting specific 
examinations. In 2015, the Scientific Working Group on DNA Analysis Methods 
(SWGDAM) published guidelines for Collection and Serological Examination of Biological 
Evidence. The document highlights key rules to follow by Forensic DNA laboratories in 
order to evaluate reliability, sensitivity, specificity, stability, and reproducibility of their 
methods. Unlike mRNA profiling, many validation experiments have been carried out on 
DNA marker based multiplex assay (Ensenberger et al., 2010; Oostdik et al., 2013; 
Oostdik et al., 2014). The authors have reported specifically validation of DNA multiplex 
kits with addition of more loci to the 13 core CODIS loci, enhanced buffer system with 
hot-start Taq DNA polymerase, sensitivity, concordance, inhibition tolerance amongst 
other criteria, following SWGDAM developmental validation guidelines; all these have 
made DNA typing more efficient and less time consuming. In addition, the guidelines 
have enhanced the ease of human STR typing and its standardization between 
laboratories.  
In this study, the developmental validation of a 14-RNA marker multiplex PCR assay was 
carried out. The study was designed to satisfy SWGDAM, as there are currently no 
validation guidelines published on mRNA analysis. 
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5.2 Aim and objectives 
The main aim of this section of the study was to carry out developmental validation of 
the mRNA-based multiplex PCR assay.  
Specific objectives of this chapter were:  
 To carry out sensitivity study using the assay on four different body fluids – 
blood, saliva, vaginal secretion and semen. 
 To carry out degradation of the body fluid sample and study assay performance 
using such samples. 
 To conduct other validation experiments including mixture, reaction volume, 
different cycle number and annealing temperatures, cross reactivity, species 
specificity studies.  
 To establish the use of most appropriate master mix by testing different PCR 
mastermix for the assay. 
 To establish the robustness of the assay using mock casework samples. 
5.3 Methods 
The methods used for the validation experiment was reported in Chapter 2, section 9. 
5.4 Results 
All results and experimental conditions are stated below each electropherogram 
generated. Unless otherwise stated, electrophoresis conditions were outlined in 
Chapter 2, sections 2.17-2.18. 
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5.4.1 Sensitivity study 
All samples were diluted using the dilution series in Chapter 2, Section 2.9.7. The results 
are discussed in the sections below. 
5.4.1.1 Blood 
The results in the Figures 5.1i-5.1iv display a gradual decrease in peak heights with 
increase in dilution ratio of body fluid samples. Both blood markers (ALAS2 and PF4) 
were fully expressed at 1:1500 dilution. The relative sensitivities of the assay on blood 
sample is shown in Figures 5:1a-h. There was a significant decrease in peak heights of 
both markers with increase in dilution ratio. PF4 dropped out at 1:3000th dilution.  
 
Figure 5.1i: EPG showing (a) 1:10, (b) 1:50 of 5 ng/µl input mRNA of blood sample. A volume of 
1 µl of the dilution was used for sample amplification at 58 0C, 33 cycles, n=5; where n is the 
number of repeats of experiment. 
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Figure 5.1ii: EPG showing (c) 1:100, (d) 1:250 and (e) 1:500 dilutions of 5 ng/µl mRNA of blood 
sample. A volume of 1 µl of the dilution was used for sample amplification at 58 0C, 33 cycles, 
n=5; where n is the number of repeats of experiment 
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Figure 5.1iii: EPG showing (f) 1:1000, (g) 1:1500 dilutions of 5 ng/µl mRNA of blood sample. A 
volume of 1 µl of the dilution was used for sample amplification at 58 0C, 33 cycles, n=5; where 
n is the number of repeats of experiment. 
 
 
Figure 5.1iv: EPG showing (h) 1:3000 dilution of 5 ng/µl mRNA of blood sample. A volume of 1 
µl of the dilution was used for sample amplification at 58 0C, 33 cycles, n=5; where n is the 
number of repeats of experiment. 
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5.4.1.2 Semen 
Four markers were incorporated into the 14-plex assay for semen sample identification; 
these included PRM1, MSMB, NKX3-1, and TGM4.  All the four markers were well 
expressed throughout the dilution series. MSMB displayed the highest expression 
amongst the four, with the remaining three having a near balanced expression (Figures 
5.2i-iii). All the four markers were still fully expressed at 1:3000 dilution. 
 
Figure 5.2i: EPG showing (a) 1:10, (b) 1:50, (c) 1:100, (d) 1:250, (e) 1:500 dilutions of 5 ng/ µl 
mRNA of semen sample. A volume of 1 µl of the dilution was used for sample amplification at 
58 0C, 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.2ii: EPG showing (f) 1:1000, (g) 1:1500 dilutions of 5 ng/ µl mRNA of semen sample. A 
volume of 1 µl of the dilution was used for sample amplification at 58 0C, 33 cycles, n=5; where 
n is the number of repeats of experiment. 
 
 
Figure 5.2iii: EPG showing (h) 1:3000 dilution of 5 ng/ µl mRNA of semen sample. A volume of 1 
µl of the dilution was used for sample amplification at 58 0C, 33 cycles, n=5; where n is the 
number of repeats of experiment. 
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5.4.1.3 Saliva 
Saliva markers (STATH and HTN3) were both expressed in the assay all through the 
dilution series and represented in the red panel (Figures 5.3i-iii). Also in this panel are 
the reference genes ACTB and UCE. Despite several attempts at increasing the 
concentration of ACTB, it was not expressed at all in the assay. However, UCE was 
expressed in every amplification. An increase in dilution of saliva sample resulted in a 
significant decrease in expression of UCE, the expression of which was lost at 1:1000, 
1:1500 and 1:3000 dilutions.  
 
Figure 5.3i: EPG showing (a) 1:10, (b) 1:50, (c) 1:100, (d) 1:250, (e) 1:500 dilutions of 5 ng/ µl 
mRNA of saliva sample. A volume of 1 µl of the dilution was used for sample amplification at 58 
0C, 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.3ii: EPG showing (f) 1:1000, (g) 1:1500 dilutions of 5 ng/ µl mRNA of saliva sample. A 
volume of 1 µl of the dilution was used for sample amplification at 58 0C, 33 cycles, n=5; where 
n is the number of repeats of experiment. 
 
 
Figure 5.3iii: EPG showing (h) 1:3000 dilution of 5 ng/ µl mRNA of saliva sample. A volume of 1 
µl of the dilution was used for sample amplification at 58 0C, 33 cycles, n=5; where n is the 
number of repeats of experiment. 
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5.4.1.4 Vaginal secretion 
Vaginal secretion markers (MUC4, CRYP2B7PI, SFTA2 and L. crispatus) were optimised 
for specificity on vaginal secretion samples. While the four markers displayed specific 
expression for vaginal secretion in the five-plex assay (Chapter 4), SFTA2 and L. cris were 
the only markers expressed in the validation study. They both displayed a high 
expression till 1:1500th dilution series (Figures 5.4i/ii). However, both markers dropped 
out at 1:3000th dilution (Figures 5.4iii).  
 
Figure 5.4i: EPG showing (a) 1:10, (b) 1:50, (c) 1:100, (d) 1:250, (e) 1:500 dilutions of 5 ng/ µl 
mRNA of vaginal secretion sample. A volume of 1 µl of the dilution was used for sample 
amplification at 58 0C, 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.4ii: EPG showing (f) 1:1000 and (g) 1: 1500 dilutions of 5 ng/ µl mRNA of vaginal 
secretion sample. A volume of 1 µl of the dilution was used for sample amplification at 58 0C, 33 
cycles, n=5; where n is the number of repeats of experiment. 
 
 
Figure 5.4iii: EPG showing (h) 1: 3000 dilutions of 5 ng/ µl mRNA of vaginal secretion sample. A 
volume of 1 µl of the dilution was used for sample amplification at 58 0C, 33 cycles. 
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+++ = strong expression; ++ = weak expression; + = very weak expression; - = negative/no 
expression. 
The scale was developed based on the use of number of markers expressed in the study. 
For semen with four markers, the expression was classified as strong when all four or 
three are amplified, weak with two markers, very weak with one marker and no 
expression with no marker amplified (See Table 5.1) 
5.4.2 Reproducibility study 
The independent laboratory where the primermix was sent for reproducibility study 
generated similar results with experiments carried out at UCLan laboratory as all the 
markers were expressed for the target body fluids. However, over-amplification of 
samples was generated and this was reported to be because of unquantified and sample 
overload (Appendix 5). 
5.4.3 Mixture study 
Mixture of all four body fluids were first prepared in equimolar concentrations, and then 
modified in order to obtain a near balanced peak height for the overall profile (see 
Figures 5.26iii-iv). In practise, occurrence of mixture of all four body fluids at any specific 
Table 5.1: Amplification success levels of mRNA multiplex assay using samples at various 
dilution ratios of blood, saliva, semen, vaginal secretion and the reference genes. 
Dilution 
factor 
Blood Saliva Semen Vaginal secretion Reference 
genes 
1:10 +++ +++ +++ +++ ++ 
1:50 +++ +++ +++ +++ ++ 
1:100 +++ +++ +++ +++ ++ 
1:250 +++ +++ +++ +++ ++ 
1:500 +++ +++ +++ +++ ++ 
1:1000 +++ +++ +++ +++ ++ 
1:1500 ++ +++ +++ +++ ++ 
1:3000 + ++ ++ - + 
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time is rarely possible; this prompted subsequent mixture experiments to be carried out 
in duplex reactions.  
5.4.3.1 Semen + Vaginal secretion 
Mixture of semen and vaginal secretion samples in equimolar and varying proportions 
is shown in Figures 5.5i-iv. All four semen markers displayed high expression for all 
mixture ratios. However, three out of four vaginal secretion markers were expressed in 
all mixture ratios. Equimolar mixture of semen and vaginal secretion showed a decrease 
in peak heights of vaginal secretion markers (Figures 5.5ii (di-ii)). The same was noticed 
to decrease further with increase in proportion of semen sample (Figures 5.5iii-iv). 
Overall, all four semen markers and three out of four vaginal secretion markers were 
expressed through the dilution series. 
 
Figure 5.5i: EPG showing mixture of semen and vaginal secretion in proportions. A volume of 1 
µl of each sample which indicates 1 proportion was used. (ai/aii) 1:2, (bi/bii) 1:4. These were 
amplified at 58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.5ii: EPG showing mixture of semen and vaginal secretion in proportions. A volume of 1 
µl of each sample which indicates 1 proportion was used. (ci/cii) 1:9, (di/dii) 1:1. These were 
amplified at 58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.5iii: EPG showing mixture of semen and vaginal secretion in proportions. A volume of 
1 µl of each sample which indicates 1 proportion was used. (ei/eii) 2:1, (fi/fii) 4:1. These were 
amplified at 58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.5iv: EPG showing mixture of semen and vaginal secretion in proportions. A volume of 1 
µl of each sample which indicates 1 proportion was used. (gi/gii) 9:1. These were amplified at 
58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
Several artefacts were noticed in the EPGs. These were because of overload of a 
particular cDNA sample at any given mixture ratio. 
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5.4.3.2 Blood + Vaginal secretion 
Two blood and three vaginal secretion markers, respectively were expressed upon 
mixture in both equimolar and varied proportions. There was a decrease in the 
expression of vaginal secretion markers upon increase in proportion of blood samples. 
All markers for both body fluids were expressed in all proportions (Figures 5.6 i-iv). 
 
Figure 5.6i: EPG showing mixture of blood and vaginal secretion in proportions. A volume of 1 
µl of each sample which indicates 1 proportion was used. (ai/aii) 1:2, (bi/bii) 1:4. These were 
amplified at 58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.6ii: EPG showing mixture of blood and vaginal secretion in proportions. A volume of 1 
µl of each sample which indicates 1 proportion was used. (ci/cii) 1:9, (di/dii) 1:1. These were 
amplified at 58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.6iii: EPG showing mixture of blood and vaginal secretion in proportions. A volume of 1 
µl of each sample which indicates 1 proportion was used. (ei/eii) 2:1, (fi/fii) 4:1. These were 
amplified at 58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.6iv: EPG showing mixture of blood and vaginal secretion in proportions. A volume of 1 
µl of each sample which indicates 1 proportion was used. (gi/gii) 9:1. These were amplified at 
58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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5.4.3.3 Blood + Semen 
Semen markers were seen to display a stable and high expression through all the dilution 
series.  A 1:1 dilution showed a low expression of blood markers, which only were 
increased at 4:1 mixture of blood and semen. Increase in the mixture proportion of 
blood markers did not have an effect the expression of semen markers (Figures 5.7i-ii). 
 
Figure 5.7i: EPG showing mixture of blood and semen in proportions. A volume of 1 µl of each 
sample which indicates 1 proportion was used. (a) 1:2, (b) 1:4, (c) 1:9, (d) 1:1. These were 
amplified at 58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.7ii: EPG showing mixture of blood and semen in proportions. A volume of 1 µl of each 
sample which indicates 1 proportion was used. (e) 2:1, (f) 4:1, (g) 9:1. These were amplified at 
58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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5.4.3.4 Blood + Saliva 
An increase in mixture proportion of saliva had no major effect on expression of blood 
markers ALAS2 and PF4. Both markers were stably expressed in all dilution series, with 
increase in RFU generated at 4:1 and 9:1 blood and saliva (Figures 5.8iii (fi-gi)). Saliva 
markers as well as reference gene marker, UCE also displayed a stable expression 
throughout the dilution series (Figures 5.8i-iv). 
 
Figure 5.8i: EPG showing mixture of blood and saliva in proportions. A volume of 1 µl of each 
sample which indicates 1 proportion was used. (ai/aii) 1:2, (bi/bii) 1:4. These were amplified at 
58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.8ii: EPG showing mixture of blood and saliva in proportions. A volume of 1 µl of each 
sample which indicates 1 proportion was used. (ci/cii) 1:9, (di/dii) 1:1. These were amplified at 
58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.8iii: EPG showing mixture of blood and saliva in proportions. A volume of 1 µl of each 
sample which indicates 1 proportion was used. (ei/eii) 2:1, (fi/fii) 4:1. These were amplified at 
58 0C and 33 cycles, n=5; where n is the number of repeats of experiment. 
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Figure 5.8iv: EPG showing mixture of blood and saliva in proportions. A volume of 1 µl of each 
sample which indicates 1 proportion was used. (gi/gii) 9:1. These were amplified at 58 0C and 33 
cycles, n=5; where n is the number of repeats of experiment. 
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5.4.4 Controlled degradation 
Controlled degradation experiment was carried out for all body fluid samples at room 
temperature, 37 oC, 56 oC and under UV crosslinker. The results are shown in sections 
5.4.4.1 -5.4.4.4.9. 
5.4.4.1 Blood: Room temperature 
The blood samples that were prepared on microscopic slides showed no apparent effect 
of degradation in the first four weeks of the experiment (Figures 5.9a, b). However, at 
the end of the sixth week, there was a noticeable change as the amount of mRNA 
recovered was almost halved compared to what was recovered at week 0 (Figure 5.9c). 
See appendix 4d-h for EPGs showing results of blood sample prepared on glass slide, can 
of coke, plastic bag, facemasks, and scalpels. 
 
Figure 5.9: EPG showing degradation of blood sample in a dark, cool cupboard at room 
temperature over a period of six weeks. (a) week 0, (b) week 2 (c) week 6. A volume of 1 µl 
amplified sample was used for CE, 56 oC, n=5; where n is the number of repeats of experiment.
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5.4.4.2 Semen  
Low RFUs were generated for expression of three semen markers –MSMB, NKX3-1 and 
TGM4, which was consistent over the six weeks’ period. Also, there was a noticeable 
difference in amount of mRNA sample recovered at the end of six weeks compared to 
the results at weeks zero and four (Figure 5.10).  
 
Figure 5.10: EPG showing degradation of semen sample in a dark, cool cupboard at room 
temperature over a period of six weeks. (a) week 0, (b) week 2 (c) week 6. A volume of 1 µl 
amplified sample was used for CE, n=5; where n is the number of repeats of experiment. 
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5.4.4.3 Saliva 
Unlike semen and blood samples, saliva displayed a notable degradation rate over the 
six weeks’ period. The amount of mRNA recovered and amplified was almost halved at 
the end of week 6, compared to week 1. This was established by the RFU generated in 
Figure 5.11.  
 
Figure 5.11: EPG showing degradation of saliva sample in a cool, dark cupboard at room 
temperature over a period of six weeks. (a) week 0, (b) week 2 (c) week 6. A volume of 1 µl 
amplified sample was used for CE, n=5; where n is the number of repeats of experiment. 
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5.4.4.4.2 Blood: Incubator 
From the result obtained in Figure 5.12, the high temperature appeared to have a 
significant effect on the blood mRNA sample as the expression of both blood markers 
decreased gradually with the most reduced effect noticeable at the end of 90 mins 
(Figure 5.12e). 
 
Figure 5.12: EPG showing degradation of blood sample in an incubator at 56 oC over a period of 
90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 min. A volume of 1 µl amplified 
sample was used for CE, n=5; where n is the number of repeats of experiment. 
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5.4.4.4.3 Blood: Ultraviolet cross-linker 
The effect of UV light on mRNA blood sample was distinct after 5 mins of exposure. 
While the expression of both blood markers were considerably reduced after 5 min, PF4 
dropped out after 10 mins of exposure to UV (Figure 5.13). 
 
Figure 5.13: EPG showing degradation of blood sample in ultraviolet (UV) cross linker (X100 
µJ/cm2) over a period of 90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 min. A 
volume of 1 µl amplified sample was used for CE, n=5; where n is the number of repeats of 
experiment. 
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5.4.4.4.4 Saliva: Incubator 
Saliva markers appeared stably expressed post incubation as there was no noticeable 
change in the RFU generated all through the incubation period (Figure 5.14). 
 
Figure 5.14: EPG showing degradation of saliva sample in an incubator at 56 oC over a period of 
90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 min. A volume of 1 µl amplified 
sample was used for CE, n=5; where n is the number of repeats of experiment. 
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5.4.4.4.5 Saliva: Ultraviolet cross-linker 
In contrast to the result obtained from samples degraded in the incubator, UV had a 
significant effect on saliva mRNA samples. The RFU generated reduced with increasing 
time of degradation. After 60th minute, the expression of STATH dropped out, leaving 
HTN3, which eventually dropped out at before the 90th minute. The expression of UCE 
was seen to be stable and not affected by the UV light (Figure 5.15). 
 
Figure 5.15: EPG showing degradation of saliva sample in ultraviolet (UV) cross linker (X100 
µJ/cm2) over a period of 90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 min. A 
volume of 1 µl amplified sample was used for CE, n=5; where n is the number of repeats of 
experiment. 
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5.4.4.4.6 Semen: Ultraviolet light 
The results obtained from exposure of semen mRNA samples to UV light showed all four 
markers with high expression. After 10 min of exposure, TGM4 reduced gradually 
reaching an RFU of less than 1000 at the end of 90 min (Figure 5.16). 
 
Figure 5.16: EPG showing degradation of semen sample in ultraviolet (UV) cross linker (X100 
µJ/cm2) over a period of 90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 min. A 
volume of 1 µl amplified sample was used for CE, n=5; where n is the number of repeats of 
experiment. 
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5.4.4.4.7 Semen: Incubator 
Incubation of semen samples at 56 oC did not appear to have to have much effect on its 
degradation. All the four markers displayed high expression which remained stable all 
through the incubation times (Figure 5.17). 
 
Figure 5.17: EPG showing degradation of semen sample in an incubator at 56 oC over a period 
of 90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 min. A volume of 1 µl amplified 
sample was used for CE, n=5; where n is the number of repeats of experiment. 
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5.4.4.4.8 Vaginal secretion: Ultraviolet light 
Three out of four vaginal secretion markers were expressed after exposure to UV light. 
MUC4 and vaginal bacterial marker L. crispatus both showed a decrease in RFU through 
the 90 minutes of exposure. However, SFTA2 dropped out at 30 and 90 minutes (Figure 
5.18). 
 
Figure 5.18: EPG showing degradation of vaginal secretion sample in ultraviolet (UV) cross linker 
(X100 µJ/cm2) over a period of 90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 
min. A volume of 1 µl amplified sample was used for CE, n=5; where n is the number of repeats 
of experiment. 
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5.4.4.4.9 Vaginal secretion: Incubator 
Incubation at 56 oC appeared not have a noticeable effect on the expression of MUC4, 
SFTA2 and L. cris as RFU generated remained the same (Figure 5.19). 
 
Figure 5.19: EPG showing degradation of vaginal secretion sample in an incubator at 56 oC over 
a period of 90 minutes. (a) 5 min, (b) 10min (c) 30 min. (d) 60 min, (e) 90 min. A volume of 1 µl 
amplified sample was used for CE, n=5; where n is the number of repeats of experiment. 
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5.4.5 Non-controlled degradation 
Non-controlled degradation was carried out as outline in Chapter 2, section 2.9.8.2. The 
result is reported in sections 5.4.5.1 – 5.4.5.3. 
5.4.5.1 Blood sample 
The high temperature and humidity did not affect the expression of the two blood 
markers ALAS2 and PF4. They both displayed a stable but reduced expression 
throughout the period of the experiment. Figure 5.20 displays EPG obtained from 
samples prepared on glass slide and recovered on days zero (day sample was prepared), 
day 25 and day 50.  
 
Figure 5.20: EPG showing uncontrolled degradation of blood sample stained on glass slide over 
a period of 51 days in Saudi Arabia, in the summer of 2014. Samples were taken every 48-72 hrs 
under 49.5 oC, 6.3 oC maximum and minimum temperatures respectively, 95% maximum and 
minimum relative humidity. (a) day 1, (b) day 25 and (c) day 50, n=5; where n is the number of 
repeats of experiment. 
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5.4.5.2 Saliva  
Unlike blood samples, the environmental conditions had an adverse effect on saliva 
samples as both saliva markers and reference gene were only expressed up till day 25 
of the experiment. The markers dropped out after day 25 (Figure 5.21).  
 
Figure 5.21: EPG showing uncontrolled degradation of saliva sample stained on cotton cloth over 
a period of 51 days in Saudi Arabia, in the summer of 2014. Samples were taken every 48-72 hrs 
under 49.5 oC, 6.3 oC maximum and minimum temperatures respectively, 95% maximum and 
minimum relative humidity. (a) day 1, (b) day 25 and (c) day 50, n=5; where n is the number of 
repeats of experiment. 
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5.4.5.3 Semen 
Semen samples prepared and recovered from glass slides, cotton cloth and metal all 
displayed expression up until day 30. All four markers dropped out after day 30 on 
samples recovered from metal and cotton cloth while MSMB and NKX3-1 were the only 
markers expressed at day 30 on samples recovered from glass slides (Figure 5.22).  
 
Figure 5.22: EPG showing uncontrolled degradation of semen sample stained on glass slide over 
a period of 51 days in Saudi Arabia, in the summer of 2014. Samples were taken every 48-72 hrs 
under 49.5 oC, 6.3 oC maximum and minimum temperatures respectively, 95% maximum and 
minimum relative humidity. (a) day 1, (b) day 25 and (c) day 50. 
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+++ = very strong expression; ++ = weak expression; + = very weak expression; - = no 
expression, ns= not supplied. 
C= cotton cloth, G= glass slide, M= metal/knife. 
 
Table.5.2: Expression of body fluid markers in environmentally degraded samples 
over 51 days. 
 Sample 
Blood Saliva Semen 
Day C M G C M G C M G 
1 +++ +++ +++ +++ +++ ns +++ +++ +++ 
5 +++ +++ +++ +++ ++ ns +++ +++ +++ 
10 +++ +++ +++ +++ ++ ns +++ +++ +++ 
15 +++ +++ +++ ++ ++ ns +++ +++ +++ 
20 +++ +++ +++ ++ + ns +++ +++ +++ 
25 +++ +++ +++ ++ + ns ++ +++ +++ 
30 +++ +++ +++ + + ns ++ + ++ 
35 +++ +++ ++ - + ns ++ + + 
40 +++ +++ ++ - - ns - - - 
45 +++ ++ ++ - - ns - - - 
50 +++ ++ ++ - - ns - - - 
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5.4.6 Equimolar mixture of all body fluid sample 
All body fluid samples; blood, semen, saliva and vaginal secretion were mixed in 1:1 
proportion and 1µl of the mixture was amplified. All blood, saliva, semen and reference 
gene markers were highly expressed (Figures 5.23ai, aiii). However, only SFTA2 was 
expressed for vaginal secretion (Figures 5.23ii). 
 
Figure 5.23: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in equal proportions. A volume of 1 µl of each sample which indicates 1 proportion was used. 
(ai/aii/aiii) 1:1, n=5; where n is the number of repeats of experiment. 
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5.4.7 Primer titration 
Primer concentration plays a key role in amplification reaction. The effect of primer 
concentration was determined by optimising 1 µl, 1.5 µl, and 3.5 µl primer mix added to 
the reaction components. As primer concentrations increase, there was an increase in 
peak heights of all the markers (Figures 5.24i-vi). With an optimal primer concentration 
being 3.5 µl, better profile was generated using Qiagen PCR mastermix (See Figures 
5.24iv and 5.24vi). 
 
Figure 5.24i: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Qiagen PCR mastermix (Qiagen Ltd) and a volume of 1 µl 
primermix. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva and reference gene, n=5; 
where n is the number of repeats of experiment. 
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Figure 5.24ii: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Qiagen PCR mastermix (Qiagen Ltd) and a volume of 1.5 
µl primermix. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva and reference gene, n=5; 
where n is the number of repeats of experiment. 
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Figure 5.24iii: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Qiagen PCR mastermix (Qiagen Ltd) and a volume of 3.5 
µl primermix. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva and reference gene, n=5; 
where n is the number of repeats of experiment. 
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Figure 5.24iv: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Platinum PCR mastermix (Life Technologies Ltd) and a 
volume of 3.5 µl primermix. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva and 
reference gene, n=5; where n is the number of repeats of experiment. 
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Figure 5.24v: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Platinum PCR mastermix (Life Technologies Ltd) and a 
volume of 1.5 µl primermix. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva and 
reference gene, n=5; where n is the number of repeats of experiment. 
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Figure 5.24vi: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Platinum PCR mastermix (Life Technologies Ltd) and a 
volume of 3.5 µl primermix. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva and 
reference gene, n=5; where n is the number of repeats of experiment. 
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5.4.8 Reaction components and thermal cycling conditions 
Reaction components need to be optimised as a slight departure from optimal annealing 
temperature, cycle number or master mix could lead to generation of artefacts. For 
consistent and robust results, two different mastermix, Qiagen PCR multiplex mix 
(Qiagen Ltd) and Platinum supermix (Life technologies Ltd) were optimised at 54 oC, 56 
oC, 58 oC and 60 oC with 58 oC being the optimal annealing temperature (see Figures 4:1-
7; 5.25i-iv).  
 
Figure 5.25i: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Platinum PCR mastermix (Life Technologies Ltd) and a 
volume of 3.5 µl primermix at 54 oC Tm. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva 
and reference gene, n=5; where n is the number of repeats of experiment. 
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Figure 5.25ii: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Platinum PCR mastermix (Life Technologies Ltd) and a 
volume of 3.5 µl primermix at 56 oC Tm. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva 
and reference gene, n=5; where n is the number of repeats of experiment. 
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Figure 5.25iii: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Platinum PCR mastermix (Life Technologies Ltd) and a 
volume of 3.5 µl primermix at 58 oC Tm. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva 
and reference gene, n=5; where n is the number of repeats of experiment. 
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Figure 5.25iv: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl using 10 µl Platinum PCR mastermix (Life Technologies Ltd) and a 
volume of 3.5 µl primermix at 60 oC Tm. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva 
and reference gene, n=5; where n is the number of repeats of experiment. 
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5.4.9 Reduced reaction volume 
Many forensic laboratories tend to reduce the reaction volume for their experiments as 
a cost saving measure. In this study, final reaction volume was modified by reducing the 
volume of mastermix in the reaction while other reaction components were kept 
constant. Final reaction volumes of 12.2 µl and 17.2 µl were tested. The result in Figures 
5.26i shows expression of all the body fluid markers, although in varied proportions and 
a low efficiency in amplification using 5 µl Qiagen PCR mastermix (Figure 5.26i). A similar 
profile was obtained using 5µl Platinum PCR mastermix but with low expression of 
vaginal secretion markers (Figure 5.26ii). The use of 10 µl Platinum PCR and Qiagen 
mastermix (Figures 5.26iii and 5.26iv respectively) generated an improved profile with 
expression of all the body fluid markers. 
 
Figure 5.26i: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in proportions with a reduced volume (5 µl) Qiagen PCR mastermix (Qiagen Ltd). Varied 
concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and vaginal 
secretion: 1.8 ng/µl proportion was used. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva 
and reference gene. Final reaction volume was 12.2 µl., n=5; where n is the number of repeats 
of experiment. 
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Figure 5.26ii: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in proportions with a reduced volume (5 µl) Platinum PCR mastermix (Life Technologies Ltd). 
Varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl proportion was used. (ai) blood and semen, (aii) vaginal secretion, 
(aiii) saliva and reference gene. Final reaction volume was 12.2 µl, n=5; where n is the number 
of repeats of experiment. 
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Figure 5.26iii: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in proportions with a reduced volume (10 µl) Platinum PCR mastermix (Life Technologies Ltd). 
Varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl proportion was used. (ai) blood and semen, (aii) vaginal secretion, 
(aiii) saliva and reference gene. Final reaction volume was 17.2 µl, n=5; where n is the number 
of repeats of experiment. 
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Figure 5.26iv: EPG showing mixture of all body fluids: blood, saliva, semen and vaginal secretion 
in proportions with a reduced volume (10 µl) Qiagen PCR mastermix (Qiagen Ltd). Varied 
concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and vaginal 
secretion: 1.8 ng/µl proportion was used. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva 
and reference gene. Final reaction volume was 17.2 µl, n=5; where n is the number of repeats 
of experiment. 
5.4.9i Comparison of reduced and full reaction volume results 
Figures 5.26i-iv display the results of full and reduced reaction volumes. As expected, 
both multiplex mix used (Qiagen PCR and Platinum PCR multiplexes) displayed varied 
results with each reaction volume. These effects were evident mostly in semen markers 
PRM1, NKX3-1, and TGM as low RFUs were generated with reduced reaction volume 
using Qiagen multiplex mix (Figure 5.26i). An improved EPG was generated with reduced 
and full volume Platinum multiplex mix, however, with artefacts (Figures 5.26ii, iii). A 
more improved result was generated with full volume Qiagen PCR mastermix with 
minimal artefacts (Figure 5.26iv). 
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5.4.10 Cycle number  
Extracted mRNA was evaluated using 28, 30, 33 and 35 amplification cycles. Partial 
profile was generated for 28-cycle amplification as only one semen marker was 
expressed. Saliva markers had reduced peak heights and there was no expression for 
any of the vaginal secretion markers (Figure 5.27i). An improved profile was generated 
with 30 cycles of amplification (Figure 5.27ii) while many artefacts were observed at 35 
cycles of amplification (Figure 5.27ii). Optimal amplification was recorded at 33 cycles 
with all semen, blood, saliva and two vaginal secretion markers expressed (Figure 
5.27iii). 
 
 
Figure 5.27i: EPG showing amplification of all body fluids: blood, saliva, semen and vaginal 
secretion in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 
ng/µl and vaginal secretion: 1.8 ng/µl using 10 µl Qiagen PCR mastermix (Qiagen Ltd) and 3.5 µl 
primermix at 58 oC Tm, 28 cycles. (a) blood and semen, (b) vaginal secretion, (c) saliva and 
reference gene, n=5; where n is the number of repeats of experiment. 
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Figure 5.27ii: EPG showing amplification of all body fluids: blood, saliva, semen and vaginal 
secretion in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 
ng/µl and vaginal secretion: 1.8 ng/µl using 10 µl Qiagen PCR mastermix (Qiagen Ltd) and a 
volume of 3.5 µl primermix at 58 oC Tm 30 (a-c) and 35 (d-f) cycles. (a/d) blood and semen panel, 
(b/e) vaginal secretion panel, (c/f) saliva and reference gene panel, n=5; where n is the number 
of repeats of experiment. 
 
173 
 
 
 
 
Figure 5.27iii: EPG showing amplification of all body fluids: blood, saliva, semen and vaginal 
secretion in varied concentration of each sample: semen: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 
ng/µl and vaginal secretion: 1.8 ng/µl using 10 µl Qiagen PCR mastermix (Qiagen Ltd) and 3.5 µl 
primermix at 58 oC Tm, 33 cycles. (ai) blood and semen, (aii) vaginal secretion, (aiii) saliva and 
reference gene, n=5; where n is the number of repeats of experiment. 
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5.4.11 Species specificity 
Human DNA samples from blood, saliva and bone were tested for specificity of the assay. 
A few peaks were observed but were not within the range of the body fluid specific 
markers. Furthermore, mammalian samples from horse, pig, wood mouse, rat, and 
rabbit was amplified with the assay. In addition, no peaks were observed within the 
range of body fluid specific markers. 
5.4.12 Negative controls 
Negative controls were prepared with every batch of sample amplified. There was no 
amplification in any of the negative controls (See Figure 5.28i). 
 
Figure 5.28i: EPG showing negative control and RFU’s determined for each dye channel. (a) 
Yakima yellow, (b) FAM, (c) ATTO550, (d) ATTO565, n=5; where n is the number of repeats of 
experiment.
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Key: Full expression/observed                   not observed       Partial expression/sporadically observed        
Table 5.3: Heat map of validation experiment and body fluid expression under different reaction conditions (Summary of validation study in Chapter 
5) 
Body fluid Blood Saliva Semen Vaginal secretion Reference 
genes 
ALAS2 PF4 STATH HTN3 PRM1 MSMB NKX3-
1 
TGM4 SFTA2 MUC4 L. 
cris 
CRYP2B7P1 UCE ACTB 
Degradation               
Sensitivity               
Reproducibility               
Mock 
casework 
              
Reduced vol.               
Mixtures               
Separate 
multiplex 
              
Diff. mastermix               
Cycle number               
Spp. Specificity               
Reduced 
primer 
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Furthermore, LIZ 500 and LIZ 600 size standards were used for marker size detection. LIZ 
500 displayed the expected size for every marker; however, there was a maximum of one 
base pair difference in size of markers when LIZ 600 size standard was used.  
Minimum and maximum peaks were noted for all the negative controls and used to 
establish the limit of detection for each panel. Two separate calculations were done as 
marker sizes were detection on ABI 3500 using LIZ 500 and LIZ 600 size standards. 
5.5 Limits of detection (LOD) and quantitation (LOQ) 
The lowest concentration of sample (LOD) that can be detected, but not necessarily 
quantified was calculated. In addition, limit of quantitation (LOQ) which is the lowest 
concentration of sample that can be determined with acceptable precision and accuracy 
was also calculated using the formula below: 
LOD = (Average peak height + (3 x Standard deviation of the noise)) 
LOQ = (Average peak height + (10 x Standard deviation of the noise)) 
 
Table 5.4: Results obtained from 50 PCR negative controls analysed with LIZ500 
at 1RFU across four dye channels. 
Dye Blue 
(FAM) 
Yellow 
(ATTO550) 
Green (YAKIMA 
YELLOW) 
Red 
(ATTO565) 
Minimum RFU 1 2 1 2 
Maximum RFU 68 61 52 56 
Average RFU 23.48 23.8 22.39 21.34 
SD 5.09 5.15 4.01 4.05 
Ave. RFU + 3SD 38.75 39.25 34.42 33.49 
Ave. RFU + 10SD 74.38 75.3 62.49 61.84 
2 x (Ymax – Ymin) 134 118 102 108 
 
From table 5.4, the limits of detection for blue, yellow, green and red panels are 134 RFU, 
118 RFU, 102 RFU and 108 RFU respectively using LIZ 500 size standard. 
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Table 5.5: Results obtained from 30 PCR negative controls analysed with LIZ600 
at 1RFU across four dye channels. 
Dye Blue 
(FAM) 
Yellow 
(ATTO550) 
Green (YAKIMA 
YELLOW) 
Red 
(ATTO565) 
Minimum RFU 1 1 1 1 
Maximum RFU 62 54 45 48 
Average RFU 20.01 18.03 16.52 16.91 
SD 5.68 4.66 3.15 3.76 
Ave. RFU + 3SD 37.05 32.28 25.97 28.19 
Ave. RFU + 10SD 76.81 63.63 48.02 54.51 
2 x (Ymax – Ymin) 122 106 88 94 
Table 5.5 displays the limits of detection for blue, yellow, green and red panels, which are 
122 RFU, 106 RFU, 88 RFU and 94 RFU respectively using LIZ 600 size standard. 
5.6 Statistical Analysis 
Statistical analyses were carried out in R studio using ‘R’ statistical software. Blood, semen 
and saliva samples prepared on glass slides, cotton cloth and knives, and exposed to 
environmental insults were analysed using ANOVA (Analysis of variance). The model was 
used to test if there was any difference in means of sample quantities prepared and 
recovered from glass slides, cotton cloth and knives. 
Given the null hypothesis: 
H0 = “There are no significant differences in the degradation rates of samples prepared on 
glass slides, cotton cloth and knives”, the null hypothesis is rejected if p<0.05 and 
accepted if p>0.05. 
In order to determine the ideal type of model, the samples were tested for normal 
distribution using qq norm plot (see Figure 5.29a). The data appeared to be normally 
distributed. 
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Figure 5.29a: qq-norm plot of saliva samples showing the normal distribution of data generated 
from the uncontrolled degradation of saliva and semen that were spotted on cotton cloth and knife, 
p>0.05, n = 33; where n equals the number of samples. 
For saliva samples, there was no significant difference (p>0.05) between quantity of mRNA 
recovered from samples prepared on cotton cloth and knife (F1,96 = 0.37, p =0.54). Saliva 
mRNA recovered from knife (mean = 284.75 RFU) were not significantly more than those 
recovered from cotton cloth (mean = 256.47; TukeyHSD: p=0.54), (See box plot, Figure 
5.29b). 
 
Figure 5.29b: Boxplot showing interactions between peak heights (RFU) and substrates (saliva 
samples prepared and recovered from cotton cloth and knife), n =5, where n is the number of 
repeats of experiments, p>0.05. 
There was a significant difference (p<0.05) between quantity of semen mRNA recovered 
from samples prepared on cotton cloth, glass slide and knife (F2.167 = 72.95, p <0.001). 
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Semen samples recovered from glass slide (mean = 7585.18 RFU) was significantly greater 
than cotton cloth samples (mean=941.43RFU). Knife samples were intermediate (mean 
=1265.52), but not significantly different from cotton (Tukey HSD: p>0.05). See Figure 
5.30a,b below. 
 
Figure 5.30a: qq-norm plot of semen samples showing the normal distribution of data generated 
from the uncontrolled degradation of saliva and semen spotted on cotton cloth, glass slide and knife, 
p>0.05, n = 33; where n equals the number of samples. 
 
Figure 5.30b: Boxplot showing interactions between peak heights (RFU) and substrates (semen 
samples prepared and recovered from cotton cloth, glass slides and knife), n =5, where n is the 
number of repeats of experiments, p<0.05 for cotton and knife compared to glass slide. 
In addition, there was a significant difference (p<0.05) between quantity of blood mRNA 
recovered from samples prepared on cotton cloth, glass slide and knife (F2.119 = 0.37, p 
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<0.001). Blood mRNA recovered from cotton cloth (mean = 2371.89 RFU) being significantly 
more than glass (mean=541.09RFU) and knife being intermediate (mean =1373.14), but not 
significantly different from cotton (Tukey HSD: p=0.05). See Figures 5.31a and 5.31b. 
 
Figure 5.31a: qq-norm plot of blood samples showing the normal distribution of data generated 
from the uncontrolled degradation of saliva and semen spotted on cotton cloth, glass slide and knife, 
p=0.05, n = 33; where n equals the number of samples. 
 
 
Figure 5.31b: Boxplot showing interactions between peak heights (RFU) and substrates (blood 
samples prepared and recovered from cotton cloth, glass slides and knife), p=0.5, n =5, where n is 
the number of repeats of experiments. 
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5.7 Final validated conditions for the developed assay 
Upon adequate optimisation and validation, 11 markers were consistently expressed for 
their respective target body fluids. These include ALAS2 and PF4 (Blood), PRM1, MSMB, 
NKX3-1 and TGM4 (Semen), STATH and HTN3 (Saliva), SFTA2 and L. cris (Vaginal secretion) 
and UCE (Reference gene). ACTB reference gene, MUC4, and CRYP2B7P1 vaginal secretion 
markers displayed either low or no expression through the validation process. 
Optimised reaction conditions include: 0.3 ng/µl, saliva: 0.3 ng/µl, blood: 1.3 ng/µl and 
vaginal secretion: 1.8 ng/µl, 10 µl Qiagen PCR mastermix (Qiagen Ltd) and 3.5 µl primermix 
at 58 oC Tm (See Figure 5.27c). Cycling parameters and CE conditions are highlighted in 
Chapter 2, Tables 2.10.1 and 2.9 respectively. 
5.8 Discussion 
This chapter describes the developmental validation of a 14-marker mRNA assay for 
forensic identification of human body fluids. A synopsis of the overall analyses is 
represented in Figure 5.27c and Table 5.3. As most forensic samples are recovered in a 
compromised state, with varying degree of degradation because of microbial and 
environmental impact, the developed assay was robust, enabling each of the body fluids to 
be detected without ambiguity and non-specificity.  
Reference genes, which were selected as positive controls, displayed varied expressions 
throughout the course of the study. While UCE was uniformly expressed, ACTB was only 
expressed in the reproducibility and independent multiplex studies, which was inconsistent 
with the reports of Ghani and Rogaeva, (2013) and Lindenbergh, et al., (2012). The 
expression of a minimum of one reference gene marker indicates optimal PCR conditions 
and that no single reference gene is ideal for body fluid identification (Vandesompele, et 
al., 2002). While several authors (Lindenbergh, et al., 2012; Juusola, and Ballantyne, 2005; 
Cossu et al., 2009; Roeder and Haas, 2013) have reported cross reaction of their body fluid 
specific markers with non-target body fluids, the 14-markers in this study displayed high 
specificity with no cross reactivity noticed with the non-target body fluids. (Roeder and 
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Haas, 2013) reported a majority of the markers in their assay being detected at low 
frequencies and in non-target body fluids, hence, the need to develop a scoring system that 
was used to identify the body fluids. Similarly, sporadic expression of blood markers was 
determined in saliva by (Lindenbergh et al., 2012) which the authors described to occur 
because of possible presence of blood in the saliva samples.   
Both blood markers (ALAS2 and PF4) were expressed throughout the course of the 
experiment without cross reactivity with non-target body fluids. A similar result was seen 
with saliva markers. Although, an added transcript of STATH for saliva was reported by 
(Juusola and Ballantyne, 2005) which was explained to be a possible representation of a 
spliced Histatin isoform, this was not detected in this study; both saliva markers (STATH and 
HTN3) were expressed in their target body fluids. Only two out of four vaginal secretion 
markers (L. crispatus, SFTA2, MUC4 and CRYP2B7P1) were consistently expressed in this 
study. These were SFTA2 and vaginal bacterial marker L. crispatus. The composition of 
vaginal secretion is complex as it is mostly affected by the menstrual cycle and which in turn 
has an effect on the hormonal component of the sample donor (Gipson et al., 1999; Fleming 
et al., 2003). Although these factors were not considered during sample collection, it had 
no effect on the expression of vaginal secretion samples and no cross-reactivity occurred. 
A cross-reactivity was reported by Haas et al., (2012) and Song et al., (2015) with vaginal 
secretion markers and saliva samples; the authors described this to be due to both vaginal 
secretion and saliva originating from identical source –the epithelial cell. Vaginal bacterial 
marker, L. cris. was consistent in expression and did not cross react with non-target body 
fluids. This was expected theoretically, as the bacteria is known to be specific to vaginal. 
There has been reports of non-stability of its components during menstrual cycle due to 
variation in numbers of lactobacilli (Eschenbach et al., 1989; Gupta et al., 1998; Keane et 
al., 1997). Although, expressed consistently, non-stability could not be determined with 
certainty, as menstrual cycle of participants was not put into consideration when samples 
were donated. All four semen specific markers were expressed consistently for semen 
samples only with no cross reaction with non-target body fluids; this is in concordance with 
Lindenbergh et al., (2012) and Roeder and Haas, (2013). 
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Sensitivity test on the assay established all the body fluid markers to be highly sensitive (See 
Figures 5.1-5.4). A similar result was observed for the specificity test on the body fluids. 
Sample from human bone, pig tissue and DNA from mammals -horse, wood mouse, rabbit, 
dog and rat were tested. Reference gene UCE was expressed in all the samples. In addition, 
only bone samples displayed expression of four peaks, however, these were not in the range 
of any body fluid specific markers. Conversely, other authors have reported cross reactivity 
of their assay with primate samples, this was concluded to be as a result of very close 
evolutionary relatedness between the primates and humans (Haas et al., 2011; Haas et al., 
2012). 
In order to control sample variations that could occur, equimolar concentration of mRNA 
extracts from blood, semen, vaginal secretion and saliva was used for the controlled 
degradation in the laboratory. This was done over six weeks in incubator and under UV light. 
While mRNA samples degraded in incubator at 56 oC showed little or no significant level of 
degradation, samples degraded quicker and more significantly under UV light. This was 
found to be inconsistent with the speculation of Hall et al., (2014), and Sirker et al., (2016) 
that there are radiation-absorbing molecules in the cytoplasm, which could prolong 
samples subjected to UV-induced degradation. This speculation cannot be totally faulted as 
the authors used fresh samples and not mRNA extracts. The degradation study using the 
mRNA markers was novel. While most degradation studies were carried out in controlled 
environmental conditions, mostly at room temperature, therefore this was replicated and 
then an extended study on uncontrolled environmentally degraded samples was carried 
out. This tested the developed mRNA marker based assay using highly degraded samples. 
The results obtained from this further established the robustness of the assay. Table 5.2 
summarises the expression of blood, saliva and semen that were prepared for uncontrolled 
degradation study over the period of 51 days.  
The two blood markers were expressed up to the last day of the experiment while semen 
and saliva displayed only sporadic expression after day 30 (Table 5.2). In theory, it is known 
that RNAs degrades faster compared to DNA due to the presence and activities of 
ubiquitous RNases. However, mRNA could still be recovered from saliva and semen samples 
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until day 30 and blood throughout the course of the experiment. This was expected as 
mRNA expression in blood has been previously demonstrated in 23- year old bloodstain, 
although using a different marker HBB (Kohlmeier and Schneider, 2012).  
Semen and saliva samples only displayed sporadic expression after day 30. Even though 
Sirker et al., (2016) demonstrated the expression of semen samples throughout their entire 
study, this was carried out in a controlled environment. A similar result was reported by 
Haas et al., (2009), Noreault-Conti, (2007), Setzer et al., (2008) with semen samples stored 
in 1-2 years. Saliva markers were also sporadically observed after day 30. This was 
consistent with the results of Setzer et al., (2008) and Sirker et al., (2016) where the authors 
suggested that saliva markers were highly sensitive to hydrolytic damage. Fordyce et al., 
(2013) further argued that when samples are dehydrated, RNases activities are inhibited, 
which in turn shields the nucleic acids against degradation. Also discussed was the presence 
of stronger N-glycosidic bonds and depyrimidation process in RNA molecules, enabling 
them to resist hydrolytic depurination and prevention of phosphodiester bond hydrolysis. 
These reasons could be valid as to why mRNA was still expressed in blood, semen and saliva 
after being exposed to such harsh environmental conditions.  
Efforts were made to not to overload the PCR with cDNA as this could result in a major PCR 
failure. The results obtained from mixture studies showed that each body fluid was still 
detectable irrespective of the mixture ratios. Though there were a few artefacts –mainly 
pull-ups that were noticed in the EPGs generated, there was no cross-reaction with non-
target body fluids. Several studies have reported cross-reactivity with non-target body fluids 
especially with an increased amount of template (Cossu et al., 2009; Haas et al., 2011; Fleming 
and Harbison, 2010), thereby leading to false positive and negative identification of body 
fluids. A similar result was reported by Moore et al., (2016) where the authors described 
artefacts observed in PowerPlex Y23 kit associated with excess background quantities of 
female DNA.  
Further attempt was made to balance the peak heights generated during the validation test. 
Despite optimising all possible parameters, with the main parameter being the template 
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quantity, it was nearly impossible to balance the peak heights. This could be due to 
differences in the expression of mRNA in cell types, individuals and pathological conditions 
(Bauer 2008; Carson et al., 2002; Raj and van Oudenaarden, 2008; Whitehead, 2005).  
In conclusion, methods that are more appropriate were adopted during the development 
of the mRNA assay during this study. Analyses in separate multiplexes were carried out first 
to study cross reactivity, which was reported for mRNA markers earlier (Lindenbergh et al., 
2012; Roeder and Haas, 2013; Song et al., 2015). It had been determined in previous studies 
that no single mRNA marker is capable of identifying a particular body fluid; hence, the 14-
plex mRNA assay was developed, with a minimum of two markers specific for a particular 
body fluid. The high sensitivity and specificity displayed by the assay during the degradation 
study further established its robustness in forensic body fluid identification. The 
developmental validation carried out on the developed 14 plex mRNA assay for body fluid 
identification has been carried out for the first time showing that the SWGDAM standards 
for STR kit validation are appropriate for mRNA marker based CE assays though further 
developments might also be required.  
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CHAPTER SIX 
 
 
GENERAL DISCUSSION, CONCLUSION 
AND SCOPE OF FUTURE WORK  
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6.1 General discussion 
The main aim of this project was to evaluate genetic markers in order to identify five 
commonly encountered body fluids, which include blood, semen, saliva, vaginal secretion 
and menstrual blood. The outcomes of the study are assessed in this section with reference 
to the original aims (Section 1.11.2; Chapter 1).  
A majority of crimes involve the deposition of body fluids at the scene. The identification of 
body fluid provides important clues in casework. Numerous studies have been reported 
recently on the significance of body fluid identification. Traditionally, techniques involved 
in forensic body fluid identification rely mainly on enzymatic reactions, which require high 
template, are prone to contamination with presumptive tests being carried out before a 
confirmatory test, are non-specific, and body fluid mixtures are difficult to analyse. New 
techniques have been reported which might enable body fluids to be identified with more 
robustness and limited ambiguity. 
In this study, 10 commonly used reference genes were evaluated and analysed for 
specificity, sensitivity and efficiency. This was the first such study at the best of our 
knowledge. This was necessary before the start of the project as most authors reported the 
use of their reference genes to be because of reports from other studies but no in depth 
evaluation of the reference genes used in body fluid, identification was reported. Ghani et 
al., (2013) had recommended adequate evaluation of reference genes for fitness of purpose 
before being used.  For this study, the markers included 18S-rRNA, ACTB, UCE, B2M, OAZ1, 
RPS29, S-15, β-Actin, TEF and GAPDH. Initially, marker efficiency was tested using SYBR 
Green chemistry. Although this has major disadvantages of no multiplexing ability and 
fluorescence on binding to any available dsDNA which overall lowers the efficiency of the 
system, it was still considered as it is less expensive and still a robust enough method for 
initial evaluation. The hypothesis was that if the markers were able to attain 95-100% 
efficiency with SYBR Green chemistry, better efficiency would be expected for Taqman 
probes. Efficiency test using SYBR Green showed five markers with less than 95-100% 
efficiency and these were GAPDH, 18S rRNA, β-Actin, OAZ1 and S15. Contrary to this finding, 
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these were previously reported by several authors to be ideal reference markers for 
forensic body fluid identification; however, they failed the efficiency test. The reasons for 
the markers not attaining the set threshold were discussed earlier (Section 3.10.1; Chapter 
3). ACTB, UCE, RPS29, B2M and TEF passed the efficiency test and were selected for 
evaluation using Taqman probe detection method. Taqman probes were designed and real 
time PCR assays were optimized for each reference gene marker. The sensitivity test using 
Taqman probes displayed detection down to 25-picogram input RNA with the exception of 
TEF, which was detected at 100 picogram of input RNA. Furthermore, these markers were 
tested on 6-month old body fluid samples stored at room temperature. Ten samples were 
used from each of the body fluids for this purpose, from five volunteers.  
ACTB, B2M, UCE and RPS29 were stably expressed across the whole samples, with TEF had 
the least expression (Table 3.1a/b). This result with TEF was contrary to the findings of 
Fleming and Harbison, (2010) where the authors’ reported a high expression for the marker. 
The variable expression of all the reference genes across the body fluids tested further 
established the reports of Meller et al., (2005), Pohjanvirta et al., (2006), and Vandesompele 
et al., (2002) that no single reference gene is universally stable. Hence, the use of multiple 
reference genes in an assay had been recommended. This study empirically showed the 
value of using more than one reference gene in an assay. 
Chapter four of this study highlighted the design and optimization of the developed mRNA 
assay. Initially, 32 markers were selected from relevant literature. These comprised; seven 
markers (Glyco-A, ALAS2, PF4, HBB, CCL5, PPBP and SPTB) for blood; four markers (MSX-1, 
SFRP, MMP11 and LEFTY2) for menstrual blood; six markers (PRM1, PRM2, TGM4, MSMB, 
and NKX3-1, SEMG) for semen; six markers (SFTA2, MUC4, L. crispatus, L. gasseri, 
CRYP2B7P1, and HBD1) for vaginal secretion; and three markers (HTN3, FDCSP and STATH) 
for saliva; and five markers (B2M, ACTB, RPS29, TEF and UCE) for reference genes. 
Optimization was carried out first using non-florescent primers and results analysed on 
agarose gel. Two different multiplex mix were also used, Platinum PCR mastermix (Life 
technologies Ltd) and Qiagen PCR mastermix (Qiagen Ltd). Upon optimization and agarose 
gel analysis, the markers that displayed clearly visible bands on the gel (of expected sizes) 
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were noted and the forward primers for these were then labelled with fluorescent dyes 
(Figure 4.8).  
First phase of optimization resulted in 19 body fluid specific markers, which were expressed 
in their respective body fluids (Table 2.12, 4.3). Five separate multiplex were developed, 
one for each body fluid. This was required in order to establish the specificity of each marker 
to the body fluid of origin. For the vaginal secretion assays, all the markers except HBD1 
were expressed in vaginal secretion at 33 cycles. However, CRYP2B7P1 and HBD1 were only 
expressed in positive control sample from Qiagen Ltd. The non-expression of HBD1 was in 
concordance with the results of Lindenbergh et al., (2012) as the authors reported similar 
issue with expression of the marker. Also, Roeder and Haas, (2013) and Jakubowska et al., 
(2013) reported the marker non-expression in saliva samples, and in menstrual blood 
samples (Juusola and Ballantyne, 2005). These could infer the markers non-specificity for 
vaginal secretion samples.  
Blood and Saliva assays were optimised at 35 amplification cycles. CCL5 and PPBP were not 
expressed in blood, contrary to the reports of Park et al., (2013). The three saliva markers 
were expressed in saliva, which further supported the report of Park et al., (2013), 
Lindenbergh et al., (2012), and Park et al., (2013).  
All semen markers were expressed in semen sample. Only MSX-1 was expressed in 
menstrual blood. MMP11 (Roeder and Haas, 2013) and SFRP4 (Lindenbergh et al., (2012) 
were both reported specific for menstrual blood; however, they were not expressed in this 
study. Further optimization was carried out on the five-plex assay using fluorescently 
labelled dyes and the results analysed on the ABI 3500 genetic analyser. All blood markers 
were expressed apart from SPTB, which has been previously reported not optimal for mRNA 
profiling of blood (Kohlmeier and Schneider, 2012).  
All vaginal secretion markers were expressed except MUC4, which displayed low 
expression. The marker had been reported to cross- react with saliva (Mara et al., 2012; 
Nussbaumer et al., 2006; Cossu et al., 2009; Haas et al., 2009). All saliva and semen markers 
expressed in saliva and semen respectively which was consistent with the reports of 
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Lindenbergh et al., (2012), Roeder and Haas, (2013), Mara et al., (2012), and Park et al., 
(2014). LEFTY2 was not expressed in menstrual blood sample. Roeder and Haas, (2013) 
reported this marker to be detected in non-target body fluids as well. This was not an issue 
in this project as menstrual blood markers were not included in the developed assay. 
In order to reduce sample processing time and cross-contamination between primers, all 
the five markers that displayed high expression in the individual five-plex assay were 
combined into a single multiplex assay. A 14-marker assay, comprising of ALAS2 and PF4 
(blood), STATH and HTN3 (saliva), PRM1, TGM4, MSMB, NKX3-1 (semen), ACTB and UCE 
(reference genes), CRYP2B7P1, SFTA2, MUC4 and L. crispatus (vaginal secretion) was 
developed and optimised. Menstrual blood markers were excluded from the final assay, as 
they were not expressed despite all modifications to the concentration and cycling 
conditions. In addition, ACTB was highly expressed in all experiments carried out and led to 
pull up peaks in the blue, red and yellow panels of the electropherograms (Figure 4.17). The 
primer concentration was modified by reducing the working concentration; however, this 
did not make much difference in the high expression of ACTB. Overall, all markers were 
expressed in their target body fluids except for MUC4 in vaginal secretion that did not 
display expression. 
A developmental validation was carried out for the 14-marker assay, this was essential in 
order to establish robustness of the developed assay. SWGDAM guidelines were used to 
conduct this validation. Because of pull-ups displayed by ACTB during assay optimisation 
both reference genes (ACTB & UCE) were modified by labelling the forward primers with 
ATT0565, which is a red florescent dye, therefore making the green panel free for possible 
incorporation of more markers. The validation experiments commenced with sensitivity 
study where all body fluid samples were diluted in different proportions, with the least 
being 1:10 and highest 1:3000 (Table 5.1). All body fluid samples were detected down to 
1:3000 dilution except vaginal secretion that displayed expression up to 1:1500. In addition, 
specificity test was carried out using samples from bone, pig tissue, human DNA (blood), 
horse, wood mouse, rabbit, dog and rat. None of the body fluid specific markers was 
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expressed in any of these samples. However, reference genes were expressed which was a 
normal and expected occurrence.  
For the degradation experiments, the main aim was to validate the robustness of the 
developed mRNA assay on samples that have undergone various stages of degradation and 
not to make comparisons between the rates of degradation that have occurred using 
different mechanisms. Degradation study was carried out in a controlled manner in the 
laboratory at room temperature, in the incubator and under the UV-light. In addition, 
samples that were exposed to outdoor environmental conditions (uncontrolled) were 
analysed. UV light was found to have a significant effect on sample degradation compared 
to temperature. Although Hall et al., (2014) and Sirker et al., (2016) speculated that UV 
would have a lower effect on degradation as there are radiation- absorbing molecules in 
the cytoplasm which could shield samples from UV rays, thereby prolonging their rate of 
degradation. These authors used fresh samples in their study whereas mRNA samples were 
used in this study. mRNA samples were used as these compared sample concentrations as 
against sample volume as used by other authors. By using sample concentrations and 
keeping it constant, it is possible to monitor the rate of degradation, which is not possible 
when volumes are used. For instance, when same aliquots of blood sample is extracted for 
mRNA, different concentrations would be obtained. This infers that when the authors 
mentioned prepared their mock casework samples, the rate of degradation would be 
monitored efficiency, knowing that each aliquot of body fluid sample prepared contained 
different amount of mRNA. 
In the uncontrolled degradation experiment, body fluid samples were identified up to at 
least day 30 of 51. Interestingly, to current knowledge, this was the first attempt to carry 
out an extensive degradation study for evaluating the genetic markers for body fluid 
identification. There were only a few experiments that had been reported studying the 
stability of RNA over a longer period with the longest being detection of blood in 23-year 
old stains (Kohlmeier and Schneider, 2012), however, these studies were all carried out in 
controlled environment. This further established the robustness of the developed assay for 
body fluid identification as theoretically; RNA’s are not stable and thus easily degraded 
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because of ubiquitous ribonucleases in the environment. Mixture study displayed no cross-
reaction of the markers in non-target body fluids. In order to reduce the cost of reagents 
and time of analysis, different mastermix were optimised and the primer concentrations 
and volumes were reduced. While Platinum PCR mix also yielded an acceptable result, 
Qiagen mastermix (Qiagen Ltd) was found to be optimal for this developed assay.  
Finally, attempts were made to obtain balanced peak heights for all the markers in the 
assay. This was not possible as other authors have reported it to be due to difference in 
mRNA expression in different cells, and because of pathological conditions (Bauer, 2008; 
Carson et al., 2002; Raj et al., 2008; Whitehead, 2005). However, as the expression of the 
markers in various body fluids can be ascertained through the presence or absence of a 
peak in a CE based system; the features of the peaks for individual loci were consistent and 
comparable across the samples and the assay led to identification of body fluids in different 
laboratories.  
6.2 Conclusion 
Initial multiplex design in this study targeted a total of 35 body fluid specific markers and 
reference genes (See Figure 6.1). However, after extensive validation process, a final assay, 
which comprise 14-markers, was developed (See Figure 6.2). In addition, all previously 
developed mRNA assays for body fluid identification have reported a minimum of one cross-
reaction of one or more markers, which were detected in non-target body fluids. There 
were no cross reactions with non-target body fluids in the developed assay reported in this 
thesis. The reference gene marker study, together with extensive study of body fluids that 
were subjected to non-controlled environmental degradation, have sufficed for the novelty 
of this project. Thus, the developed novel assay was found to be robust and fit for purpose. 
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Figure 6.1: Initial schematic representation of the developed multiplex assay consisting of 35 body 
fluid specific marker and reference genes. Each marker was represented based on their expected 
amplicon size before optimisation (Drawn by hand). 
 
Figure 6.2: Final schematic representation of the developed multiplex mRNA assay. This consists of 
14 mRNA markers that have been adequately optimised, validated, and reported fit for purpose. 
Each marker was represented based on the established amplicon size after optimisation. The blue 
panel represents blood and semen markers; yellow panel represents vaginal secretion markers; red 
panel represents saliva and reference genes (Drawn by hand). 
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6.3 Pitfalls and troubleshooting issues 
1. The main limitation of the project was sample collection. Most potential donors 
were hesitant to participate in the study, especially with intimate samples such as 
semen, vaginal secretion and menstrual blood. This slowed down the project though 
a fair number of samples were analysed and the degradation study was the largest 
such study to date. 
2. Unlabelled primers that gave results when optimised initially and analysed using gel 
electrophoresis did not give similar results when they were fluorescently labelled. 
These primers were sent to the vendor company where they were resynthesized at 
additional cost. 
3. The genetic analyser broke down at the crucial stage of the study and this took about 
4 months to be rectified. This slowed down the project a great deal as it was the 
main equipment used to generate final EPG of gene expression in the body fluids. 
If I have to repeat this study, the following will be put into consideration in order to save 
time, cost of primer synthesis and reagents. 
1. Enhanced education of prospective participants. This could be achieved by 
organising a presentation to keep them informed of the nature of the project as well 
as what is required of them. This procedure is necessary as poster advertisement 
was could not contain all the required information. 
2. The intending participants would be reassured that other than the intended scope 
of the study, the results generated will not be submitted into the police database as 
this was a major concern for them. 
3. A test sample of all reagents and consumables required will be requested from 
respective companies concerned. This will prevent unforeseen costs should any of 
their products fail. 
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6.4 Scope for Future Studies 
With additional time and resources, the following is recommended: 
a) RNA analogues with a high affinity and ‘locked’ ribose ring could be used for more 
sensitivity and specificity of the designed assay. In its chemistry, for every 
incorporated nucleic acid probe, there is an increase of 2-8 oC in melting 
temperature (Tm) of the duplex. The overall high Tm thus increases affinity for the 
complementary strand which overall would increase the specificity of the markers 
in PCR. 
b) Next Generation Sequencing (NGS) has gained popularity in body fluid identification 
recently; the same could be implemented and compared in parallel with the 
performance of the developed assay. 
c) Samples obtained and analysed for effects of environmental insults on body fluids 
prepared at different times compared to the controlled degradation experiments 
carried out in the lab. With more time and available resources, a parallel experiment 
could be used to compare the effects of both conditions simultaneously on body 
fluid identification. 
d) Also, it is important to incorporate more markers, both miRNA and mRNA could 
increase the robustness of the assay. However, adequate care would be required to 
avoid cross-reactivity with non-target samples. 
e) Measure total protein in each body fluid sample. 
f) Investigate the effect of environmental insults on the different samples and then 
measure the different genes in each body fluid. 
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Appendix 4c: EPGs of blood sample spotted on facial mask and incubated 
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231 
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232 
 
Appendix 4g: EPG of saliva sample spotted on a straw and incubated at 
room temperature for 6 weeks. 
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Appendix 5: CE results of primer-mix sent to an independent laboratory 
for testing. 
sample reverse transcription positive reverse transcription negative 
 
Sample 
File Name 
Marker Size Heig
ht 
Sampl
e File 
Name 
Marker Size Height 
Semen A01_1.fsa ACTB 69.6 1441 
    
3 ul A01_1.fsa MSMB ~100 ~360
0 
    
 
B01_2.fsa NKX3-1 ~139 ~360
0 
    
 
A01_1.fsa PF4 118.3 1918 
    
 
A01_1.fsa PRM1 84.03 3412 
    
 
A01_1.fsa TGM4 212.0
5 
3850 
    
 
A01_1.fsa UCE 237.6
3 
3923 
    
Semen B01_2.fsa ACTB 70.23 2667 
    
3 ul on 
swab 
B01_2.fsa MSMB 99.49 3861 
    
 
B01_2.fsa NKX3-1 138.4
1 
3890 H04_2-
.fsa 
NKX3-1 139.0
8 
643 
234 
 
 
B01_2.fsa PF4 116.0
5 
1099 H04_2-
.fsa 
PF4 117.0
6 
1547 
 
B01_2.fsa PRM1 83.91 2861 
    
 
B01_2.fsa TGM4 212.3
6 
3988 
    
 
B01_2.fsa UCE 237.6
4 
2870 
    
Semen C01_3.fsa ACTB 70.46 1607 
    
5 ul C01_3.fsa MSMB 98.83 4009 
    
 
C01_3.fsa NKX3-1 138.2
2 
3792 
    
 
C01_3.fsa PRM1 84.13 3744 
    
 
C01_3.fsa TGM4 212.8
5 
2249 
    
 
C01_3.fsa UCE 237.6
8 
3964 
    
Semen D01_4.fsa ACTB 70.29 2632 
    
5 ul on 
swab 
D01_4.fsa MSMB 99.07 3898 
    
 
D01_4.fsa NKX3-1 138.4
2 
4023 
    
235 
 
 
D01_4.fsa PF4 116.5
7 
1114 
    
 
D01_4.fsa PRM1 84.01 3081 
    
 
D01_4.fsa TGM4 211.9
5 
4128 
    
 
D01_4.fsa UCE 237.7
3 
3909 
    
Semen E01_5.fsa ACTB 70.36 748 
    
10 ul E01_5.fsa MSMB 99.79 434 
    
 
E01_5.fsa NKX3-1 138.9
3 
1950 
    
 
E01_5.fsa PF4 115.5
8 
1297 
    
 
E01_5.fsa PRM1 83.91 3362 
    
 
E01_5.fsa TGM4 212.6 ~170 
    
 
E01_5.fsa UCE 237.6
5 
250 
    
Semen F01_6.fsa ACTB 71.57 2339 
    
10 ul on 
swab 
F01_6.fsa MSMB 99.25 4216 
    
 
F01_6.fsa NKX3-1 138.2
4 
3822 D05_6-
.fsa 
NKX3-1 139.0
8 
1210 
236 
 
 
F01_6.fsa PRM1 83.69 3447 
    
 
F01_6.fsa TGM4 212.0
2 
3963 
    
 
F01_6.fsa UCE 237.8
5 
3881 
    
menstru
al 
G01_7.fsa ACTB 68.65 2029 
    
blood G01_7.fsa ALAS2 75.3 223 
    
vaginal 
swab 
G01_7.fsa CRYP2B7
P1 
201.4
4 
4402 
    
 
G01_7.fsa MUC4 141.6 4344 
    
 
G01_7.fsa NKX3-1 ~170 139 E05_7-
.fsa 
NKX3-1 139 1362 
 
G01_7.fsa SFTA-2 187.0
8 
4543 
    
 
G01_7.fsa UCE 238.1
1 
1076 
    
menstru
al 
H01_8.fsa ACTB 70.6 1684 
    
blood H01_8.fsa ALAS2 75.42 371 
    
vaginal 
swab 
H01_8.fsa CRYP2B7
P1 
202 1207 
    
237 
 
 
H01_8.fsa MUC4 142.1
5 
1506 
    
 
H01_8.fsa NKX3-1 139.0
9 
2200 F05_8-
.fsa 
NKX3-1 139 2219 
 
H01_8.fsa PF4 117.5
8 
2818 
    
 
H01_8.fsa SFTA-2 187.4
2 
747 
    
 
H01_8.fsa UCE 238.0
6 
423 
    
menstru
al 
A02_9.fsa ACTB 70.07 2261 
    
blood A02_9.fsa ALAS2 74.87 3356 
    
vaginal 
swab 
A02_9.fsa CRYP2B7
P1 
202.1
1 
4408 
    
 
A02_9.fsa MUC4 141.5
4 
3645 
    
 
A02_9.fsa NKX3-1 138.7
1 
3647 G05_9-
.fsa 
NKX3-1 139 3971 
 
A02_9.fsa PF4 117.2
4 
2920 
    
 
A02_9.fsa SFTA-2 187.1
3 
3408 
    
238 
 
 
A02_9.fsa UCE 237.6
7 
104 
    
menstru
al 
B02_10.fs
a 
ACTB 70.45 2210 
    
blood B02_10.fs
a 
CRYP2B7
P1 
202.1
9 
4519 
    
vaginal 
swab 
B02_10.fs
a 
MUC4 141.5
4 
4239 
    
 
B02_10.fs
a 
NKX3-1 138.9
3 
254 H05_1
0-.fsa 
NKX3-1 139.0
8 
1160 
 
B02_10.fs
a 
PF4 117.5
9 
943 
    
 
B02_10.fs
a 
SFTA-2 187.1
6 
4348 
    
 
B02_10.fs
a 
UCE 237.6
8 
578 
    
menstru
al 
C02_11.fs
a 
ACTB 69.52 931 A06_1
1-.fsa 
ALAS2 74.93 665 
blood C02_11.fs
a 
CRYP2B7
P1 
201.8
8 
752 
    
vaginal 
swab 
C02_11.fs
a 
MUC4 142.1
8 
1100 
    
239 
 
 
C02_11.fs
a 
NKX3-1 139.5
2 
2073 A06_1
1-.fsa 
NKX3-1 138.1
7 
2875 
     
A06_1
1-.fsa 
PF4 117.8
6 
1087 
 
C02_11.fs
a 
SFTA-2 187.0
3 
157 
    
menstru
al 
D02_12.fs
a 
ACTB 70.38 1499 B06_1
2-.fsa 
ACTB 69.69 858 
blood D02_12.fs
a 
CRYP2B7
P1 
201.5
1 
4413 
    
vaginal 
swab 
D02_12.fs
a 
MUC4 142.7
9 
3465 
    
 
D02_12.fs
a 
NKX3-1 139 3553 B06_1
2-.fsa 
NKX3-1 138.5
2 
3982 
 
D02_12.fs
a 
SFTA-2 187.1
9 
3947 
    
 
D02_12.fs
a 
UCE 237.6
4 
965 
    
vaginal E02_13.fs
a 
Lcrispatu
s 
307.3
2 
4018 C06_1
3-.fsa 
Lcrispat
us 
306.9
6 
4243 
secretio
n 
E02_13.fs
a 
NKX3-1 139 228 C06_1
3-.fsa 
NKX3-1 139 359 
240 
 
vaginal 
swab 
E02_13.fs
a 
PF4 116.1
7 
1079 
    
vaginal F02_14.fs
a 
ACTB 69.09 1255 D06_1
4-.fsa 
ACTB 69.55 875 
secretio
n 
F02_14.fs
a 
CRYP2B7
P1 
202.0
1 
4557 
    
vaginal 
swab 
F02_14.fs
a 
MUC4 141.4
6 
3660 
    
 
F02_14.fs
a 
NKX3-1 138.2
5 
3463 D06_1
4-.fsa 
NKX3-1 138.4
3 
3941 
 
F02_14.fs
a 
PF4 117.2
5 
349 
    
 
F02_14.fs
a 
SFTA-2 187.4
5 
4374 
    
 
F02_14.fs
a 
UCE 237.8
9 
833 
    
vaginal G02_15.fs
a 
ACTB 70.56 2771 E06_1
5-.fsa 
ACTB 70.46 165 
secretio
n 
G02_15.fs
a 
CRYP2B7
P1 
201.3
1 
4571 
    
vaginal 
swab 
G02_15.fs
a 
MUC4 141.5
4 
4407 
    
241 
 
 
G02_15.fs
a 
NKX3-1 139 1283 
    
 
G02_15.fs
a 
PF4 117.2
8 
290 
    
 
G02_15.fs
a 
SFTA-2 186.7
7 
4647 
    
 
G02_15.fs
a 
UCE 237.6
7 
2622 
    
vaginal H02_16.fs
a 
ACTB 69.4 1886 F06_16
-.fsa 
ACTB 70.27 304 
secretio
n 
H02_16.fs
a 
CRYP2B7
P1 
201.9 5208 
    
vaginal 
swab 
H02_16.fs
a 
Lcrispatu
s 
306.6
8 
1933 F06_16
-.fsa 
Lcrispat
us 
305.4
7 
4427 
 
H02_16.fs
a 
MUC4 141.5
1 
4603 
    
 
H02_16.fs
a 
NKX3-1 139.1
8 
997 F06_16
-.fsa 
NKX3-1 138.9
2 
2319 
 
H02_16.fs
a 
SFTA-2 187.3
4 
5132 
    
 
H02_16.fs
a 
UCE 238.1
8 
1908 
    
242 
 
vaginal A03_17.fs
a 
ACTB 70.41 3227 
    
secretio
n 
A03_17.fs
a 
CRYP2B7
P1 
201.0
9 
2313 
    
vaginal 
swab 
A03_17.fs
a 
MUC4 141.4 4382 
    
     
G06_1
7-.fsa 
NKX3-1 139.0
8 
1411 
 
A03_17.fs
a 
SFTA-2 186.3
8 
2375 
    
 
A03_17.fs
a 
UCE 237.5
1 
2576 
    
vaginal B03_18.fs
a 
ACTB 70.45 3630 
    
secretio
n 
B03_18.fs
a 
CRYP2B7
P1 
201.5
7 
2261 
    
vaginal 
swab 
    
H06_1
8-.fsa 
Lcrispat
us 
305.9
3 
455 
 
B03_18.fs
a 
MUC4 142.5
2 
4687 
    
 
B03_18.fs
a 
SFTA-2 186.9
1 
2285 
    
243 
 
 
B03_18.fs
a 
UCE 237.5
5 
595 
    
blood C03_19.fs
a 
ACTB 70.69 841 
    
3 ul 
blood 
C03_19.fs
a 
ALAS2 74.48 1242 
    
 
C03_19.fs
a 
NKX3-1 138.9
2 
383 
    
 
C03_19.fs
a 
PF4 116.7
3 
2018 
    
 
C03_19.fs
a 
UCE 237.6 2647 
    
blood D03_20.fs
a 
ACTB 70.51 1394 
    
3 ul 
blood 
D03_20.fs
a 
ALAS2 74.51 1115 
    
 
D03_20.fs
a 
NKX3-1 138.5 ~140 
    
 
D03_20.fs
a 
PF4 116.9
1 
3742 
    
 
D03_20.fs
a 
UCE 237.8
5 
2604 
    
244 
 
blood E03_21.fs
a 
ACTB 70.57 1235 
    
3 ul 
blood 
E03_21.fs
a 
ALAS2 74.5 1485 
    
 
E03_21.fs
a 
NKX3-1 139 2593 
    
 
E03_21.fs
a 
PF4 117.7
8 
3727 
    
 
E03_21.fs
a 
UCE 237.8
2 
2604 
    
blood F03_22.fs
a 
ACTB 70.68 2136 
    
3 ul 
blood 
F03_22.fs
a 
ALAS2 75.36 391 
    
 
F03_22.fs
a 
NKX3-1 138.5 ~170 
    
 
F03_22.fs
a 
PF4 118.3
1 
3437 
    
 
F03_22.fs
a 
UCE 237.1
6 
2575 
    
blood G03_23.fs
a 
ACTB 70.46 274 
    
245 
 
3 ul 
blood 
G03_23.fs
a 
ALAS2 74.59 1544 
    
 
G03_23.fs
a 
NKX3-1 139 282 
    
 
G03_23.fs
a 
PF4 117.0
8 
3536 
    
 
G03_23.fs
a 
UCE 237.2
4 
2652 
    
blood H03_24.fs
a 
ALAS2 75.28 1361 
    
1 ul 
blood 
on 
cotton 
fabric 
H03_24.fs
a 
PF4 116.4 1375 
    
saliva A04_25.fs
a 
ACTB 70.34 3991 
    
10 ul 
saliva 
on swab 
A04_25.fs
a 
STATH 96.79 1699 
    
saliva B04_26.fs
a 
ACTB 70.34 3532 H07_2
6-.fsa 
ACTB 70.47 378 
246 
 
5 ul 
saliva 
on swab 
B04_26.fs
a 
HTN3 135.9
9 
3902 
    
 
B04_26.fs
a 
NKX3-1 139 ~170 
    
 
B04_26.fs
a 
STATH 97.26 2827 
    
saliva C04_27.fs
a 
ACTB 70.36 3784 
    
5 ul 
saliva 
C04_27.fs
a 
HTN3 135.6
7 
3490 
    
 
C04_27.fs
a 
MUC4 142.0
6 
635 
    
 
C04_27.fs
a 
NKX3-1 139 291 
    
 
C04_27.fs
a 
STATH 97.79 3740 
    
saliva D04_28.fs
a 
ACTB 70.4 270 
    
5 ul 
saliva 
D04_28.fs
a 
NKX3-1 138.9
3 
554 B08_2
8-.fsa 
NKX3-1 139 265 
saliva E04_29.fs
a 
ACTB 70.39 4023 
    
247 
 
buccal 
swab 
E04_29.fs
a 
HTN3 135.7
9 
4028 
    
 
E04_29.fs
a 
STATH 98.33 3616 
    
saliva F04_30.fs
a 
ACTB 70.32 2619 
    
buccal 
swab 
F04_30.fs
a 
HTN3 136.1 3430 
    
 
F04_30.fs
a 
MUC4 142.1
7 
1657 
    
 
F04_30.fs
a 
NKX3-1 138.9
2 
762 
    
 
F04_30.fs
a 
PF4 117.7
1 
1400 
    
 
F04_30.fs
a 
SFTA-2 186.9
9 
251 
    
 
F04_30.fs
a 
STATH 97.42 2730 
    
 
F04_30.fs
a 
UCE 237.4
1 
163 
    
 
C05_neg.f
sa 
ALAS2 75.94 336 
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Appendix 6: Conferences and proceedings  
Poster Presentation: Reference genes study: A requisite in qRT-PCR experiments at ISFG 
conference, Krakow, August 2015. 
Attendee/Participant: American Academy of Forensic Sciences (AAFS), Las Vegas, February 
2016. 
Poster Presentation: Evaluation of genetic markers for forensic identification of human 
body fluids at Postgraduate Research Conference, University of Central Lancashire, Preston, 
September, 2016. 
Appendix 7: Publications 
Reference gene study for Forensic body fluid identification (2015) Forensic Science 
International: Genetics Supplement Series 5, Pages e167-e169. 
Current advances in Forensic Body Fluid Identification Techniques: A review (Under 
preparation). 
Developmental validation of a 14-marker mRNA multiplex assay for Forensic Identification 
of Human Body Fluids (Under preparation). 
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